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Abstract		It	 is	 well	 established	 that	 Matrix	 metalloproteinase-8	 (MMP8)	 suppresses	growth	 and	 metastasis	 of	 tumours,	 and	 accumulating	 data	 suggest	 that	 this	protective	 effect	 is	 propagated	 via	 the	 immune	 system.	 Recent	 reports	 links	MMP8	to	TGFb	signaling,	which	is	known	to	induce	polarization	of	neutrophils	and	 macrophages	 towards	 their	 pro-tumorigenic	 phenotypes;	 N2	 and	 M2.	However,	the	role	of	MMP8	as	a	regulator	of	the	TGFb	mediated	polarization	of	myeloid	 cells	 is	unexplored.	The	present	 study	analysed	 the	 transcriptome	of	tumours	from	MMTV-PyMT	mice,	intercrossed	with	Mmp8-null	mice,	to	explore	whether	depletion	of	MMP8	affects	myeloid	cell	polarisation	and,	to	investigate	novel	pathways	affected	by	MMP8	signaling.	Results	from	qRT-PCR	suggests	an	increased	 infiltration	 of	 both	 anti-	 and	 pro-tumorigenic	myeloid	 cells	 at	 later	time	points,	however,	these	results	were	not	confirmed	by	RNAseq	analysis.	In	contrast	 to	 these	results,	analysis	of	 the	whole	 transcriptome	of	MMTV-PyMT	tumours	showed	that	depletion	of	MMP8	induces	an	up-regulation	of	gene	sets	specific	 for	B-	and	T-lymphocytes	and,	 lipid	and	glycerol	metabolism	at	6	and	10	 weeks,	 respectively,	 as	 well	 as	 inducing	 a	 disturbance	 in	 the	 web	 of	proteases.	 Additionally,	 several	 oncogenic	 proteins	 showed	 increased	expression	 in	 Mmp8-null	 mice.	 Although	 further	 validation	 is	 required	 to	confirm	 the	 current	 findings,	 these	 results	 suggest	 a	 complex	 role	 of	 MMP8	during	 tumour	 progression,	 in	 which	 pleiotropic	 changes	 are	 observed	 in	response	to	MMP8	ablation.	These	findings	should	be	further	explored	in	future	studies	to	achieve	a	better	understanding	of	the	mechanistic	actions	of	MMP8,	which,	 in	 turn,	 could	 provide	 important	 implications	 for	 treatment	 of	 breast	cancer	patients.	
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1.	INTRODUCTION	
1.1.	Breast	Cancer	Breast	 cancer	 is	one	of	 the	major	 causes	of	 female	deaths	and	 represents	 the	most	frequent	malignancy	in	women	worldwide	(Torre	et	al.,	2015;	Siegel	et	al.,	2015).	 Together	 with	 in-vitro	 and	 in-vivo	 models,	 comprehensive	 studies	 of	tumours	from	patients	with	different	clinical	parameters	have	led	to	important	discoveries	 in	 the	 field	 of	 breast	 cancer,	 and	 also	 significantly	 improved	 our	understanding	of	 the	underlying	mechanisms	of	 the	malignancy.	Despite	 this,	breast	 cancer	 still	 remains	 a	 scientific	 and	 clinical	 challenge,	which	 is	mainly	due	to	the	variety	and	complexity	of	malignant	cells	and	their	interactions	with	the	host	environment.	Thus,	future	studies	still	need	to	address	and	resolve	the	current	major	gaps	in	breast	cancer	research	(Eccles	et	al.,	2013).				The	 normal	 breast	 is	 composed	 of	 adipose,	 connective	 and	 gland	 tissues,	 in	which	the	latter	is	divided	into	lobes	that	are	connected	to	the	nipple	through	a	network	 of	 milk	 ducts	 (Cancer	 Research	 Uk,	 2016).	 Malignant	 cells	 most	commonly	 develop	 from	 cells	 in	 the	 lobules	 or	 milk	 ducts	 with	 subsequent	evolution,	initially,	into	ductal	carcinoma	in	situ	and	further	into	invasive	breast	cancer,	which	finally	results	in	metastatic	disease	(Burnstein	et	al.,	2004).																	
Figure	 1.1:	 Anatomy	 of	 the	 female	
breast.	 Carcinogenesis	 commonly	arises	from	lobules	or	the	milk	ducts.	Adapted	from	Cancer	Research	UK.		
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Breast	 cancer	 is	 highly	 heterogeneous	 and	 has	 been	 divided	 into	 distinct	subgroups	 to	 facilitate	 the	 study	 and	 clinical	 management	 of	 the	 disease.	Although	 a	 universal	 classification	 is	 not	 in	 place,	most	 studies	 divide	 breast	cancer	 into	 subgroups	 based	 on	 receptor	 status,	 which	 results	 in	 four	 main	subtypes:	 luminal	 A,	 luminal	 B,	 HER-2	 (human	 epidermal	 growth	 factor	receptor	 2)	 type,	 and	 triple-negative/basal-like	 breast	 cancer.	 Luminal	 A	 and	luminal	 B	 tumours	 are	 estrogen	 receptor	 (ER)	 and/or	 progesterone	 receptor	(PR)	 positive,	 in	 which	 luminal	 A	 is	 HER-2	 negative	 and	 have	 low	 grade,	whereas	luminal	B	is	highly	proliferative	and/or	HER-2	positive.	Also,	luminal	B	tends	to	be	node-positive,	have	larger	tumour	size	and	predict	poorer	outcome.	In	 contrast,	 HER-2	 types	 are	 negative	 for	 both	 ER	 and	 PR,	 while	 also	 being	node-positive	 and	 have	 poorer	 tumour	 grade.	 Further,	 triple-negative	 and	basal-like	 tumours	 are	 negative	 for	 ER,	 PR	 and	 HER-2.	 Receptor	 negative	tumours	 are	 considered	 to	 be	 the	 most	 aggressive	 breast	 cancer	 subtypes,	which	 have	 poorer	 prognosis	 compared	 to	 receptor	 positive	 breast	 cancers	(Fan	et	al.,	2006;	Voduc	et	al.,	2010;	Foukakis	&	Bergh,	2015;	Carey	et	al.,	2014;	Howlader	et	al.,	2014;	Perou	et	al.,	2000).		The	 primary	 treatment	 of	 cancer	 has	 previously	 relied	 solely	 on	 surgery	 in	combination	with	cytotoxic	chemotherapy	and	radiation	therapy	(Tinoco	et	al.,	2013).	 For	 the	 last	 two	 decades	 however,	 a	 better	 understanding	 of	 the	underlying	biology	of	cancer	cells	has	led	to	more	individualised	and	targeted	treatment	strategies.	In	breast	cancer,	such	therapy	involves	tailored	strategies	based	on	the	absence	or	presence	of	receptors,	specifically	ER,	PR,	and	HER-2.	For	 instance,	 patients	 positive	 for	 hormone	 receptors	 can	 be	 treated	 with	endocrine	 therapy	to	 inhibit	 the	effect	 that	estrogen	and	progesterone	has	on	tumour	growth.	Further,	patients	with	tumours	overexpressing	HER-2	typically	receive	 therapy	 that	 inhibits	 HER-2	 that,	 in	 turn,	 suppress	 growth	 and	proliferation	 of	 tumour	 cells.	 Both	 strategies	 are	 given	 in	 combination	 with	cytotoxic	 chemotherapeutic	 agents	 and/or	 other	 treatment	 options,	 such	 as	radiation	therapy.	Patients	with	triple	negative	breast	cancer	(TNBC)	however,	are	insensitive	to	these	targeted	treatment	options	as	they	lack	expression	of	all	
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three	receptors.	TNBC	patients	are	thus	primarily	treated	with	cytotoxic	agents	(Tinoco	et	al.,	2013;	Hernandez-Aya	et	al.,	2011;	Ismail-Khan	&	Bui,	2010).		
1.2.	The	Tumour	Microenvironment	Previously,	 cancer	 was	 considered	 to	 be	masses	 of	 malignant	 cells,	 in	 which	abnormal	 cell	 growth	 and	 metastasis	 were	 thought	 to	 be	 solely	 driven	 by	genetic	mutations	 (Hanahan	&	 Coussens,	 2012;	Hanahan	&	Weinberg,	 2011).	Recent	 advances	 however	 have	 revealed	 that	 tumours	 are	 complex	 organs	comprised	 of	 a	 variety	 of	 cells	 that	 can	 be	 re-educated	 by	malignant	 cells	 to	drive	tumour	progression	and	metastasis	(Balkwill	et	al.,	2012).		Specifically,	 the	 tumour	 microenvironment	 (TME)	 consists	 of	 non-malignant	cells,	 including	 tumour-infiltrating	 leukocytes	 (TILs),	 stromal	cells,	 fibroblasts	and	cells	of	the	vasculature,	in	addition	to	secreted	factors	such	as	chemokines,	cytokines	and	growth	factors	(Whiteside,	2008).	In	the	context	of	the	immune	system,	it	was	previously	thought	that	tumour-infiltrating	immune	cells	solely	recognized	 and	 eliminated	 cancer	 cells,	 a	 process	 described	 as	 immune	surveillance	 (Burnet,	 1957).	 However,	 later	 research	 has	 revealed	 that,	 in	addition	to	killing	 tumour	cells,	 the	 immune	system	can	even	promote	cancer	progression	 as	 a	 response	 to	 the	 tumour-immune	 cross-talk.	 This	 process	 is	described	 as	 immunoediting	 and	 is	 divided	 into	 three	 phases;	 elimination,	equilibrium	and	escape	(Schreiber	et	al.,	2011,	Dunn	et	al.,	2004).		The	 eliminating	 phase,	 also	 termed	 immune	 surveillance,	 includes	 efficient	elimination	of	 tumour	 cells	by	 innate	and	adaptive	 immune	 responses.	 In	 the	equilibrium	phase,	tumour	cells	evolve	in	response	to	the	immune	pressure	and	new	phenotypes	resistant	to	the	immune	system	emerges.	As	a	consequence,	an	equilibrium	between	 immunogenic	and	non-immunogenic	 tumour	cells	occur.	This	 battle	 between	 the	 tumour	 and	 the	 immune	 system	 might	 occur	 for	several	years	and	is	described	as	the	longest	of	the	three	phases.	In	the	escape	phase	 however,	 the	 balance	 tilts	 towards	 tumour	 progression	 due	 to	 an	extensive	 emergence	 of	 tumour	 cell	 variants	 that	 are	 capable	 of	 evading	 the	immune	 response.	 These	 cells	 do	 not	 only	 become	 non-responsive	 to	 the	
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immune	system’s	defence	but	also	secrete	factors	that	suppresses	the	function	of	or	kill	leukocytes	(Dunn	et	al.,	2006).		Researchers	 increasingly	 emphasise	 the	 potential	 of	 targeting	 components	 of	the	TME,	 in	which	 the	 immune	 cell	 repertoire	 has	 been	of	 particular	 interest	(e.g.	Fang	&	Declerck,	2013;	Shekarian	et	al.,	2015;	Quail	&	Johanna,	2013).	This	type	of	therapy	includes	re-programming	of	immune	cells	towards	phenotypes	capable	 of	 specific	 and	 enhanced	 responses	 against	 the	 tumour.	 Importantly,	targeting	immune	cells	not	only	reduces	the	probability	of	resistance,	but	also	generally	 results	 in	 fewer	 side	 effects	 (Mittendorf	 &	 Hunt,	 2015;	 Soliman,	2013).	However,	 a	 better	understanding	of	 the	 characteristics	 of	 the	 immune	cell	repertoire	and	its	interactions	with	other	components	of	the	TME,	as	well	as	 the	 underlying	 mechanisms	 of	 action,	 is	 required	 in	 order	 to	 develop	efficient	 immune	therapy	strategies	 that	can	 improve	the	 life	of	breast	cancer	patients.			
1.2.1.	The	Inflammatory	Cell	Repertoire	Tumour-related	 inflammation	 can	 be	 induced	 through	 two	 different	 circuits;	the	 extrinsic	 or	 intrinsic	 pathways	 (Mantovani	 et	 al.,	 2008).	 The	 extrinsic	pathway	 is	 triggered	 by	 an	 inflammatory	 condition,	 such	 as	 inflammatory	bowel	disease	or	prostatitis,	which	can	induce	cancer	initiation.	In	contrast,	the	intrinsic	 pathway	 is	 triggered	 by	 oncogenic	 events	 that	 induce	 expression	 of	inflammatory	 pathways,	 such	 as	 leukocyte	 recruitment	 and	 survival,	angiogenesis	and	tumour-cell	homing	to	lymph	nodes	(Mantovani	et	al.,	2008).	Immune	 cells	 infiltrating	 the	 TME	 include	 innate	 immune	 cells	 such	 as	macrophages,	neutrophils,	dendritic	cells	and	myeloid	derived	suppressor	cells,	as	well	 as	 T-lymphocytes	 and	 B-lymphocytes,	which	 are	 part	 of	 the	 adaptive	immune	system.			
	
	
	
  16 
	
	
The	 tumour	 inflammatory	 repertoire	has	 shown	 to	play	a	key	 role	 in	 tumour	progression	 due	 to	 its	 characteristics	 of	 high	 plasticity.	 Interestingly,	 as	 the	tumour	evolves,	inflammatory	cells	can	switch	from	anti-tumorigenic	towards	a	more	pro-tumorigenic	function	in	response	to	cues	from	the	microenvironment	(Lin	 &	 Karin,	 2007;	 Smyth	 et	 al.,	 2008).	 In	 early	 malignancies,	 the	 balance	between	pro-	and	anti-tumorigenic	inflammation	is	generally	tilted	towards	an	anti-tumorigenic	 state,	 which	 protects	 the	 host	 against	 tumour	 progression.	However,	 in	 established	 tumours,	 a	more	 pro-tumorigenic	 inflammation	 that	supports	progression	of	 the	 tumour	 is	evident.	A	consequence	of	 the	 immune	cells	 gradually	 acting	 as	 tumour-promoting	 cells	 is	 a	 decreased	 expression	of	pro-inflammatory	 proteins,	 reduced	 antigen-presenting	 capabilities	 and	secretion	 of	 factors	 that	 promote	 growth	 and	 metastasis	 of	 tumour	 cells	(Grivennikov	 et	 al.,	 2010).	 This	 process	 of	 immune	 cell	 transformation	influences	 the	 tumour’s	 ability	 to	 escape	 the	 immune	 system	which,	 in	 turn,	allows	the	tumour	to	rapidly	progress	into	a	more	aggressive	phenotype.			
Figure	 1.2:	 Leukocyte	 subpopulations	 within	 the	 tumour	 microenvironment.	Leukocytes	 play	 both	 anti-	 and	 pro-tumorigenic	 roles	 during	 tumour	 progression.	Adapted	from	Balkwill	et	al.,	2012	
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1.2.1.1.	Dendritic	Cells	Denditric	 cells	 (DCs)	 play	 an	 important	 role	 in	 the	 communication	 between	innate	and	adaptive	 immunity	by	acting	as	antigen	presenting	cells	(APCs).	 In	cancer,	 DCs	 initiate	 an	 adaptive	 immune	 response	 against	 the	 tumour	 by	recognising	mutated	proteins	 as	 foreign	 (Zitvogel	 et	 al.,	 2008).	These	 tumour	antigens	 are	 captured	 and	 processed	 by	 DCs	 before	 they	 cross-present	 the	antigen	 to	T	helper	 lymphocytes	 (CD4+)	and	cytotoxic	T-lymphocytes	 (CD8+)	which,	 in	 turn,	 initiate	 a	 highly	 specific	 immunological	 response	 against	 the	tumour	 (Steinman	 et	 al.,	 2007;	 Banchereau	 et	 al.,	 2000;	 Banchereau	 et	 al.,	2005).	Accordingly,	studies	have	found	a	positive	association	between	tumour-infiltrating	DCs	and	prolonged	 survival	 in	 a	number	of	different	malignancies	including	breast,	head	and	neck,	lung	and	prostate	cancers	(Lotze,	1997).		During	 tumour	 progression,	 the	 number	 of	 DCs	 within	 the	 TME	 generally	decreases,	which	might	be	explained	by	either	 tumour	driven	secretion	of	DC	apoptotic	factors	or	by	a	decreased	differentiation	of	monocytes	into	DCs,	or	a	combination	of	these	two	mechanisms	(Koido	et	al.,	2005).	Rather	than	guiding	differentiation	of	monocytes	 into	DCs,	breast	cancer	cells	 favor	differentiation	of	 monocytes	 into	 macrophages.	 More	 specifically,	 breast	 cancer	 cells	 have	shown	 to	 secrete	 IL-6,	which	 acts	 together	with	 fibroblast	 secreted	M-CSF	 to	promote	 the	 macrophage	 directed	 differentiation	 (Chomarat	 et	 al.,	 2000).	Additionally,	 a	 reduction	 in	 functionality	 has	 been	 observed	 for	 resident	DCs	that	is	partly	due	to	a	recruitment	of	immature	DCs.		Mature	 DCs	 suppress	 tumour	 progression	 whereas	 immature	 DCs	 promote	tumour	 growth	 and	 angiogenesis	 (Fainaru	 et	 al.,	 2010).	Mature	 DCs	 can	 also	change	 functionality	 in	 response	 to	 cues	 from	 the	 TME	 towards	 more	 pro-tumorigenic	phenotypes	(Cunha	et	al.,	2014,	Markiewski	et	al.,	2008;	Korkaya	et	al.,	2011).	Additionally,	tumour	cells	can	indirectly	suppress	DC	functionality	by	recruiting	and	induce	generation	of	immunosuppressive	cells,	such	as	Tregs	(Liu	 et	 al.,	 2011).	 For	 instance,	 breast	 cancer	 cells	 have	 shown	 to	 induce	expression	of	TGFb	and/or	IL-10	in	DCs	which,	in	turn,	expand	the	number	of	immunosuppressive	 Treg	 cells	 (Aspord	 et	 al.,	 2007).	 In	 summary,	 DCs	 are	 a	
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critical	 mediator	 between	 the	 innate	 and	 adaptive	 immune	 system	 that	 are	crucial	 for	 a	 sophisticated	 and	 specific	 immune	 response	 against	 the	 tumour.	Reduced	 tumour-infiltration,	 combined	 with	 a	 change	 in	 functionality	 of	resident	 DCs	 as	 a	 result	 of	 a	 pro-tumorigenic	 microenvironment,	 is	characteristic	during	tumour	progression.		
1.2.1.2.	B-Lymphocytes	B-lymphocytes	are	part	of	the	adaptive	immune	system	where	they	play	crucial	roles	 in	 the	 humoral	 immune	 response.	 More	 specifically,	 they	 bind	 specific	antigens	via	B-cell	receptors	(BCRs)	and	subsequently	differentiate	into	plasma	cells	 that	 produce	 and	 secret	 large	 amounts	 of	 antibodies.	 Additionally,	 B-lymphocytes	 act	 as	 antigen-presenting	 cells	 and	 secrete	 various	 cytokines	(Browning,	 2006).	 In	 cancer,	 B-lymphocytes	 are	 most	 commonly	 found	 in	lymphoid	structures	adjacent	 to	 the	TME	or	 in	draining	 lymph	nodes	and	are	less	abundant	at	the	invasive	margin	of	tumours	(Balkwill	et	al.,	2012).		The	presence	of	B-lymphocytes	within	the	TME	has	been	associated	with	better	survival	in	breast	and	ovarian	cancer	(Coronella	et	al.,	2001;	Milne	et	al.,	2009).	However,	 other	 studies	 have	 shown	 that	 B-lymphocytes	 are	 capable	 of	promoting	tumour	development	(Qin	et	al.,	1998;	Andreu	et	al.,	2010;	de	Visser	et	 al.,	 2005).	 For	 instance,	 a	 subpopulation	 of	 B-lymphocytes	 described	 as	regulatory	 B-cells	 (Bregs)	 suppress	 immune	 responses	 and	 increase	 tumour	burden	 in	 skin	 cancer	 (Schioppa	 et	 al.,	 2011).	 Accordingly,	 Olkhanud	 et	 al.	(2011)	 found	 an	 association	 between	 the	 presence	 of	 Bregs	 and	 increased	metastasis	 to	 the	 lungs	 when	 employing	 a	 breast	 cancer	 mouse	 model.	Additionally,	 subpopulations	 of	 B-lymphocytes	 have	 been	 shown	 to	 secrete	factors,	such	as	IL-2,	IL-4	and	IL-6,	that	support	tumour-promoting	activity	of	T	helper	 cells	 (Nelson,	 2010).	 Interestingly,	 research	 thus	 shows	 that	 B-lymphocytes	can	either	protect	the	host	from	tumour	development	or	support	tumour	progression.	The	mechanisms	of	action	appear	 to	be	suppression	and	modulation	of	other	immune	cells	rather	than	a	direct	effect	on	the	cancerous	cells.		
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1.2.1.3.	T-Lymphocytes	T-lymphocytes	are	a	broad	and	complex	group	of	 lymphocytes	 that	 is	 further	divided	into	subtypes	based	on	cell	surface	receptors.	T-cells	found	to	infiltrate	the	tumour	site	includes	cytotoxic	T-cells	(CD8+	CD45RO+),	and	T	helper	cells	(CD4+);	 Th1,	 Th2,	 T-regulatory	 cells	 (Tregs)	 and	 Th17	 cells,	 and	 γd	 T-cells	(Fridman	 et	 al.,	 2012).	 The	 different	 roles	 of	 T	 cells	 are	 highly	 complex	 and	highly	dependent	on	the	tumour	context,	in	which	they	are	in	close	interaction	with	 the	 tumour	and	other	cells	of	 the	stroma.	For	 instance,	CD8+	T-cells	are	able	 to	 recognise	 specific	 antigens	 on	 the	 surface	 of	 tumour	 cells	 and	 to	 kill	tumour	 cells	 by	 inducing	 apoptosis	 (Maher	 &	 Davides,	 2004).	 In	 support	 of	these	findings,	correlational	studies	have	identified	an	association	between	the	presence	 of	 CD8+	 cells	 and	 good	 prognosis	 in	 breast	 cancers,	 as	 well	 as	 in	multiple	other	cancer	types	(Fridman	et	al.,	2012;	Mahmoud	et	al.,	2011).		Th1	 and	 Th2	 cells,	 as	 well	 as	 Treg	 and	 Th17	 cells,	 are	 all	 derived	 from	 a	common	 T	 helper	 progenitor	 (Th0).	 Th1	 cells	 have	 been	 shown	 to	 suppress	tumour	 growth	 by	 supporting	 CD8+	 cells	 and	 other	 immune	 cells,	 and	 by	secretion	 of	 cytotoxic	 cytokines	 (such	 as	 IL-2,	 IL-12,	 TNFa	 and	 IFNg)	(Burkholder	et	al.,	2014).	Moreover,	Hung	et	al.	(1998)	reported	that	Th1	cells	secrete	 cytokines	 involved	 in	 recruitment	 and	 activation	 of	 macrophages.	 In	contrast	to	Th1	cells,	Th2	cells	are	generally	found	to	suppress	host	protective	immunity	and	to	promote	angiogenesis.	Th2	cells	are	induced	by	IL-4	and	IL-13	and	 are	 characterised	 by	 high	 expression	 of	 IL-4,	 IL-5,	 IL-6,	 IL-10	 and	 IL-13.	Further,	 Th2	 cytokines	 supports	 polarisation	 of	macrophages	 towards	 an	M2	phenotype.	Once	Th0	cells	have	derived	 into	Th1	or	Th2	cells,	 their	plasticity	decreases	and	they	tend	to	preserve	their	phenotype	(Burkholder	et	al.,	2014).		Treg	 cells	 (Tregs)	 (CD4+,	 CD25+,	 FoxP3+)	 normally	 play	 a	 crucial	 role	 in	 the	regulation	of	autoimmunity	by	maintaining	 tolerance	 to	self-antigens	 (Legoux	et	al.,	2015).	 In	cancer,	Tregs	have	 immunosuppressive	properties	and	 inhibit	Th1	 polarisation	 by	 secretion	 of	 IFNg	 and	 IL-2	 (Bettelli	 et	 al.,	 2006).	Accordingly,	 a	 positive	 correlation	 has	 been	 found	 between	Tregs	 infiltration	and	 invasive	 and	 metastatic	 cancers	 (Sakaguchi,	 2004),	 and	 the	 presence	 of	
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Tregs	in	the	TME	has	been	reported	as	a	predictor	of	poor	prognosis	in	many	cancers	(Oleinika	et	al.,	2012).	Although	it	is	yet	not	fully	understood	how	Tregs	are	 recruited	 to	 the	 tumour,	 trafficking	 is	 presumably	 driven	 by	 cytokines	secreted	from	the	tumour.	For	instance,	Tregs	express	the	chemokine	receptor	CCR4	 that	 binds	 to	 CCL22,	 which	 is	 produced	 by	 many	 types	 of	 tumours.	Differentiation	and	expansion	of	Tregs	within	 the	TME	has	been	shown	 to	be	induced	by	TGFb	(Lippitz,	2013).		The	last	type	of	T	helper	cells	is	defined	as	Th17	cells	due	to	its	high	production	of	IL-17.	However,	Th17	cells	are	also	characterised	by	the	expression	of	IL-2,	IFNg	and	GM	-CSF/CS2.	Th0	cells	are	differentiated	into	Th17	cell	in	response	to	TGFb,	IL-1a,	IL-1b,	IL-6	and	IL-23	(Zou	et	al.,	2006).	Depending	on	the	context,	Th17	 cells	 has	 shown	 to	 perform	 both	 anti-tumorigenic	 and	 pro-tumorigenic	functions	 (DeNardo	 et	 al.,	 2010,	 Gnerlich	 et	 al.,	 2010).	 For	 instance,	 tumour	infiltration	of	Th17	cells	has	been	associated	with	poor	prognosis	 in	prostate,	ovarian,	 colon	and	hepatocellular	 carcinoma	 (Miyahara	et	 al.,	 2008;	 Sfanos	et	al.,	2008;	Zhang	et	al.,	2009),	whereas	a	study	using	a	mouse	model	of	human	melanoma	 (B16)	 reported	 a	 host	 protective	 effect	 of	 Th17	 via	 activation	 of	cytotoxic	T	cells	(Martin-Orozco	et	al.,	2009).		A	more	distinct	population	of	T-cells,	termed	γd	T-cells,	has	shown	an	extensive	interest	 in	 recent	 literature	 (see	Silva-Santos	et	al.,	2015	 for	 review).	Most	T-cells	express	T-cell	receptors	(TCR),	which	is	made	up	of	an	a	and	b	chain,	and	are	 thus	 described	 as	 αβ	 T-cells.	 γd	 T-cells	 however,	 have	 distinct	 TCRs	composed	 of	 an	 γ	 and	 d	 chain,	 which	 in	 turn	 provides	 a	 unique	 antigen	specificity.			In	 similarity	 to	 other	 subgroups	 of	 T-cells,	 γd	 T-cells	 has	 found	 to	 play	 dual	roles	in	tumour	contexts	(Silva-Santos	et	al.,	2015).	Studies	have	reported	that	γd	T-cells	not	only	rapidly	recognize	and	kill	tumour	cells,	but	also	secrete	high	levels	 of	 IFNg	 (Gao	 et	 al.,	 2003).	However,	 sub-phenotypes	 of	 γd	 T-cells	 have	also	 been	 found	 to	 highly	 express	 IL-17,	 which	 promote	 tumour	 growth	
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(Wakita	 et	 al.,	 2010;	 Silva-Santos	 et	 al.,	 2015).	 Further,	 Coffelt	 et	 al.	 (2015),	showed	 that	 IL-17	 producing	 γd	 T-cells	 promote	 metastasis	 of	 mammary	carcinoma	in	mice.	The	functions	of	γd	T-cells	and	their	interconnections	with	the	 immune	cell	network,	as	well	as	 the	surrounding	stroma	are	not	yet	 fully	understood	 and	 requires	 further	 elucidation	 to	 gain	 a	 more	 comprehensive	understanding	of	the	role	of	γd	T-cells	during	tumour	progression.		
1.2.1.4.	Tumour	Associated	Macrophages	Macrophages	located	within	or	in	close	proximity	to	the	tumour	are	defined	as	tumour	 associated	 macrophages	 (TAMs)	 and	 represent	 the	 major	 type	 of	immune	 cells	 infiltrating	 the	 tumour	microenvironment	 (Biswas	 et	 al.,	 2008;	Mantovani	 et	 al.,	 2011a).	 TAMs	 may	 be	 polarised	 from	 resident	 tissue	macrophages,	but	the	majority	of	TAMs	derive	from	circulating	monocytes	that	are	recruited	to	the	site	of	inflammation	in	response	to	signals	from	the	tumour	microenvironment	 (Mantovani	 et	 al.,	 1992;	 Franklin	 et	 al,	 2014).	 More	specifically,	a	wide	variety	of	soluble	factors	produced	by	tumour	and	stromal	cells	 recruit	monocytes	 to	 the	microenvironment	 and	 differentiate	 them	 into	macrophages.	 CCL2	 was	 the	 first	 molecule	 identified	 as	 a	 tumour	 secreted	chemotactic	 factor	 (Mantovani	 et	 al.	 1986),	 and	 later	 investigations	 showed	that	 CCL2	 also	 induce	 polarisation	 and	 survival	 of	 TAMs	 (Gazzaniga	 et	 al.,	2007).	 CCL5	 and	 CXCL1	 has	 also	 shown	 to	 play	 an	 important	 role	 in	monocyte/macrophage	recruitment	(Bierie	&	Moses	2010).	Moreover,	growth	factors	 (VEGF,	PDGF,	TGFβ,	M-CSF/CSF-1)	 (Bierie	&	Moses	2010;	Linde	et	 al.,	2012)	and	non-canonical	chemotactic	peptides	such	as	urokinase	plasminogen	activator	 (uPa),	 basic	 fibroblast	 growth	 factor	 (bFGF),	 lectin	 Reg3b,	 and	 the	antimicrobial	 peptide	b-defensin-3	 (Reed	 et	 al.,	 2012;	Brierie	&	Moses,	 2010;	Gironella	et	al.,	2013;	Mantovani,	2013)	have	been	shown	to	participate	in	the	recruitment	and	polarisation	of	monocytes/macrophages.		The	 monocyte	 to	 macrophage	 lineage	 show	 high	 diversity	 and	 plasticity,	 in	which	different	environmental	signals	direct	the	cells	into	distinct	phenotypes	(Biswas	&	Mantovani,	2010;	Sica	&	Bronte,	2007).	TAMs	either	display	an	anti-tumorigenic	phenotype	defined	as	classical	M1	activated	macrophages	or	a	pro-
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tumorigenic	alternatively	M2	activated	phenotype.	 It	 is	however	 important	 to	note	that	M1	and	M2	states	only	represents	the	opposite	of	two	extremes	in	a	continuum	 with	 a	 range	 of	 different	 phenotypes.	 As	 part	 of	 the	 process	 of	immunoediting,	 anti-inflammatory	 and	 pro-tumorigenic	 factors,	 released	 by	tumour	and	stromal	cells,	skew	TAMs	along	the	continuum	towards	more	pro-tumorigenic	 phenotypes	 (Biswas	 et	 al.,	 2008;	 Mantovani	 et	 al.,	 2013).	 IFNg	alone,	 or	 in	 combination	 with	 cytokines	 (TNF,	 GM-CSF)	 or	 microbial	components	 (e.g.	 LPS),	 induce	polarisation	 towards	an	M1	phenotype	 (Sica	&	Bronte,	 2007;	 Galdiero	 et	 al.,	 2013).	 Classical	 M1	 macrophages	 possesses	inflammatory	 functions	and	are	 involved	 in	Th1	responses,	 resistance	against	microbes	 and	 tumours,	 and	 perform	 tissue	 disruptive	 actions.	 They	 produce	and	secrete	high	levels	of	pro-inflammatory	cytokines	(e.g.	IL-12,	IL-23,	IL-6,	IL-1β,	 TNF)	 and	 show	 low	 expression	 of	 the	 anti-inflammatory	 cytokine	 IL-10.	Additionally,	 M1	 cells	 show	 high	 production	 of	 reactive	 oxygen	 species	 and	reactive	nitrogen	intermediates,	higher	expression	of	major	histocompatibility	complex	class	II	and	Th1	cell-attracting	chemokines	such	as	CXCL9	and	CXCL10	(see	Figure	1.3;	Biswas	&	Mantovani,	2010).			
	
	
	
		In	contrast	to	M1	macrophages,	the	alternative	M2	activated	macrophages	are	induced	 by	 the	 Th2	 cytokines	 IL-4	 and	 IL-13	 (Gordon	&	Taylor,	 2005).	 TGFb	has	also	been	identified	as	a	key	molecule	involved	in	the	polarisation	towards	alternative	 macrophage	 activation	 (Gong	 et	 al.,	 2012).	 M2	 cells	 release	chemokines	such	as	CCL17,	CCL22,	CCL24,	which	is	involved	in	recruitment	of	Treg	 cells,	 Th2	 cells,	 eosinophils	 and	 basophils	 (Mantovani	 et	 al.,	 2008;	
M1 M2
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IL-4 IL-13IL-10
Figure	1.3:	A	simplified	illustration	of	anti-	and	pro-tumorigenic	
macrophages.	Information	retrieved	from	Biswas	&	Mantovani,	2010.		
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Martinez	et	al.,	2006).	They	also	show	high	expression	of	the	anti-inflammatory	cytokine	 IL-10,	 scavenger	 mannose	 and	 galactose-type	 receptors,	 low	expression	of	 the	pro-inflammatory	cytokines	 IL-12	and	 IL-23,	and	have	poor	antigen	 presenting	 capacity	 (Noel	 et	 al.,	 2004;	 Mantovani	 et	 al.,	 2013).	 M2	macrophages	participate	in	the	Th2	response,	suppress	Th1	adaptive	immunity	and	 inflammation,	 they	 promote	 wound	 healing,	 tissue	 remodelling	 and	angiogenesis,	and	have	a	low	tumoricidal	activity	(Biswas	&	Mantovani,	2010).	Several	 research	groups	have	demonstrated	 that	 the	M2-like	pro-tumorigenic	phenotype	is	reversible	(e.g.	Guiducci	et	al.,	2005;	Buhtoiarov	et	al.,	2005).	For	instance,	 Duluc	 et	 al.	 (2009)	 purified	M2-like	 TAMs	 from	 ovarian	 cancer	 and	treated	them	with	IFNγ,	which	caused	the	TAMs	to	switch	towards	an	M1-like	immunostimulatory	phenotype.	Additionally,	up-regulation	of	Notch	signalling	in	 macrophages	 has	 shown	 to	 favour	 M1	 polarisation	 and	 pro-inflammatory	functions	 (Wang	 et	 al.,	 2010).	 This,	 together	with	 the	 evidenced	 plasticity	 of	TAMs,	provides	hope	in	developing	treatment	strategies	that	re-educate	TAMs	towards	tumour-destructive	phenotypes.		It	is	important	to	note	that	the	nature	of	TAMs	is	complex	and	highly	dependent	on	location,	tumour	type	and	grade	(Biswas	&	Mantovani,	2010).	Interestingly,	although	the	presence	of	TAMs	in	the	majority	of	human	and	mouse	tumours	is	correlated	 with	 poor	 prognosis,	 TAM	 infiltration	 in	 some	 tumour	 types	 is	associated	with	a	favorable	outcome	(Galon	et	al.,	2006;	Lewis	&	Pollard,	2006).	For	 example,	 analysis	 of	 clinical	 specimen	 from	 colorectal	 cancer	 patients	showed	 that	 TAM	 infiltration	 was	 positively	 associated	 with	 anti-metastatic	behavior	 and	 overall	 survival	 (Funada	 et	 al.,	 2003).	 Additionally,	 analysis	 of	TAMs	 from	 gastric	 cancer	 patients	 identified	 a	 host-protective	 phenotype	reflected	by	high	cytotoxicity	and	antigen	presentation	capabilities	(Ohno	et	al.,	2003).	 Macrophage	 phenotype	 has	 also	 shown	 to	 be	 dependent	 on	 the	localisation	or	compartmentalisation	within	the	tumour.	In	a	mouse	mammary	tumour	 model,	 M2-like	 TAMs	 were	 found	 to	 be	 localised	 in	 hypoxic	 tumour	areas,	whereas	the	anti-tumorigenic	M1	phenotypes	was	enriched	in	normoxic	tumour	 tissues.	They	also	reported	an	 increase	 in	number	of	pro-tumorigenic	macrophages	as	the	tumour	progressed	(Movahedi	et	al.,	2010).	These	findings	
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demonstrate	 that	 results	 must	 be	 interpreted	 with	 caution	 and	 that	 a	phenotypic	 profiling	 of	 TAMs	 is	 necessary	 in	 prognostic	 and	 therapeutic	contexts.	 In	 conclusions,	 several	 lines	 of	 evidence	 show	 that	 tumour	 cells	exploit	the	plasticity	of	TAMs	by	secreting	factors	that	re-educate	the	immune	cells	towards	phenotypes	that	supports	growth	and	metastasis	of	the	tumour.		
1.2.1.5.	Tumour	Associated	Neutrophils	In	the	circulatory	system,	neutrophils	account	for	50	to	70%	of	total	leukocytes	and	 are	 the	 first	 recruited	 immune	 cells	 at	 the	 site	 of	 inflammation	 and	infections	 (Fridlender	 et	 al.,	 2012).	 However,	 neutrophils	 represent	 only	 a	small	 proportion	of	 the	 leukocyte	 tumour	 infiltrate,	with	macrophages	 as	 the	predominating	 subpopulation	 (Biswas	 et	 al.,	 2008;	 Mantovani	 et	 al.,	 2011a).	Generally,	 neutrophils	 are	 involved	 in	 elimination	 of	 pathogens,	 immune	regulation	 and	 cleavage	 of	 damaged	 tissue,	which	 is	 achieved	by	 secretion	 of	proteases	(Kolaczkowska	&	Kubes,	2013;	Mantovani	et	al.,	2011b).	Neutrophils	have	 been	 implicated	 in	 cancer	 research	 since	 its	 early	 days,	 as	 they	 were	observed	in	close	proximity	to	tumour	cells	in-vivo	(Welch	et	al.,	1989).	Despite	the	 fact	 that	 TAMs	 dominate	 the	 infiltrate,	 tumour	 associated	 neutrophils	(TANs)	 have	 been	 shown	 to	 play	 an	 important	 role	 in	 tumour	 initiation	 and	progression.	 Later	 research	 has	 identified	 TANs	 as	 a	 prognostic	 marker	 for	recurrence	free	and	overall	survival	in	localised	and	metastatic	clear	cell	renal	cell	carcinoma,	as	well	as	in	head	and	neck	squamous	cell	carcinoma	(Donskov	et	al.,	2006;	Jensen	et	al.,	2009;	Trellakis	et	al.,	2011).	TAN	infiltration	has	been	found	to	correlate	with	a	more	aggressive	phenotype	in	pancreatic	cancer	(Reid	et	al.,	2011),	with	a	higher	grade	 in	human	gliomas	(Fossati	et	al.,	1999),	and	with	 a	 poorer	 survival	 in	 metastatic	 melanomas	 (Schmidt	 et	 al.,	 2005).	 In	contrast,	 and	 as	 observed	 for	 TAMs,	 some	 malignancies	 show	 a	 more	favourable	outcome	in	response	to	neutrophilia	(e.g.	gastric	cancer)	(Caruso	et	al.,	2002).		The	 mechanisms	 responsible	 for	 neutrophil	 extravasation,	 translocation	 and	subsequent	 TAN	 polarisation	 are	 poorly	 understood.	 Normally,	 neutrophils	extravasate	and	translocate	to	tissues	under	the	influence	of	specific	cytokines	
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(e.g.	IFNγ	and	TNFα)	and	chemokines	(e.g.	MIP2a/CXCL2	and	KC/CXCL1),	and	by	 interaction	 of	 their	 own	 surface	 adhesion	 molecules	 with	 adhesion	molecules	 on	 the	 surface	 of	 endothelial	 cells	 (Kobayashi,	 2008).	 Several	mediators	released	from	tumour	and	stromal	cells	have	been	suggested	to	play	a	role	 in	the	recruitment	to	tumour	sites.	More	specifically,	high	levels	of	GM-CSF	 have	 been	 associated	 with	 neutrophil	 infiltration	 in	 lung,	 pancreas,	melanoma	and	breast	cancer	(McGary	et	al.,	1995).	In	addition,	G-CSF,	IL-1β,	IL-6	and	VEGF	expression	have	been	suggested	to	induce	neutrophilia	(Lechner	et	
al.,	 2010).	TANs	have	also	been	shown	 to	 initiate	a	positive	 feedback	 loop	by	producing	 CXCL2,	 CXCL1,	 and	 CCL3	 that	 attracts	 more	 neutrophils	 to	 the	tumour	site	(Fridlender	et	al.,	2012).	Moreover,	elevated	expression	of	CXCL6	has	 been	 associated	 with	 neutrophil	 recruitment	 in	 melanoma	 tumours	(Verbeke	et	al.,	2011).	TGFβ	has	also	shown	to	play	a	role	in	recruitment,	as	an	increase	 in	 neutrophil	 counts	 was	 observed	 after	 blockade	 of	 the	 TGFβ	receptor.	This	might	be	due	to	an	impaired	neutrophil	transmigration	along	the	endothelium,	 as	 TGFβ	 is	 shown	 to	 inhibit	 endothelial	 adhesiveness	 for	neutrophils	(Smith	et	al.,	1996;	Allen	et	al.,	2008).	Further,	several	studies	have	found	 that	 T-lymphocytes	 and	 macrophages	 play	 an	 important	 role	 in	neutrophil	 recruitment	 by	 releasing	 neutrophil	 chemo-attracting	 factors	 such	as	IL-17,	CXCL8,	CXCL2	and	CXCL1	(Coffelt	et	al.,	2015;	Benevides	et	al.,	2015;	Himmel	et	al.,	2011;	Richards	et	al.,	2010).			TANs	have	 recently	been	 shown	 to	possess	 similar	plasticity	 as	described	 for	TAMs,	 as	 they	 are	 able	 to	 polarise	 into	 either	 anti-tumorigenic	 (N1)	 or	 pro-tumorigenic	 (N2)	 phenotypes	 in	 response	 to	 different	 external	 stimulus	(Fridlender	et	al.,	2009).	This	observation	can	thus	explain	the	contradictory	roles	reported	for	TANs	(e.g.	Caruso	et	al.,	2002;	Donskov	et	al.,	2006;	Jensen	et	al.,	2009).	TANs	are	polarised	towards	an	N2	phenotype	 in	response	to	TGFβ,	whereas	 IFNβ	 or	 depletion	 of	 TGFβ	 promote	 polarisation	 towards	 an	 anti-tumorigenic	N1	phenotype	(Fridlender	et	al.,	2009).			
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										Host	protective	N1	neutrophils	are	cytotoxic	and	immuno-stimulatory,	whereas	pro-tumorigenic	N2	states	are	immunosuppressive	and	promote	angiogenesis.	N1	 phenotypes	 are	 typically	 characterised	 by	 high	 expression	 of	 chemokines	(e.g.	 Ccl3,	 CXCL9,	CXCL10)	 and	 cytokines	 (e.g.	 IL-12),	GM-CSF,	VEGF,	 and	 low	expression	 of	 Arginase	 I.	 In	 contrast,	 N2	 phenotypes	 show	 a	 strong	 down-regulation	 of	 cytokine	 and	 chemokine	 expression,	 but	 a	 high	 expression	 of	Arginase	II	(Mantovani	et	al.,	2008;	Fridlender	et	al.,	2012).	 In	summary,	TAN	have	been	shown	to	play	similar	dual	roles	in	the	tumour	microenvironment	as	observed	for	TAMs,	in	which	they	are	implied	to	have	an	important	impact	on	tumour	 progression.	 However,	 a	 precise	 understanding	 of	 the	 characteristics	and	mechanisms	 of	 action,	 including	 its	 interactions	with	 the	 tumour	 and	 its	surrounding	stroma,	is	lacking	and	requires	further	elucidation.		
1.3.	Matrix	Metalloproteinases	TAMs	and	TANs	produce	high	levels	of	matrix	metalloproteinases	(MMPs)	that	have	 been	 described	 as	 crucial	modulators	 of	 the	 tumour	microenvironment.	Importantly,	 accumulating	 evidence	 implies	MMPs	 as	 potential	 players	 in	 the	cross-talk	between	tumour	and	stromal	cells.	MMPs	comprise	a	large	family	of	extracellular	 endopeptidases	 that	 fulfil	 a	 variety	 of	 functions	 in	 tissue	remodeling	 processes,	 organ	 development,	 inflammatory	 processes	 and	 in	carcinomas	 (Page-McCaw	 et	 al.,	 2007).	 Twenty-three	 members	 have	 been	identified	 and	 described	 for	 the	 MMP	 family	 in	 humans,	 in	 which	 the	 basic	structure	 is	made	up	of	a	characteristic	pro-peptide,	a	 catalytic	domain	and	a	
oxidative damage caused by reactive oxygen species secreted from
neutrophils are capable of inducing tumor cell lysis (6,103,104).
Interestingly, there seems to be a difference between the cytotoxicity
of neutrophils to primary versus metastatic cells, the latter being less
affected (82). Furthermore, it is possible, as recently shown by Granot
et al. (105), that tumor-entrained neutrophils can actually inhibit met-
astatic seeding in the lungs, inducing a neutrophil-mediated inhibitory
process at the metastatic site.
A second mechanism by which neutrophils were shown to be capable
of directly inhibiting tumor cells is by mediating Fas-ligand-associated
apoptosis (106). This is in line with our observation that an increased
percentage of N1 TAN are Fas positive (6). A third mechanism of
killing mediated by neutrophils, mostly shown following treatment, is
antibody-dependent cellular cytotoxicity (2,107), for example, as part
of the mechanism of the epidermal growth factor receptor antibodies—
panitumumab and zalutumumab (108).
Activation and proper direction of the adaptive immune system and
tumor rejection. The ability of the adaptive immune system, and spe-
cifically the CD8þ cytotoxic T lymphocytes, to reject tumors is a key
process for the success of any immunotherapy. As suggested above, N2
neutrophils can bemajor inhibitors of T-cell effector functions in a similar
way previously proposed for M2 tumor associated macrophages
(6,12,91–93,109). However, others and we have shown that N1 neutro-
phils can actually be immunostimulatory, supporting tumor rejection.
These proinflammatory N1 neutrophils can promote CD8þ recruitment
and activation by producing T-cell attracting chemokines (e.g. CCL-3,
CXCL9 and CXCL10) and pro-inflammatory cytokines (e.g. IL-12,
TNF-a and GM-CSF) (6,63). Furthermore, neutrophils have been shown
to cross-present antigens in vitro, and antigen-pulsed neutrophils pro-
moted the activation of CD8þ T cells (110). Additional examples of
this neutrophil-CD8þ lymphocytes interaction include studies showing
that photodynamic therapy-induced CD8þ T-cell induction required the
presence of neutrophils (91) and that depletion of neutrophils signif-
icantly impaired T-cell trafficking and reduced efficacy of Bacillus
Calmette–Guerin immunotherapy of bladder cancer (97)
There is also evidence that TAN can activate dendritic cells via
cell–cell contact and through secretion of TNF-a (64), activate CD4þ
T cells, promote antitumoral memory (111) and induce IL-12-induced
tumor regression (112). Depletion of these N1 TAN thus either aug-
ments tumor growth and/or blunts the antitumor effects of immuno-
logic treatments (6,49,91,97). Neutrophils can also be involved in the
known ‘bystander’ effect of antitumor treatment with oncolytic viruses.
Breitbach et al. (113) demonstrated that in vivo, most of the tumor
killing activity of vesicular stomatitis and vaccinia viruses is caused
by indirect killing of uninfected tumor cells, mediated by an influx of
neutrophils to the tumor, and that depletion of neutrophils inhibited
their antitumor effects.
Figure 3 summarizes, in a simplified scheme, the pro-tumor and
antitumor effects that have been described in neutrophils, ascribing
these effects to N1 versus N2 TANs.
N1 and N2—polarization or hyperactivation?
In their recent review on TAN as targets for cancer therapy (7), Gregory
and Houghton raised the interesting question whether the differences
between N1 and N2 TAN were due to two unique transcriptional
programs as suggested in our work (6) or instead represented two
states of activation, i.e. that N1 TANs produce the same mediators,
but at higher levels. In our unpublished data, comparing the mRNA
expression of N1 versus N2 TAN, we found that a vast majority of the
changes were indeed upregulation of the same genes and pathways in
N1 TAN compared with N2 TAN. However, there were some clear
exceptions. For example, we noted that the chemokine CCL-17
(which attracts T regulatory cells) was much more highly expressed
in N2 TAN than in N1 TAN. The important question whether TAN can
be manipulated to undergo frank irreversible polarization or possibly
reversible activation states remains unresolved and should be a matter
of further research.
Summary
It is becoming increasingly clear that TAN play a major role in cancer
biology. TAN are a distinct population of neutrophils, which in their
basic unmanipulated state are induced by the tumor microenviron-
ment (by TGF-b and probably other factors) to elicit pro-tumor
responses (N2 TAN). However, recent evidence shows that these cells
can be altered to assume antitumor roles (N1 TAN). Neutrophils are
thus an important underappreciated cell population in cancer biology,
and their functions need to be better characterized. A more complete
under tanding of the way these cells support or fight cancer will be
important to develop strategies to direct the immune system against
tumors.
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Fig. 3. A simplified schematic representation summarizing the pro-tumor
and antitumor effects that have been described in neutrophils.
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Figure	 1.4:	 A	 simplified	 illustration	 of	 anti-	 and	 pro-
tumorigenic	neutrophils. IFNb	and	TGFb	are	key	players	in	polarisation	 of	 neutrophil	 phenotypes.	 Adapted	 from	Fridlender	&	Albelda	(2012). 
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hemopexin-like	C-terminal	domain.	Additionally,	a	flexible	hinge	region	links	to	the	catalytic	domain	to	the	C-terminal	domain.	Based	on	variations	 in	domain	arrangements	as	well	as	 substrate	specificity,	MMPs	has	been	 further	divided	into	 five	 subgroups;	 collagenases,	 stromelysins,	 gelatinases,	 matrilysins	 and	membrane-type	MMPs.		Collagenases	 (MMP1,	MMP8,	MMP13,	 and	 in	 some	 species,	MMP18)	 are	 best	known	to	cleave	collagen	I,	II	and	III	into	¼	and	¾	length	fragments	(Sun	et	al.,	2000).	The	collagenases	recognize	a	sequence	within	the	collagen	which	span	about	30	residues	(Fields,	1991;	Minond	et	al.,	2006;	Minond	et	al.,	2007).	The	N-terminal	 of	 this	 cleavage	 site	 consist	 of	 a	 tight	 wound	 helix	 rich	 in	 imino	amino	 acids,	whereas	 the	 C-terminal	 side	 contains	 a	 loos	 triple-helix	 poor	 in	imino	 acids.	 The	 loos	 triple-helix	 are	 unwound	by	 collagenases	 prior	 binding	and	subsequent	cleavage	of	the	a	chains	(Fields,	1991).	In	addition	to	collagens,	collagenases	have	shown	to	digest	other	molecules	and	soluble	proteins	in	the	extracellular	 matrix	 (ECM)	 (Visse	 &	 Nagase,	 2003).	 Stromelysins	 (MMP3,	MMP10,	MMP11)	are	similar	to	collagenases	by	domain	arrangement	but	have	different	 substrate	 specificity.	 For	 instance,	 MMP3	 and	 MMP10	 cleave	 the	majority	 of	 ECM	 molecules	 and	 activate	 proMMPs	 (Murphy	 et	 al.,	 2002).	 In	contrast,	MMP11	weakly	degrades	ECM	molecules,	but	play	important	roles	in	the	cleavage	of	serpins	(Murphy	et	al.,	1993;	Pei	et	al.,	1994).			Gelatinases	 (MMP2	 and	 MMP9)	 cleave	 gelatins	 and	 various	 ECM	 molecules,	including	 laminin,	 collagens	 (type	 IV,	 V	 and	 XI)	 and	 aggregan	 core	 protein	(Nagase	et	al.,	2006).	Further,	MMP2	cleaves	collagen	 I,	 II,	and	 III	 in	a	similar	fashion	 as	 collagenases	 (Aimes	 &	 Quigley,	 1995).	 Furthermore,	 Matrilysins	(MMP7	and	MMP26)	are	classified	based	on	their	lack	of	a	hemopexin	domain	(Ló	pez-Otıń	et	al.,	2009).	Mechanistically,	MMP7	processes	ECM	molecules	and	cell	 surface	 molecules	 such	 as	 pro-a-defensin,	 E-cadherin	 and	 pro-tumour	necrosis	 factor	 a.	 MMP26	 also	 processes	 several	 ECM	 components,	 but	 in	contrast	to	most	MMPs,	the	proteinase	 is	stored	intracellularly	(Marchenko	et	al.,	 2004).	 Lastly,	 membrane-type	 MMPs	 (MMP14,	 MMP15,	 MMP16,	 MMP17,	MMP24,	MMP25)	are	transmembrane	proteins,	except	for	MMP17	and	MMP25,	
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which	 are	 glycosylphosphatidylinositol-anchored	 proteins.	 However,	 all	membrane-type	MMPs,	which	have	a	furin	recognition	sequence,	are	activated	intracellularly	 before	 they	 are	 expressed	 on	 the	 cell	 surface.	 Further,	 all	membrane-type	 MMPs,	 with	 the	 exception	 of	 MMP17,	 participate	 in	 the	activation	of	proMMP2	(Murphy	et	al.,	2002;	English	et	al.,	2000).			In	 general,	 MMPs	 are	 secreted	 as	 inactive	 pro-enzymes	 that	 are	 dependent	upon	 other	 molecules	 to	 become	 proteolytic	 activated.	 Mechanistically,	 the	enzyme	is	maintained	inactive	by	a	pro-domain	consisting	of	a	cysteine	residue	interacting	with	a	Zn2+	 ion	at	 the	active	site.	Modification	of	 the	cysteine	thiol	group,	 or	 removing	 the	 pro-domain	 by	 proteolysis,	 will	 disrupt	 the	 blocking	mechanism	and	convert	the	enzyme	into	its	active	form,	a	process	described	as	the	cysteine-switch	mechanism	(Visse	&	Nagase,	2003)	(see	Figure	1).																				
Figure	1.5:	MMP	activation	by	the	cysteine-switch	mechanism. The	MMP	is	activated	upon	removal	of	the	cysteine	thiol	group.	Adapted	from	VanLint	&	Libert	(2006). 
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Reactive	oxygen	 species	 and	 some	proteases	 (such	as	MMPs	and	 trypsin)	 are	among	 molecules	 that	 have	 been	 shown	 to	 activate	 MMPs	 (Van	 Wart	 &	Birkedal-Hansen,	1990;	Knauper	et	al.,	1993;	Balbin	et	al.,	1998;	Knauper	et	al.,	1996;	Holopainen	et	al.,	2003;	Okamoto	et	al.,	1997).	Providing	a	spatial	control	of	enzymatic	activity,	MMPs	can	be	cleaved	at	both	the	cell	surface	and	in	the	peri-cellular	 environment.	 Additionally,	 MMPs	 are	 controlled	 by	 specific	inhibitors,	 such	 as	 tissue	 inhibitors	 of	 metalloproteinases	 (TIMPs),	 RECK,	alpha-macrogobulins	and	some	serine	protease	inhibitors	(e.g.	Egeblad	&	Werb,	2002;	Oh	et	al.,	2001;	Barrett,	1981;	Herman	et	al.,	2001).	Four	different	TIMPs	(TIMP-1,	TIMP-2,	TIMP-3,	and	TIMP-4)	are	expressed	by	vertebrates,	in	which	all	 types	 form	 1:1	 stoichiometric	 complexes	 with	 proteolytic	 active	 MMPs.	Consequently,	enzyme	activity	is	inhibited	(Egeblad	&	Werb,	2002).	TIMPs	also	inhibits	 other	 metalloproteinase	 families,	 including	 a	 disintegrin	metalloproteinase	 (ADAM)	 and	 a	 disintegrin	 and	 metalloproteinase	 with	thrombospondin	 motifs	 (ADAMTS)	 families.	 These	 metalloproteinases	 are	 in	close	 relation	 to	 MMPs	 and	 also	 play	 important	 roles	 in	 tissue	 remodeling	processes	 (see	 Edwards	 et	 al.,	 2008	 and	 Porter	 et	 al.,	 2005	 for	 extensive	reviews).			RECK	 is	 a	 GPI-anchored	 glycoprotein	 that	 inhibits	 MMP2,	 MMP9	 and	membrane	type-1	MMP	(MT1-MMP)	and,	that	has	been	shown	to	downregulate	the	 levels	 of	 and	 activate	 MMP9	 and	 MMP2,	 respectively	 (Oh	 et	 al.,	 2001;	Takahashi	 et	 al.,	 1998).	 Further,	 the	 serine	 protease	 inhibitor	 tissue	 factor	pathway	 inhibitor-2	 (TFPI-2),	 has	 been	 shown	 to	 inhibit	 several	 MMPs,	including	 MMP1,	 MMP2,	 MMP9	 and	 MMP13	 (Herman	 et	 al.,	 2001).	 The	mechanism	 of	 action	 of	 both	 RECK	 and	 TFPI-2	 is	 poorly	 understood.	 Plasma	alpha2-macroglobulins	 however,	 are	 known	 to	 inhibit	 endopeptidases	 by	proteolysis	of	 the	 ‘bait’	region	causing	a	conformational	change	that	 traps	the	proteinase	within	the	macroglobulin.	This	inhibitor	in	able	to	trap	both	MMPs	and	 ADAMs	 (Barrett,	 1981).	 Together	 with	 other	 proteases	 and	 protease	inhibitors,	metalloproteinases	 form	 a	 complex	 network	 in	 the	 ECM,	 in	which	proteolytic	 activity	 is	 dependent	 upon	 direct	 interaction	 between	 different	proteases	 and	 their	 interaction	with	 protease	 inhibitors.	 This	 interconnected	
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network	 is	described	as	the	 ‘protease	web’	and	is	responsible	 for	maintaining	homeostasis	 in	 the	 ECM.	 Importantly,	 dysregulation	 of	 the	 protease	web	 has	been	 linked	 to	 several	 pathologies	 including	 inflammatory	 conditions	 and	cancer	(Decock	et	al.,	2011).			
1.3.1.	MMPs	in	Cancer	MMPs	has	been	implicated	in	cancer	research	for	almost	half	a	century.	Initially,	MMPs	were	thought	to	mediate	degradation	of	the	ECM,	leading	to	tumour	cell	invasion	 and	 metastasis	 (Liotta	 et	 al.,	 1980).	 Inhibition	 of	 MMPs	 was	 then	shown	 to	 suppress	 the	 invasive	and	metastatic	behaviour	of	 tumours	 in	mice	(Reich	 et	 al.,	 1988;	 Sledge	 et	 al.,	 1995).	 Due	 to	 these	 compelling	 results,	synthetic	metalloproteinase	inhibitors	(MPIs)	were	developed	and	routed	into	clinical	 trials	 (e.g.	 see	 Coussens	 et	 al.,	 2002	 for	 an	 extensive	 review).	Surprisingly,	 the	 inhibitors	 failed	 the	 trials,	 in	 which	 an	 increase	 of	 patient	survival	 was	 not	 identified	 as	 predicted	 (e.g.	 Bramhall	 et	 al.,	 2001;	 Brown,	2000)	 and	 some	 patients	 even	 showed	 poorer	 survival	 rate	 compared	 to	 the	placebo	group	(e.g.	Moore	et	al.,	2003).		The	disappointing	results	from	the	clinical	trials	led	MMP	research	into	a	new	paradigm.	 MMPs	 were	 no	 longer	 considered	 solely	 as	 pro-tumorigenic,	 as	MMPs	 were	 shown	 to	 possess	 more	 complex	 functions	 within	 the	 tumour	microenvironment	 during	 tumour	 progression.	 For	 instance,	 in	 addition	 to	their	 roles	 in	 physiological	 processes	 such	 as	 tissue	 remodelling,	MMPs	were	shown	to	regulate	a	variety	of	signalling	molecules	in	the	ECM	involved	in	cell	proliferation,	 apoptosis,	 vascularisation,	 inflammation,	 tissue	 invasion	 and	metastasis	(see	Kessenbrock	et	al.,	2010	and	López-Otıń	&	Matrisian,	2007	for	detailed	 reviews).	 In	 addition,	 by	 acting	 as	 regulators	 of	 the	 tumour	microenvironment,	 MMPs	 also	 provided	 suppressive	 effects	 against	 the	tumour,	which	was	identified	as	a	major	reason	of	MPIs	failing	the	clinical	trials	(López-Otıń	 et	 al.,	 2009).	 Interestingly,	 studies	 revealed	 that	 some	 MMPs	possessed	both	pro-	and	anti-tumorigenic	 functions,	depending	on	 the	source	of	 the	MMPs,	 disease	 stage	 and	 tumour	 type	 (Lopez-Otin	 &	Matrisian,	 2007;	Martin	 &	 Matrisian,	 2007).	 For	 instance,	 MMP3	 was	 first	 shown	 to	 promote	
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mammary	 tumorigenesis	 in	 mice	 (Sternlicht	 et	 al.,	 1999),	 whereas	 a	 more	recent	 study	 using	Mmp3-null	mice	 reported	 a	 reduced	 initial	 growth	 rate	 of	squamous	cell	carcinoma	tumours	(McCawley	et	al.,	2004).	Such	dual	roles	have	also	 been	 described	 for	MMP9,	MMP11	 and	MMP19	 (Egeblad	&	Werb,	 2002;	Coussens	et	al.,	2000;	Andarawewa	et	al.,	2003;	Pendas	et	al.,	2004;	Jost,	2006).	Additionally,	 some	 MMPs	 such	 as	 MMP8,	 MMP12,	 MMP26,	 were	 shown	 to	solely	 provide	 protective	 effects	 during	 tumour	progression	 (e.g.	 reviewed	 in	López-Otıń	et	al.,	2009).	Of	these,	MMP8	turned	out	to	be	the	most	extensively	studied	 tumour-suppressive	MMP,	 in	which	accumulating	evidence	 show	 that	MMP8	play	an	important	role	in	the	regulation	of	immune	cell	infiltration	(e.g.	Balbin	et	al.,	2003a;	Decock	et	al.,	2015).		
1.4.	Matrix	Metalloproteinase	8	MMP8	is	a	member	of	the	collagenase	subfamily	of	MMPs	and	is	also	known	as	collagenase-2	 or	 neutrophil	 collagenase.	 This	 enzyme	 is	 expressed	 by	neutrophils	 and	 stored	within	 intracellular	 granules	prior	 to	 secretion,	which	causes	 a	 high	 degree	 of	 glycosylation	 (Hasty	 et	 al.,	 1990).	 Later	 studies	 have	however	revealed	the	protein	is	not	only	produced	by	neutrophils,	but	also	by	macrophages,	 fibroblasts,	 epithelial	 cells,	 keratinocytes,	 endothelial	 cells,	chondrocytes	and	plasma	cells.	Importantly	however,	secretion	from	these	cells	are	mainly	associated	with	an	inflammatory	condition.	The	cells	lack	the	ability	to	 store	 in	 granules	 and	 thus	 promptly	 secrete	 the	 protein	 following	expression,	which	 is	 reflected	by	 its	poor	degree	of	glycosylation	and	smaller	molecular	 weight	 compared	 to	 neutrophil	 derived	 MMP8	 (Kiili	 et	 al.,	 2002;	Kostamo	 et	 al.,	 2005;	 Hanemaaijer	 et	 al.,	 1997;	 Bergmann	 et	 al.,	 1989;	Devarajan	et	al.,	1991;	Hasty	et	al.,	1990).	MMP8	is	most	frequently	secreted	as	a	soluble	protein	localised	in	the	ECM.	In	some	cases,	however,	the	proteinase	appears	as	a	membrane-bound	protein	 that	has	shown	to	be	more	stable	and	resistant	to	inhibition	by	TIMPs	(Owen	et	al.,	2004).		MMP8	 is	 secreted	 as	 an	 inactive	 pro-peptide	 that	 requires	 breakage	 of	 a	peptide	 bond	 to	 open	 the	 catalytic	 site	 (Cauwe	 &	 Opdenakker,	 2010).	 The	peptide	 bond	 can	be	disrupted	 via	 proteolysis	 or	 autocatalysis	 by	proteolytic	
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cleavage	or	oxidative-/nitrosative	stress,	respectively.	For	instance,	pro-MMP8	has	 been	 shown	 to	 be	 activated	 by	 MT1-MMP	 (Holopainen	 et	 al.,	 2003),	chemotrypsin	and	the	neutrophil	serine	protease,	Cathepsin	G	(Knauper	et	al.,	1999).	Hydrogen	peroxide	(H2O2)	and	reactive	nitrogen	intermediates	such	as	nitrogen	 dioxide	 (NO2)	 and	 peroxynitrite	 (ONOO-)	 has	 also	 been	 shown	 to	convert	 pro-MMP8	 into	 its	 active	 form	 (Okamoto	 et	 al.,	 1997;	 Cauwe	 &	Opdenakker,	2010;	Saari	et	al.,	1990).		Once	activated,	MMP8	efficiently	cleaves	type	I,	II	and	III	collagens	conferring	a	critical	 function	 in	 tissue	 remodeling	 processes	 during	 wound	 healing	 and	inflammatory	 conditions	 (VanLint	 &	 Libert,	 2006).	 In	 addition,	 MMP8	 has	shown	 to	 cleave	 other	 extracellular	 proteins,	 such	 as	 chemokines,	 growth	factors,	cell	adhesion	proteins,	and	protease	inhibitors	(e.g.	Van	den	Steen	et	al.,	2003a;	 Van	 den	 Steen	 et	 al.,	 2003b;	 Tester	 et	 al.,	 2007).	 Cleavage	 results	 in	activation	 or	 inhibition	 of	 the	 substrate	 that,	 in	 turn,	 activates	 or	 inhibit	 a	biologic	 activity.	 Due	 to	 a	 wide	 range	 of	 substrates,	 MMP8	 is	 involved	 in	 a	variety	 of	 processes	 in	 the	 extracellular	 matrix,	 including	 breakdown	 of	 the	ECM	as	well	as	release	and	activation	of	signaling	factors.		
1.4.1.	MMP8	in	Wound	Healing	Wound	healing	 is	 a	 natural	 response	 to	 tissue	 injury	were	 damaged	 and	 lost	cellular	structures	and	tissue	are	replaced.	Crucial	in	this	process	is	the	MMP-driven	degradation	of	ECM	components.	The	most	abundant	protein	in	the	ECM	is	collagens,	which	consists	of	three	polypeptide	alpha	chains	that	can	only	be	degraded	by	collagenases,	especially	MMP1,	MMP8	and	MMP13	(Xue	&	Jackson,	2015).			MMP8	is	the	main	collagenase	produced	by	healing	wounds	and	has	thus	been	suggested	to	play	a	crucial	role	in	wound	healing	(Pirila	et	al.,	2001;	Nwomeh	et	al.,	 1999).	 Interestingly,	 studies	 using	 Mmp13-null	 mice	 has	 reported	 an	increased	secretion	of	MMP8	at	the	site	of	wounding,	which	is	suggestive	of	a	compensation	 mechanism	 that	 results	 in	 a	 restoration	 of	 wound	 healing	(Hartenstein	 et	 al.,	 2006).	 Gutiérrez-Fernández	 et	 al.	 (2007)	 investigated	
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MMP8’s	 individual	contribution	to	the	healing	process	by	knocking	out	MMP8	in	 a	 mouse	 model	 for	 cutaneous	 wound	 healing.	 They	 reported	 a	 delay	 in	wound	closure	and	re-epithelialization	in	response	to	the	MMP8	ablation.	They	also	 found	 a	 delay	 in	 neutrophil	 infiltration	 at	 early	 stages	 and	 a	 sustained	inflammation	at	 later	 time	points,	 suggesting	 that	 the	MMP8	effect	on	wound	closure	 is	 propagated	 via	 innate	 immune	 pathways.	 The	 altered	 immune	response	was	accompanied	by	an	alteration	in	the	TGFβ1	signaling	pathway,	an	up-regulation	of	MMP9	and	an	inhibition	of	neutrophil	apoptosis.	Bone	marrow	transplantation	 from	 Mmp8-wild-type	 mice	 rescued	 the	 observed	 delay	 in	wound	 closure	 in	Mmp8-null	 mice	 suggesting	 that	 the	 effect	 is	 solely	 due	 to	absence	of	MMP8	in	inflammatory	cells	derived	from	the	bone	marrow.			Taken	together,	these	results	demonstrate	that	MMP8	play	an	essential	role	in	wound	 healing.	 Although	 results	 suggest	 that	 MMP8	 acts	 via	 immune	regulatory	 pathways,	 the	 precise	 role	 of	 MMP8	 in	 the	 course	 of	 cutaneous	wound	repair	is	still	largely	unclear	and	requires	further	investigations.		
1.4.2.	MMP8	in	Cancer	In	 addition	 to	 its	 role	 during	 normal	 wound	 healing,	 MMP8	 has	 also	 been	implied	 in	 a	 variety	 of	 inflammatory	 conditions,	 including	 cancer.	 The	 first	study	to	demonstrate	its	anti-tumorigenic	role	during	tumour	progression	was	performed	 in	 the	 context	 of	 a	 skin	 cancer	mouse	model.	 Balbin	 et	 al.	 (2003)	showed	that	knocking	out	MMP8	in	male	mice	strongly	increased	skin	tumour	incidence.	Interestingly,	a	similar	change	was	not	observed	in	female	knock-out	mice.	However,	removal	of	the	ovaries	or	treatment	with	the	estrogen	receptor	antagonist,	tamoxifen,	resulted	in	an	increased	tumour	susceptibility	compared	to	 wild	 type	 animals.	 These	 results	 suggest	 that	 ovarian	 estrogen	 protects	against	tumour	formation	in	female	Mmp8-null	mice,	at	least	in	skin	carcinoma.	Furthermore,	bone	marrow	transplantation	restored	the	effect,	 indicating	that	MMP8	produced	 from	bone	marrow	hematopoietic	 stem	cells	are	responsible	for	the	primary	effect.		
  34 
In	line	with	the	findings	by	Balbin	et	al.	(2003),	Korpi	et	al.	(2008)	reported	a	positive	 association	 between	 MMP8	 expression	 and	 improved	 survival	 in	tongue	 cancer,	 in	 which	 the	 tendency	 was	 stronger	 in	 females.	 The	 same	research	 group	 revealed	 that	 estrogen	 induces	 MMP8	 expression	 in	 HSC-3	tongue	 carcinoma	 cells,	 and	 that	 MMP8	 cleaves	 both	 α	 and	 β	 estrogen	receptors.	 In	 addition	 to	 a	 link	 between	 MMP8	 and	 estrogen,	 Balbin	 et	 al.	(2003)	showed,	by	histopathological	analysis	of	tumour	sections,	that	depletion	of	 MMP8	 induces	 a	 sustained	 inflammation	 at	 later	 stages	 of	 tumour	development,	 which	 suggests	 a	 defect	 in	 restoring	 the	 cancer-related	inflammation.	MMP8	dependent	regulation	of	the	inflammatory	response	is	 in	line	with	results	generated	from	wound	healing	mouse	experiments	(Gutiérrez-Fernández	 et	 al.,	 2007).	 Altogether,	 these	 results	 suggest	 that	MMP8	have	 an	estrogen	 related	 role	 in	 tumour	 growth,	 as	 well	 as,	 acting	 as	 a	 regulator	 if	inflammatory	pathways.		Tumour-suppressor	effects	of	MMP8	have	also	been	reported	for	human	breast	cancer,	 in	 which	 down-regulation	 and	 up-regulation	 of	 MMP8	 in-vitro	 has	resulted	in	increased	or	decreased	metastatic	behavior,	respectively	(Montel	et	al.,	 2004).	 Analysis	 of	 clinical	 breast	 tumour	 specimen	 has	 supported	 these	findings,	 in	which	an	 inverse	correlation	between	 lymph	node	metastasis	and	MMP8	 expression	 has	 been	 identified	 (Decock	 et	 al.,	 2007).	 Further,	 MMP8	expression	has	been	shown	to	facilitate	cell	adhesion	to	ECM	that	might	directly	suppress	metastasis	 (Gutierrez-Fernandez	 et	 al.,	 2008).	 A	more	 recent	 study	reported	a	positive	association	between	MMP8	serum	levels	and	disease	stage,	degree	 of	 necrotic	 tumour	 tissue	 and	 blood	 neutrophil	 count	 in	 colorectal	cancer.	 MMP8	 serum	 levels	 were	 also	 positively	 associated	 with	 tumour-destroying	inflammatory	infiltration,	low	grade	Crohn’s-like	lymphoid	reaction	(CLR),	 distant	 metastasis	 and	 low	 body	 mass	 index	 (BMI)	 (Väyrynen	 et	 al.	2011).		In	concurrence	with	these	findings,	Decock	et	al.	(2015)	reported	a	significant	increase	 in	 tumour	 growth	 and	 lung	 metastasis	 in	 MMTV-PyMT;	Mmp8-null	mice	 compared	 to	 wild-type	 littermates.	 They	 also	 identified	 an	 increase	 in	
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angiogenesis	 and	 neutrophil	 infiltration	 at	 later	 stages	 of	 development,	 in	which	the	latter	confirms	findings	reported	by	earlier	wound	healing	and	skin	tumour	mouse	experiments	(Decock	et	al.,2015;	Balbin	et	al.	2003;	Gutierrez-Fernandez	 et	 al.,	 2007).	 In	 summary,	 these	 results	 clearly	 demonstrate	 the	suppressive	role	of	MMP8	in	breast	cancer	growth	and	metastasis,	additionally,	they	 suggest	 that	 MMP8	 exerts	 such	 effects	 by	 inducing	 pleiotropic	 changes	within	 the	 tumour	 microenvironment.	 However,	 a	 better	 insight	 into	 the	mechanistic	 actions	 of	 MMP8	 is	 required	 to	 understand	 the	 precise	 role	 of	MMP8	during	mammary	carcinoma	progression.		Although	the	underlying	mechanisms	responsible	for	the	effect	on	immune	cell	infiltration	is	largely	unknown,	recent	studies	have	implied	that	MMP8	act	as	a	modulator	 of	 neutrophilic	 chemotactic	 factors.	 Studies	 have	 reported	 that	MMP8	 activates	 both	 human	 interleukin-8	 (IL-8)	 and	 its	 mouse	 orthologue	lipopolysaccharide	 induced	 CXC	 chemokine	 (LIX),	 which	 is	 necessary	 for	 the	recruitment	of	neutrophils	 to	 the	site	of	 tissue	damage	or	 infection	(Tester	et	al.,	2007;	Philippe	et	al.,	2003).	Later	 investigations	have	shown	that	catalytic	active	MMP8	 induce	 expression	 of	 IL-6	 and	 IL-8	 in	 human	 breast	 cancer	 cell	lines	via	NF-	kB,	and	that	 IL-8	and	 IL-6	act	 through	autocrine	 loops	 to	 induce	expression	 of	 IL-6	 and	 MMP8,	 respectively	 (Thirkettle	 et	 al.,	 2013).	Additionally,	MMP8	has	been	shown	to	mediate	generation	of	the	fragment	N-acetyl	 Pro-Gly-Pro	 (PGP),	 which	 is	 a	 neutrophilic	 chemotactic	 peptide	 acting	through	CXC	chemokine	 receptors	on	granulocytes	 (Weathington	et	 al.,	 2006;	Rocks	 et	 al.,	 2008).	 Lin	 et	 al.	 (2008)	 described	 MMP8	 as	 a	 facilitator	 of	neutrophil	 migration	 through	 matrix	 by	 degradation	 of	 collagens	 and	production	 of	 PGP.	 In	 summary,	 these	 results	 strongly	 imply	 MMP8	 as	 a	regulator	of	the	neutrophil	chemotaxis	by	biologically	activate	relevant	chemo-attractants	 that,	 in	 turn,	 orchestrate	 recruitment	 of	 neutrophils	 to	 the	 site	 of	inflammation.		A	mutational	analysis	of	human	melanoma	identified	that	MMP8	is	 frequently	mutated	and	that	reduced	enzyme	activity	is	a	consequence	of	five	of	the	most	common	mutations	(Palavalli	et	al.,	2009).	Further,	expression	of	mutant	MMP8	
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inhibited	 growth	 of	 human	melanoma	 cells	 in-vitro	 and	prevented	melanoma	progression	 in-vivo	 (Palavalli	 et	 al.,	 2009).	 Decock	 et	 al.	 (2008)	 investigated	MMP8	gene	variations	in	breast	cancer,	and	identified	an	association	between	four	 single	 nucleotide	 polymorphism	 (SNPs)	 and	 lymph	 node	 metastasis.	Moreover,	 one	 of	 the	 SNPs	 (a	minor	 T-allele)	 located	 in	 the	 promoter	 region	was	associated	with	a	reduced	relapse	and	increased	survival,	in	particularly	in	early	 stage	 cancers.	 Subsequent	 in-vitro	 experiments	 revealed	 a	 higher	promoter	activity	from	the	T-allele	compared	to	the	C-allele,	which	is	consistent	with	 a	more	 favourable	 outcome.	 Accordingly,	 González-Arriaga	 et	 al.	 (2008)	identified	 an	 association	 between	 polymorphism	 in	 the	 promoter	 region	 of	MMP8	and	a	lower	risk	of	developing	lung	cancer	or	a	decreased	progression	in	lung	cancer	patients.		In	 conclusions,	 several	 lines	 of	 evidence	 have	 shown	 that	 MMP8	 plays	 an	important	 role	 in	 suppressing	 growth	 and	 metastasis	 of	 tumour	 cells.	Subsequent	 studies	 have	 implied	 that	MMP8	 acts	 via	 the	 immune	 system	 by	modulating	factors	involved	in	myeloid	cell	recruitment.	Despite	these	findings,	the	 mechanism	 of	 action	 is	 largely	 unknown	 and	 further	 investigation	 is	required	in	order	to	achieve	a	precise	and	holistic	understanding	of	the	tumour	opposing	actions	of	MMP8.		
1.5.	Background	and	Aims	It	 is	well-documented	 that	MMP8	has	 a	 suppressive	 effect	 on	 tumour	growth	and	 metastasis	 (Lopez-Otin	 &	 Matrisian,	 2007;	 Decock	 et	 al.,	 2011).	 In	 the	context	 of	 breast	 cancer,	 in-vivo	models	 and	 analysis	 of	 clinical	 breast	 cancer	specimen	 have	 shown	 a	 positive	 correlation	 between	 MMP8	 expression	 and	improved	 survival	 of	 mammary	 carcinoma	 (Decock	 et	 al.,	 2007;	 Gutierrez-Fernandez	 et	 al.,	 2008).	 Further,	 Decock	 et	 al.	 (2015)	 showed	 that	 MMP8	depletion	 promoted	 tumorigenesis	 and	 lung	 metastasis	 in	 a	 MMTV-PyMT	mammary	 carcinoma	 model.	 However,	 the	 mechanism	 affected	 by	 MMP8	during	tumorigenesis	is	poorly	understood.	MMP8	has	recently	been	linked	to	regulation	 of	 TGFβ	 signaling	 (Thirkettle	 et	 al.,	 2013;	 Soria-Valles	 et	 al.,	 2013;	Wen	 et	 al.,	 2015).	 TGFβ	has	been	 identified	 as	 a	 key	player	 in	 the	process	 of	
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polarisation	of	macrophages	and	neutrophils	towards	their	tumour	promoting	phenotypes	M2	and	N2,	respectively.	Further,	blockade	of	TGFβ	has	shown	to	switch	 the	polarisation	 towards	 their	M1	 and	N1	 counterparts	 (Fridlender	 et	al.,	2009;	Gong	et	al.,	2012),	but	the	mechanism	promoting	this	switch	is	poorly	understood.	A	 recent	 study	suggests	a	mechanism	of	a	MMP8	mediated	TGFβ	blockade,	 in	 which	 MMP8	 cleaves	 the	 ECM	 protein	 Decorin	 that	 results	 in	release	of	a	core	protein	that,	in	turn,	acts	to	sequester	TGFβ	(Soria-Valles	et	al.,	2013).	 Based	 on	 these	 findings,	 MMP8	 is	 hypothesised	 to	 oppose	 tumour	malignancy	through	an	effect	on	the	innate	immune	system.	More	specifically,	MMP8	 is	 thought	 to	 sequester	 TGFβ	 that	 in	 turn	 switches	 neutrophil	 and	macrophage	 polarisation	 of	 pro-tumorigenic	N2	 and	M2	 phenotypes	 towards	their	anti-tumorigenic	counterparts,	N1	and	M1.	Studying	the	role	of	MMP8	in-
vivo	 provides	 a	 model	 in	 which	 all	 immune	 components	 are	 present,	 which	allows	 for	 a	 comprehensive	 investigation	 of	 the	 immune	 regulatory	 changes	occurring	in	the	TME	at	different	stages	of	tumour	development.			In	summary,	 the	project	will	 test	 the	hypothesis	 that	MMP8	protects	 the	host	from	mammary	carcinoma	progression	by	having	an	effect	on	 innate	 immune	defenses.	More	specifically,	by	acting	via	TGFβ	signaling	to	switch	polarization	of	neutrophils	and	macrophages	towards	anti-tumorigenic	phenotypes,	N1	and	M1.	 The	 specific	 aims	 and	 objectives	 for	 the	 present	 investigation	 are	 as	follows:		
Aim	1:	To	 characterise	 phenotypes	 of	 tumour-associated	 neutrophils	 (TANs)	and	 macrophages	 (TAMs)	 in	 primary	 tumours	 from	 MMTV-PyMT;	 Mmp8-knock-out	versus	MMTV-PyMT;	Mmp8-wild-type	mice.	• Objective	1:	Quantify	RNA	expression	of	M1,	M2,	N1	and	N2	markers	at	different	stages	of	development.	• Objective	2:	Stain	tumor	sections	for	specific	immune	cell	markers.		
Aim	2:	To	evaluate	the	TGFβ	signaling	axis	and	novel	pathways	in	MMTV-PyMT;Mmp8-knock-out	and	MMTV-PyMT;	Mmp8-wild-type	tumours.	
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• Objective	1:	Identify	differentially	expressed	genes	between	Mmp8-null	and	 wild-type	 tumours	 using	 whole	 genome	 RNAseq	 transcriptomic	profiling.		
2.	METHODS	
2.1.	Mmp8-null	mice	All	 mammary	 carcinoma	 mouse	 tumours	 used	 in	 the	 present	 study	 were	generated	 previously	 by	 Decock	 et	 al.	 (2015).	 They	 intercrossed	Mmp8-null	mice	 (described	 in	Gutiérrez-Fernández	 et	 al.,	 2008;	Balbin	 et	 al.,	 2003)	with	MMTV-PyMT	 mice	 (Charles	 River	 Laboratories,	 Margate,	 UK)	 to	 generate	 a	robust	 MMP8	 knock-out	 model	 for	 mammary	 carcinoma.	 Tumours	 were	generated	 for	 multiple	 experiments	 and	 were	 harvested	 and	 portioned	 by	members	of	the	Edwards	lab	in	the	period	between	2009	–	2011.			The	Mmp8-null	mice	were	 generated	previously	by	Balbin	 et	 al.	 (2003).	They	used	pKO	scrambler	V916	(Lexicon	Genetics)	to	construct	the	targeting	vector,	which	 contained	 a	 5kb	HindIII	 fragment	 flanked	 at	 5’	 end	with	 a	 3kb	 region,	exon1,	intron	1	and	part	of	exon2.	The	3’end	comprised	a	1.3-kb	PCR	fragment	that	 contained	 intron	4	and	exon	5.	A	PGK-neo	cassette	were	used	 to	 replace	most	 of	 exon	 2,	 intron	 2,	 exon	 3,	 intron	 3	 and	 exon	 4.	 The	 cassette,	 with	transcriptional	orientation	opposite	to	that	of	MMP8,	were	cloned	into	an	AscI	site	of	the	vector.	The	construct	was	then	linearized	prior	electroporation	into	RW4	embryonic	cells	(129/ScJ	derived).	Genotyping	and	subsequent	 injection	into	blastocysts	are	described	in	Balbin	et	al.	(2003).		
	
2.2.	RNA	Isolation	Frozen	tumour	tissue	was	pulverised	with	a	chilled	mortar	and	pestle	in	liquid	nitrogen	prior	 tissue	homogenization/lysis	 in	RNAbee.	RNA	was	then	 isolated	using	a	phenol-chloroform	extraction	method	followed	by	purification	using	a	SV	 Total	 RNA	 Isolation	 System	 (#Z3100,	 Promega,	 Madison,	 WI,	 USA).	 The	samples	were	then	quantified	and	evaluated	for	quality	by	A260/A280nm	and	
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A260/A230nm	 ratios	 using	 a	 Nanodrop	 system	 (Thermo	 Fisher	 Scientific,	Frederick,	MD,	USA).	Samples	were	stored	at	-80°C.		
2.3.	Agarose	Gel	Electrophoresis	Total	RNA	was	 separated	on	a	1.2%	EtBr	 stained	agarose	gel.	Briefly,	10µl	of	sample	 stained	 with	 2ul	 of	 6x	 loading	 dye	 (#B7024S,	 New	 England	 Biolabs,	Ipswich,	UK)	was	loaded	into	each	wells	of	the	agarose	gel,	and	a	volume	of	5ul	of	 HyperLadder™	 1kb	 (BIO-33053,	 New	 England	 Biolabs,	 Ipswich,	 UK)	 was	used	 for	 size	 orientation.	 Electrophoresis	 was	 run	 at	 60V	 for	 1.5	 hour	 prior	visualisation	and	gel	imaging.		
2.4.	Quantitative	RT-PCR	cDNA	was	 synthesised	with	 1µg	 of	 total	 RNA	using	MMLV-Superscript	which	resulted	 in	 a	 final	 concentration	 of	 50ng/µl	 (Promega,	 Madison,	 WI,	 USA).	Quantitative	Real-Time	Polymerase	Chain	Reaction	 (qRT-PCR)	was	conducted	using	specific	Taqman	primer/probe	sets	(Applied	Biosystems,	California,	USA)	for	Ccl3,	VEGFA,	Arginase	I,	Arginase	II,	CD163,	MMP8,	MMP2,	MMP3,	MMP13,	Syndecan-4,	 ADAMTS-1,	 and	 ADAMTS-15	 (#mm00441259_m1	#mm00475988_m1	 #mm00477592_m1	 #mm00437306_m1	 #00477355_m1	#mm00488527_g1	#mm01176187_m1,	Applied	Biosystems,	Foster	City,	USA).			As	an	 internal	control	 for	 the	amount	of	cDNA	obtained,	gene	expression	was	normalised	 to	 18S	 rRNA	 (#mm03928990,	 Applied	 Biosystems,	 Foster	 City,	USA).	18S	was	selected	as	standard	normalization	gene	as	done	in	all	previous	studies	by	the	Edwards	lab,	 including	gene	expression	studies	using	mouse	as	model	 organism	 (e.g.	 Decock	 et	 al.,	 2015).	 In	 contrast	 to	 other	 housekeeping	genes	 (e.g.	 GADPH	 and	 β-catenin),	 rRNA	 gene	 expression	 has	 shown	 high	stability	 and	 has	 frequently	 been	 used	 as	 an	 endogenous	 control	 in	 qRT-PCR	experiments	(e.g.	Zhong	&	Simons,	1999;	Schmittgen	&	Zakrajsek,	2000;	Bhatia	et	 al.,	 1994).	 Experiments	 performed	 by	 Pennington	 et	 al.	 (2008)	 also	 shows	that	18S	serves	as	a	good	quality	control.			
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Detection	 of	 selected	 genes	 was	 performed	 using	 5ng	 cDNA	 for	 all	 genes	 of	interest	 (1ng	 for	 18S),	 8.33µl	 of	 Taqman	 mastermix,	 1.25µl	 of	 P2P	 mix	 and	5.42µl	of	dH2O	(13.42µl	for	18S).	The	cycle	conditions	for	the	polymerase	chain	reaction	was	as	follows:	2	min	at	50°C,	10	min	at	95°C,	followed	by	40	cycles	of	15	sec	at	90°C	and	1	min	at	60°C.		
2.5.	Cryosectioning	and	Immunohistochemical	Staining	The	 frozen	 tumours,	 stored	 in	 Optimal	 Cutting	 Temperature	 medium	 (OCT),	were	 sectioned	 at	 10	 µm	 using	 a	 cryostat,	 and	 sections	 were	 collected	 on	ColorfrostTM	 Plus	 Microscope	 Slides	 (Thermo	 Scientific,	 Cheshire,	 UK)	 and	stored	 at	 -20°C.	 Dry,	 defrosted	 sections	 were	 fixed	 in	 100%	 acetone	 prior	antigen	 retrieval	 in	 citric	 acid,	 pH6.	 Sections	 were	 blocked	 in	 phosphate	buffered	 saline	 (PBS)/0.2%	 Triton	 with	 10%	 normal	 goat	 serum	 to	 avoid	unspecific	 staining.	 Macrophages	 and	 blood	 vessels	 were	 detected	 using	primary	 antibody	 against	 F4/80	 (MCA497R,	 Bio-Rad,	 Kidlington,	 UK)	 and	Endomucin	(Sc-65495,	Santa	Cruz	Inc.,	Texas,	USA),	respectively,	all	at	a	1:200	dilution	 in	 blocking	 solution.	 Donkey-anti-rat	 Alexa-488-labelled	 and	 Alexia-555-labelled	 secondary	 antibodies	 were	 used	 for	 visualisation	 of	 F4/80	 and	Endomucin,	 respectively,	 at	 a	1:500	dilution	 in	PBS/1%	normal	horse	 serum.	Section	were	mounted	using	Vectashield®	Mounting	Medium	with	DAPI	(Vector	Laboratories,	Inc.,	California,	USA).	Sections	were	imaged	at	10X	magnification	with	 Zeiss	 Axioplan	 II	 Fluorescence	 Microscope	 (Carl	 Seizz,	 Jena,	 Germany),	followed	 by	 processing	 using	 the	 Zeiss	 Axio	 Vision	 Imaging	 Software	 (Carl	Zeiss,	Jena,	Germany)	and	Fiji.		
2.6.	RNA	Sequencing	and	Bioinformatics	Analysis	Total	 RNA	 was	 quantified	 on	 a	 Tecan	 Platereader	 prior	 sizing	 and	 quality	control	 (QC)	 using	 a	 LabChip	 GX	 Instrument	 (Perkin	 Elmer®).	 Quality	 was	assessed	 based	 on	 RNA	 quality	 Scores	 (RQS)	 (see	 Table	 3.1).	 Pair-end	 RNA	libraries	 were	 prepared	 according	 to	 standard	 protocols	 at	 the	 Earlham	Institute.	 The	 libraries	were	 sequenced	 on	 an	 Illumina	HiSeq2000,	 using	 two	lanes	per	sample.	Raw	data	was	quality	controlled	using	FastQC	(fastqc-0.11.2,	http://www.bioinformatics.babraham.ac.uk/projects/fastqc/),	 and	 a	
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kontaminant	 (http://www.tgac.ac.uk/kontaminant/)	 was	 used	 to	 check	 for	contamination	 in	 raw	 reads.	 As	 the	 data	 QC	 was	 good,	 no	 trimming	 was	performed	on	the	raw	data.			RNAseq	 reads	 were	 aligned	 against	 the	 mouse	 genome	 reference	 build	 38	(ftp://ussd-	 ftp.illumina.com/Mus_musculus/	 Ensembl/GRCm38/)	 using	TopHat	 (tophat-2.1.0,	 http://ccb.	 jhu.edu/software	 /tophat/manual.shtml)	(Trapnell	et	al.,	2009)	with	–min-anchor-length	12	and	–max-multihits	20.	To	control	for	between-	and	within-sample	variations,	the	expression	level	of	each	gene	was	normalised	by	calculating	fragments	per	kilobase	per	million	mapped	reads	 (FPKM).	 Alignments	 against	 the	MMP8	 allele	were	 visualized	 using	 the	Integrative	 Genome	 Browser	 (Robinson	 et	 al.,	 2011;	 Thorvaldsdóttir	 et	 al.,	2013)	to	confirm	the	Mmp8-knockout.			Transcript	 reconstruction	 and	 differential	 expression	 was	 performed	 in	Cufflinks	 (Cufflinks-2.2.1,	 http://cole-trapnelllab.github.io/cufflinks/cufflinks/	index.html),	 previously	described	 in	Trapnell	 et	 al.	 (2012).	A	mean	 log2	 ratio	(FPKM	of	gene	in	sample	X/FPKM	of	gene	in	sample	Y)	was	calculated	and	the	FDR	 method	 was	 used	 to	 identify	 differentially	 expressed	 genes	 between	groups.	 Genes	were	 considered	 as	 significantly	 differentially	 expressed	when	FDR	value	was	less	than	0.05.			The	 R	 package	 cummerbund	 (http://bioconductor.org/packages/	 release/	bioc/html/	 cummeRbund.html)	 (Goff	 et	 al.,2013)	 was	 used	 to	 visualise	 the	results	of	Cufflinks.	Further,	DAVID	Bioinformatics	Resources	6.7	(Huang	et	al.,	2009a;	Huang	et	al.,	2009b)	were	used	as	functional	annotation	tool	to	explore	functions	 of	 genes	 significantly	 differentially	 expressed	 between	 conditions.	Furthermore,	Venny	2.1	(http://bioinfogp	.cnb.csic.es/tools/venny/)	was	used	to	construct	Venn	Diagrams	and,	Gene	Cluster	3.0	(described	in	de	Hoon	et	al.,	2004)	 and	 Java	 TreeView	 1.1.6r4	 (Saldanha,	 2004)	 were	 used	 for	 heatmap	construction.			
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2.7.	Statistical	Analysis	If	not	stated	otherwise,	the	data	was	analysed	using	the	two-way	ANOVA	test	and	are	represented	as	mean	±	standard	error	of	the	mean	(SEM).	
3.	RESULTS	The	current	investigation	builds	on	previous	work	that	was	recently	published	by	Decock	et	al.	(2015).	They	intercrossed	Mmp8-null	mice	with	MMTV-PyMT	mice	to	generate	a	robust	Mmp8-knock-out	model	for	mammary	carcinoma.	As	a	 response	 to	 MMP8	 ablation,	 this	 study	 reported	 an	 accelerated	 tumour	progression	 and	 lung	 metastasis,	 in	 addition	 to,	 an	 increased	 infiltration	 of	neutrophils	 at	 later	 time	 points	 of	 tumour	 development.	 Moreover,	 they	reported	 a	 change	 in	 the	 vasculature,	 as	 well	 as	 a	 differential	 expression	 of	several	 members	 of	 the	 protease	 web.	 Thus,	 MMP8	 appears	 to	 suppresses	tumour	 progression	 by	 inducing	 pleiotropic	 changes	 within	 the	 tumour	microenvironment.		Tumours	that	were	generated	by	Decock	et	al.	(2015),	including	MMTV-PyMT;	Mmp8-knock-out,	 MMTV-PyMT;	 Mmp8-heterogenous	 and	 MMTV-PyMT;	Mmp8-wild	type	tumours,	were	stored	at	-80°C	for	future	investigations.	These	tumours	have	been	used	in	the	current	study	to	continue	the	work	of	Decock	et	al.	 (2015)	by	exploring,	 on	a	more	mechanistic	 level,	 the	 tumour	 suppressive	functions	of	MMP8	during	mammary	carcinoma	progression.	More	specifically,	the	transcriptome	has	been	analysed	to	assess	if	MMP8	acts	via	innate	immune	pathways	and	to	explore	novel	pathways	affected	by	MMP8	signaling.		
3.1.	Quality	controls	reveals	good	RNA	integrity	Decock	 et	 al.	 (2015)	 extracted	RNA	 from	MMTV-PyMT	 tumours	 to	profile	 for	gene	expression	levels	of	various	members	of	the	protease	web.	RNA	from	this	experiment	was	stored	 together	with	 the	 tumours	at	 -80°C	 for	 future	studies.	The	present	 investigation	aimed	at	using	 the	same	RNA	samples	 for	qRT-PCR	analysis	and	whole	genome	RNA	sequencing	and,	thus,	started	off	by	verifying	the	 integrity	 and	 quality	 of	 these	 RNA	 samples.	 RNA	 integrity	 was	 firstly	checked	by	qRT-PCR	by	looking	at	18S	rRNA	abundance.	Several	RNA	samples	
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showed	 18S	 Ct	 values	 ranging	 from	 16-18,	 which	 is	 indicative	 of	 degraded	ribosomal	 18S	 rRNA.	 Although	 these	 results	 suggested	 a	 poor	 quality	 of	 the	underlying	mRNA	population,	the	RNA	was	sent	to	the	Earlham	Institute	for	a	more	in-depth	quality	assessment.		At	 the	Earlham	Institute,	A	LabChip	GX	 instrument	was	used	to	measure	RNA	integrity	 by	 electrophoretic	 separation	 on	microfluidic	 sipper	 chips	 via	 laser	induced	fluorescence.	An	electropherogram	displayed	the	raw	data,	which	was	then	 converted	 into	 a	 gel-like	 image	 for	 visualization.	 An	 RNA	 quality	 score	(RQS)	was	 calculated	 based	 on	different	 parameters	 of	 the	 electropherogram	(e.g.	peak	heights	and	peak	areas)	and	sample	concentration,	and	was	reported	as	 a	 score	 between	 1-10,	 where	 a	 score	 >7	 is	 considered	 as	 passed	(CaplierLifeScience,	2009).	The	results	revealed	a	generally	poor	quality	across	samples,	 in	which	 several	 samples	did	not	 shown	detectable	18S,	28S	and	5S	(see	Supplementary	Material).	Accordingly,	out	of	49	samples,	only	4	samples	showed	 an	 RQS	 score	 >7	 and	 only	 6	 passed	 the	 overall	 quality	 control.	 This	strongly	 indicates	 that	 the	 integrity	and	quality	of	 the	RNA	was	not	 sufficient	for	downstream	gene	expression	analysis.		The	current	study	concluded	that	using	RNA	samples	from	the	Decock	et	al.	(2015)	 study	 would	 provide	 a	 high	 risk	 of	 unsuccessful	 gene	 expression	experiments.	Thus,	the	study	went	on	to	isolate	fresh	RNA	from	the	frozen	MMTV-PyMT	 tumour	 tissue.	 Initial	 quality	 assessments	 were	 again	performed	in	the	lab	by	qRT-PCR,	but	also	by	agarose	gel	electrophoresis	to	look	at	28S/18S	rRNA	ratios.	The	Ct	values	for	18S	rRNA	ranged	from	13	to	15,	 indicating	 that	 ribosomal	 18S	 rRNA	was	 intact	which,	 in	 turn,	 should	reflect	 good	 quality	 of	 the	 underlying	 mRNA	 population.	 Further,	visualisation	of	the	agarose	gel	after	electrophoretic	separation	of	total	RNA	revealed,	 in	 the	majority	 of	 samples,	 an	 upper	 band	 (28S)	 approximately	twice	 as	 intense	 as	 a	 lower	 band	 (18S)	 (Figure	 3.1).	 A	 28S:18S	 ratio	 of	approximately	2:1	indicates	good	quality	RNA	and	thus	verified	the	results	obtained	by	qRT-PCR.	Of	note,	RNA	was	separated	on	two	different	agarose	
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gels,	however,	due	to	 issues	during	 imaging,	only	one	of	 the	gels	 is	shown	here	(Figure	3.1).		
	The	samples	were	sent	to	the	Earlham	Institute	to	further	verify	the	results	obtained	by	qRT-PCR	and	agarose	gel	electrophoresis,	and	to	ensure	that	the	quality	 of	 the	RNA	 samples	was	 sufficient	 for	 subsequent	RNA	 sequencing.	Figure	3.2	shows	 the	gel	 image	 from	the	GX	experiment,	 in	which	28S,	18S	and	 5S	 is	 detected	 in	 most	 samples.	 Electropherogram	 data	 of	 all	 RNA	samples	are	included	in	Supplementary	Materials	for	a	detailed	visualisation	of	the	rRNA	peaks.	A	summary	of	various	parameters,	 including	RQS	scores	and	final	QC,	measured	and	calculated	by	the	Earlham	Institute,	is	shown	in	Table	3.1.	Out	of	42	RNA	samples,	26	passed	the	QC	and	all	samples	passed	concentration	 except	 sample	 12.	 Subsequent	 Nanodrop	 measurements	revealed	 a	 significant	 reduction	 in	 concentration	 compared	 to	 earlier	measurements,	 indicating	that	Sample	12	had	been	subject	for	degradation.	Further,	Sample	36	and	42	had	very	low	RQS	scores	and	was	thus	excluded	from	 downstream	 RNAseq	 experiments	 together	 with	 Sample	 12	 and	 all	heterogeneous	 groups.	 A	 total	 of	 27	 samples	was	 thus	 selected	 for	 library	construction	and	subsequent	RNA	sequencing	at	the	Earlham	Institute.	
Figure	3.1:	Agarose	gel	electrophoresis	of	total	RNA	from	individual	MMTV-
PyMT	 tumours.	Total	 RNA	 was	 separated	 using	 1.2%	 EtBr-stained	 agarose	 gel	and	integrity	was	assessed	based	on	28S	and	18S	abundance.	
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Figure	3.2:	Digital	gel	generated	from	a	LabChip	GX	assay,	reflecting	RNA	integrity.	Total	RNA	was	isolated	from	MMTV-	 PyMT;	 Mmp8-wild-type,	 MMTV-PyMT;	 Mmp8-heterozygote	 and	 MMTV-	 PyMT;	 Mmp8-knock-	 out	 tumours	prior	separation	on	microfluidic	sipper	chips	in	an	electrophoretic	manner.	Red,	green	and	blue	bands	represent	28S,	18S,	and	5 	rRNAs,	respectively.	Source:	The	Earlham	Institute.	
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Timepoint Genotype Sample	ID ng/ul Pass/Fail ng/ul Percentage	DNA RQS Pass/Fail
Vol.	of	
sample	(ul)
Total	
Amount	
Overall	
Pass/Fail
6weeks KO 6 44.0 Pass 4.1 9.4 7.2 Pass 55 2.4 Pass
6weeks KO 7 62.8 Pass <Min N/A 7.4 Pass 55 3.5 Pass
6weeks KO 8 39.9 Pass <Min N/A 8.5 Pass 55 2.2 Pass
6weeks KO 9 51.0 Pass 3.7 7.3 8.1 Pass 55 2.8 Pass
6weeks WT 10 53.3 Pass 3.7 6.9 8.1 Pass 30 1.6 Fail
6weeks WT 11 48.8 Pass 3.4 7.0 9.0 Pass 30 1.5 Fail
6weeks WT 14 57.8 Pass 4.4 7.6 8.1 Pass 55 3.2 Pass
6weeks WT 15 66.5 Pass 6.0 9.0 8.6 Pass 100 6.7 Pass
6weeks WT 16 51.8 Pass <Min N/A 10.0 Pass 10 0.5 Fail
8weeks KO 21 43.1 Pass 2.9 6.8 8.8 Pass 55 2.4 Pass
8weeks KO 22 52.2 Pass 3.7 7.0 8.8 Pass 55 2.9 Pass
8weeks KO 23 63.6 Pass 5.5 8.7 9.0 Pass 55 3.5 Pass
8weeks KO 24 47.4 Pass 3.3 6.9 8.2 Pass 55 2.6 Pass
8weeks KO 25 56.5 Pass 4.4 7.8 8.1 Pass 55 3.1 Pass
8weeks WT 26 51.6 Pass 3.6 7.0 8.1 Pass 55 2.8 Pass
8weeks WT 27 55.5 Pass 3.7 6.7 8.0 Pass 55 3.1 Pass
8weeks WT 28 49.6 Pass 2.8 5.6 7.1 Pass 100 5.0 Pass
8weeks WT 29 61.8 Pass 3.9 6.3 8.9 Pass 55 3.4 Pass
10weeks KO 34 48.8 Pass 1.9 3.8 7.6 Pass 55 2.7 Pass
10weeks KO 35 48.0 Pass 3.3 6.9 8.3 Pass 30 1.4 Fail
10weeks KO 36 53.0 Pass 3.5 6.6 6.8 Fail 55 2.9 Fail
10weeks KO 37 51.9 Pass 4.4 8.5 8.6 Pass 55 2.9 Pass
10weeks WT 38 50.7 Pass 3.3 6.6 7.9 Pass 55 2.8 Pass
10weeks WT 39 54.3 Pass 4.6 8.5 7.4 Pass 55 3.0 Pass
10weeks WT 41 32.7 Pass 1.9 5.8 7.8 Pass 55 1.8 Fail
10weeks WT 42 51.1 Pass 3.7 7.2 6.9 Fail 55 2.8 Fail
10weeks WT 43 50.6 Pass 4.4 8.7 7.2 Pass 55 2.8 Pass
RNA	Plate	reader DNA	Platereader GX	values
Table	3.1:	LabChip	GX	quality	control	of	RNA	extracted	from	MMTV-PyMT	mouse	tumours		
RQS	=	RNA	Quality	Score	
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3.2.	MMP8	might	suppress	tumour	progression	via	innate	immune	
responses	While	 RNA	 sequencing	 was	 carried	 out	 at	 the	 Earlham	 Institute,	 initial	experiments	were	conducted	to	assess	if	MMP8	had	an	effect	on	the	presence	of	pro-	 and	 anti-tumorigenic	 myeloid	 cells	 (i.e.	 N1,	 N2,	 M1	 and	 M2).	 The	phenotypes	of	myeloid	subpopulations	are	characterised	by	the	expression	of	a	range	of	marker	genes	that	is	specific	for	each	phenotype	and	a	comprehensive	approach	 to	 assess	 the	 presence	 of	 pro-	 and	 anti-tumorigenic	 myeloid	 cells	would	 be	 to	 profile	 for	 a	 complete	 set	 of	 such	markers	 genes.	 As	 a	 trial,	 the	current	 study	 initiated	 by	 selecting	 a	 combination	 of	 five	 markers	 genes,	including	 Ccl3,	 VEGFA,	 Arginase	 I,	 Arginase	 II	 and	 CD163,	 for	 a	 time-course	gene	 expression	 profiling	 by	 Taqman	 qRT-PCR.	 Ccl3	 and	 VEGFA	 are	 highly	expressed	 in	 N1	 phenotypes,	 Arginase	 I	 is	 lowly	 expressed	 in	 N1	 and	 highly	expressed	 in	 N2	 phenotypes.	 Further,	 M1	 phenotypes	 are	 shown	 to	 highly	express	Arginase	II,	whereas	M2	phenotypes	express	Arginase	II	at	 low	levels	and	 CD163	 at	 high	 levels	 (e.g.	 Allavena	 et	 al.,	 2008:	 Sica	&	Mantovani,	 2012:	Martinez	et	al.,	2006;	Biswas	et	al.,	2006;	Pauleau	et	al.,	2004).		The	 results	 from	 qRT-PCR	 experiments	 revealed	 a	 significant	 change	 in	expression	of	all	marker	genes	at	10	weeks	 in	tumours	from	Mmp8-null	mice,	compared	 to	 those	 from	Mmp8-wild-type	and	heterozygote	mice	 (Figure	3.3).	This	 indicates	 that	 depletion	 of	 MMP8	 induced	 an	 increased	 influx	 of	neutrophils	and	macrophages	at	later	time	points,	in	which	a	mix	of	both	pro-tumorigenic	 (N1	 and	M1)	 and	 anti-tumorigenic	 (N2	 and	M2)	 phenotypes	 are	present	in	the	infiltrate.	Notably,	this	is	inconsistent	with	the	prediction	made,	as	 a	 polarisation	 towards	 pro-tumorigenic	 phenotypes	 was	 expected	 to	 be	observed	in	Mmp8-null	tumours.	
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Figure	 3.3:	 Relative	 expression	 of	 selected	markers	 genes	 for	 N1,	 N2,	 M1	 and	M2,	 across	 all	 time	 points.	Marker	descriptions;	Ccl3	and	VEGFA	is	highly	expressed	in	N1	phenotypes,	Arginase	I	(Arg	I)	is	poorly	expressed	in	N1	and	highly	expressed	in	N2.	Arginase	II	(Arg	II)	and	CD163	is	highly	expressed	in	M1	and	M2,	respectively.	A)	Differential	expression	of	Ccl3	 and	 VEGF,	 and	 B)	 of	 Agr	 I,	 Arg	 II,	 and	 CD163.	 Graphs	 display	 mean,	 standard	 deviation,	 and	 statistical	 significance		(*	=	<	0.05).	
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In	addition	to	exploring	the	expression	of	myeloid	cell	markers,	qRT-PCR	was	performed	to	further	investigate	if	MMP8	ablation	induce	a	disturbance	in	the	protease	web.	Selected	MMP	and	TIMP	members	were	profiled	in	a	time-course	manner	 by	 qRT-PCR.	 Relative	 expression	 and	 fold-change	 expression	 was	calculated	using	the	∆∆Ct	method,	 in	which	Mmp8-null	mice	was	compared	to	wild-type	 when	 calculating	 the	 fold	 change.	 Mmp8-null	 mice	 showed	 a	significant	up-regulation	of	MMP2	and	down-regulation	of	MMP3	and	MMP13	at	 10	weeks	 of	 development	 (Figure	 3.4),	 compared	 to	wild-type	 littermates.	Further,	 no	 significant	 change	 in	 expression	was	 identified	 for	TIMP1,	TIMP3	and	TIMP4	 between	Mmp8-null,	wild-type	 and	 heterozygote	 tumours	 (Figure	3.4).	 Altogether,	 these	 results	 strongly	 demonstrate	 the	 interconnections	between	MMP8	 and	 other	MMPs	 as	 several	members	 of	 the	MMP	 family	 are	significantly	dysregulated	in	Mmp8-null	tumours.		As	 qRT-PCR	 revealed	 that	 MMP8	might	 act	 via	 innate	 immune	 responses	 to	suppress	 tumour	 progression,	 tumour	 sections	 were	 stained	 for	 selected	immune	 cell	 markers	 for	 further	 validation.	 Initially,	 tumour	 sections	 were	stained	 for	 M1	 and	 M2	 phenotypes	 using	 the	 markers	 iNOS	 and	 CD206,	respectively.	 However,	 this	 experiment	 was	 unsuccessful	 as	 no	 staining	 was	detected	by	microscopic	visualisation.	As	no	good	markers	for	N1	and	N2	were	found	in	previous	literature,	the	study	went	on	to	stain	for	total	neutrophils	and	macrophages	using	Ly6.B	and	F4/80	as	markers,	 respectively.	No	staining	 for	neutrophils	 was	 achieved,	 whereas	 macrophage	 staining	 was	 successful.	Macrophages	distribute	as	hotspots	around	the	 tumour	edge	and	quantitative	measures	 was	 performed	 by	 calculating	 the	 density	 of	 macrophages	 within	these	 hotspots.	 Three	 representative	 regions	 of	 interest	 were	 selected	 and	averaged	for	each	tumour	section.	As	illustrated	in	Figure	3.6,	tumour	sections	from	Mmp8-null	mice	showed	no	significant	change	in	macrophage	density	at	6,	8	 and	10	 weeks,	 compared	 to	 wild-type	 tumours.	 These	 results	 suggest	 that	MMP8	has	no	direct	nor	indirect	effect	on	tumour	infiltration	of	macrophages.	
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TIMP3 TIMP4TIMP1
Figure	3.4:	Relative	expression	of	selected	members	of	the	protease	web	plotted	against	time.	Mean	expression	 is	 displayed	 at	 6,	 8	 and	 10	 weeks	 of	 development	 for	 MMTV-PyMT;	 Mmp8-knock-out	 (red),	MMTV-PyMT;	Mmp8-heterozygous	 (yellow),	 and	MMTV-PyMT;	Mmp8-wild-type	 (green)	mice.	Expression	of	MMP2,	MMP3,	MMP13,	TIMP1,	TIMP3	and	TIMP4	was	measured	as	Ct	values	using	qRT-PCR	and	relative	expression	was	calculated	using	the	∆Ct	method.	
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Figure	 3.5:	 Heat	 map	 summarizing	
fold	 expression	 of	 RNA	 species	 in	
MMTV-PyMT	 tumours	 in	 a	 time-
course	manner.	A)	Fold	change	between	MMTV-PyMT;	 MMP8-knock-out	 and	MMTV-PyMT;	 wild-type	 tumours	 are	indicated	with	values	and	by	colour.	Fold	change	 was	 calculated	 using	 the	 DDCt	method	 and	 statistical	 significance	 was	calculated	 using	 the	 two-way	 ANOVA	(multivariate)	 test.	 B)	 Marker	 genes	 for	neutrophils	 and	 macrophages	 that	display	 anti-	 (N1,	 M1)	 and	 pro-tumorigenic	 (N2,	 M2)	 phenotypes.	Marker	 genes	 were	 selected	 based	 on	previous	 literature	 (e.g.	 Allavena	 et	 al.,	2008:	 Sica	&	Mantovani,	 2012:	Martinez	et	al.,	2006).				
A)	 B)	
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Figure	 3.6:	 Abundance	 of	 macrophages	 in	 MMTV-PyMT;	 Mmp8-knock-out	
and	MMTV-PyMT;	wild-type	 tumours.	Density	of	macrophages	across	 all	 time	points.	 A)	 Frozen	 sections	 were	 stained	 for	 macrophages	 using	 an	 antibody	against	 F4/80.	 For	 each	 section,	 number	 of	 cells	 were	 counted	 within	 three	regions	 of	 interest	 (ROI)	 that	 were	 considered	 representative	 as	 macrophage	hotspots.	 Number	 of	 cells	 from	 each	 ROI	 were	 averaged	 prior	 calculation	 of	macrophage	 density	 (number	 of	 macrophages/104	 µm2).	 Nucleus	 were	 stained	with	DAPI.	Images	were	catured	at	10X	magnification	and	processed	in	Fiji.	Scale	bar;	 200um.	 B)	 Quantitative	 illustration	 of	 macrophage	 density.	 Graphs	 display	both	mean	and	standard	error	of	the	mean.			
B)	
A)	
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In	 addition	 to	 staining	 for	 total	 macrophages,	 whole	 tumour	 sections	 were	stained	for	blood	vessels	to	determine	whether	MMP8	ablation	has	an	effect	on	vascularity.	Tumours	sections	from	Mmp8-null	and	wild-type	tumours	at	early	and	 late	 time	 points	 were	 selected	 for	 staining	 and	 Endomucin	 was	 used	 as	marker	for	blood	vessels.	As	shown	in	Figure	3.7,	blood	vessel	density	appears	to	 increase,	 for	 both	Mmp8	 -null	 and	wild-type	 tumours,	 from	6	weeks	 to	 10	weeks	of	development.	This	indicates	that	more	established	late-stage	tumours	are	associated	with	a	more	complex	vasculature,	which	concur	with	the	known	histology	of	highly	developed	 tumours.	 In	contrast,	no	change	 in	blood	vessel	density	 was	 found	 between	 genotypes	 at	 6	 nor	 at	 10	 weeks	 of	 disease	development.	These	results	suggest	that	MMP	depletion	has	none	or	negligible	effects	on	vasculature	development	during	mammary	carcinoma	progression.																						
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Figure	3.7:	Vascular	density	in	MMTV-PyMT	tumours	at	early-	and	late	time	points.	Representative	images	of	stained	sections	from	MMTV-PyMT;	Mmp8-knock-out	and	wild-type	 tumours,	 at	6	 and	10	weeks.	The	vasculature	was	 stained	using	an	 antibody	against	Endomucin	and	images	were	captured	at	10X	magnification,	followed	by	processing	in	Fiji.	Scale	bar;	200µm.		
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3.3.	RNA	sequencing	reveals	a	more	complex	role	of	MMP8	To	 investigate	 the	action	of	MMP8	in	more	depth,	 the	whole	 transcriptome	of	tumours	 from	 Mmp8-null	 and	 wild-type	 mice	 were	 sequenced	 followed	 by	comprehensive	 bioinformatics	 analysis.	 The	 raw	 sequence	 data	 output	 from	Illumina	was	checked	by	assessing	the	quality	of	the	reads	(see	Supplementary	Materials)	and,	as	the	overall	read	quality	was	good,	no	sequence	trimming	was	needed	 for	downstream	analysis.	Further,	TopHat	was	used	as	alignment	 tool	to	map	the	reads	 to	 the	mouse	reference	genome	(GRCm38)	prior	expression	analysis	 in	 Cufflinks.	 Cufflinks	 reports	 gene	 expression	 results	 as	 Fragments	Per	 Kilobase	 Million	 (FPKM),	 which	 is	 fragment	 counts	 normalised	 to	sequencing	depth	and	gene	length	(Anders	and	Huber,	2010).		Global	 statistics	 including	 distribution	 of	 FPKM	 scores,	 cluster	 analysis	 and	principal	 component	 analysis	 (PCA)	 were	 conducted	 to	 screen	 for	 potential	outliers	 (see	 Appendix	 1	 and	 Appendix	 2).	 Such	 comprehensive	 analysis	 in	addition	 to	 visual	 inspection	 of	 the	 data,	 identified	 3	 samples	 as	 replicate	outliers,	 one	 replicate	 from	 each	 of	 the	 following	 conditions;	 6	weeks_WT,	 6	weeks_KO	 and	 10	 weeks_WT.	 As	 outliers	 can	 have	 a	 significant	 impact	 on	statistical	 calculations	 by	 increasing	 the	 likelihood	 of	 false	 positive	 and	negative	results,	these	were	excluded	from	all	downstream	analysis.	Figure	3.8	shows	global	statistics	of	normalised	data	after	excluding	replicate	outliers.		To	 identify	 significant	 differentially	 expressed	 genes	 between	Mmp8-null	 and	wild-type	 tumours	 across	 time	 points,	 differential	 expression	 analysis	 was	performed	 using	 the	 Cuffdiff	 algorithm	 in	 Cufflinks,	 followed	 by	 statistical	computing	and	graphing	 in	R	and	other	relevant	software.	Firstly,	 the	 level	of	MMP8	expression	were	compared	between	Mmp8-null	and	wild-type	tumours.	Although	 the	 MMP8	 gene	 were	 edited	 in	 Mmp8-null	 mice,	 no	 significant	differential	expression	were	identified	between	the	two	genotypes	(see	Figure	3.9a).	This	can	be	explained	by	the	approach	used	to	generated	the	Mmp8-null	mice	 (see	Method	 section	 for	 details),	 as	 the	 knockout	were	 generated	 via	 a	genetic	 insertion	that	replaced	most	of	exon	2,	 intron	2,	exon	3,	 intron	3,	and	exon	4.	This	 should	 result	 in	 transcription	of	a	 truncated	mRNA	consisting	of	
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exon	 1	 and	 exon	 5-10	 that	 encodes	 for	 a	 pro-protein	 and	 hemopexin-like	domains,	respectively	(Yates	et	al.,	2015).	To	explore	which	regions	of	the	allele	that	 were	 transcribed	 in	 the	 Mmp8-null	 mice,	 the	 present	 study	 used	 the	Integrative	Genome	Browser	(IGV)	tool	to	visualize	the	alignments	against	the	mouse	 reference	 genome	 (GRCm38).	 As	 predicted,	 results	 showed	 that	fragments	were	mapped	against	exon	1	and	exon	5-10	(data	not	shown),	which	evidences	that	 the	gene	 is	 transcribed	as	a	 truncated	protein	that	are	missing	the	region	that	encodes	for	the	catalytic	domain.	Hence,	the	mRNA	is	quantified	by	RNAseq	analysis	but	the	protein	produced	from	the	truncated	mRNA	is	non-functional.			Venn	 Diagrams	 (Figure	 3.8)	 were	 constructed	 to	 explore	 the	 relationship	between	differentially	expressed	genes	across	time	points.	The	results	revealed	that	 374,	 327	 and	 415	 genes	 were	 significantly	 differentially	 expressed	 in	
Mmp8-null	tumours	at	6,	8	weeks	and	10	weeks,	respectively.	However,	only	30	genes	changed	significantly	at	all	three	time	points,	including	5	and	6	genes	that	were	 consistently	 up-regulated	 and	 down-regulated,	 respectively,	 across	 all	time	points	 (Figure	3.9	 and	Table	3.2).	Of	particular	 interest,	Neuropeptide	Y	(NPY)	and	serine	(or	cysteine)	peptidase	inhibitor	(Serpine2)	were	significantly	
up-regulated,	whereas	MMP3	was	 significantly	down-regulated	 across	all	 time	points.	 These	 results	 indicate	 large-scale	 changes	 in	 multiple	 regulatory	systems	as	a	consequence	of	MMP8	ablation.																			
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Figure	 3.8:	 Global	 statistics	 of	 normalized	 RNAseq	 expression	
data,	 after	 excluding	 replicate	 outliers.	 FPKM	 of	 whole	transcriptomes	 of	 MMTV-PyMT;	 Mmp8-knock-out,	 MMTV-PyMT:	Mmp8-heterozygous	 and	MMTV-PyMT;	Mmp8-wild-type	 tumours.	A)	Box	plot	showing	FPKM	distribution	across	conditions	B)	Dendrogram	indicating	hierarchic	clustering	of	 replicates.	 C)	Principal	 Component	Analysis	 (PCA)	 that	 illustrates	 gene	 expression	 variances	 between	replicates.				
 
B)	 C)	A)	
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Figure	3.9:		Generation	of	Mmp8-null	mice	A)	Schematic	representation	of	Mmp8-wild-type	 and	 targeted	 allele.	 The	 PGK-neo	 cassette	 is	 inserted	into	 the	 region	 that	 encodes	 the	 catalytic	 domain.	 Figure	 adapted	 from	Balbin	et	al.	(2013).	B)	Table	showing	FPKM	expression	value	for	MMP8	in	MMTV-PyMT:	 Mmp8-knock-out	 and	 wild-type	 tumours	 at	 6,	 8	 and	 10	weeks.	FC	=	fold	change.	 	
Weeks WT KO
6 0.02 0.14 2.91	(ns)
8 0.05 0.10 0.97	(ns)
10 0.07 0.10 0.54	(ns)
FPKM log2	FC	
KO/WT	(p-value)
A)	
B)	
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Figure	 3.10:	 Significantly	 differentially	 expressed	 genes	 in	 MMTV-PyMT;	
Mmp8-knock-out	 compared	 to	 MMTV-PyMT;	 wild-type	 tumours.	 A)	 Venn	diagram	 showing	 significantly	 differentially	 expressed	 genes	 at	 individual	 and	across	 time	points.	 These	were	 further	 divided	 into	B)	 significantly	 up-regulated	and	C)	significantly	down-regulated	genes.	
 
Table	3.2:	Significantly	up-	or	down-regulated	genes	common	across	all	time	points.		
6	weeks 8weeks 10	weeks
SPARC	related	modular	calcium	binding	1 Smoc1 0.61 0.95 0.72
desmoplakin Dsp 0.63 0.57 0.72
serine	(or	cysteine)	peptidase	inhibitor,	clade	E,	member	2 Serpine2 0.83 1.16 0.71
thrombospondin	4 Thbs4 0.98 1.58 1.13
neuropeptide	Y Npy 3.22 2.38 1.30
matrix	metallopeptidase	3 Mmp3 -3.73 -1.11 -2.08
troponin	I,	skeletal,	fast	2 Tnni2 -1.40 -3.71 -2.11
ribosomal	protein	L36 Rpl36 -1.02 -0.81 -1.07
leucine-rich	alpha-2-glycoprotein	1 Lrg1 -0.77 -0.59 -0.94
ATPase,	Ca++	transporting,	type	2C,	member	2 Atp2c2 -0.71 -1.12 -0.77
serum	amyloid	A	2 Saa2 -0.61 -1.01 -1.12
FC,	fold	change
log2	FC	KO/WT
Gene	
A)	
B)	 C)	
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To	investigate	the	effect	of	MMP8	ablation	in	a	more	time-dependent	manner,	each	 set	 of	 up-	 or	 down-regulated	 genes	 at	 individual	 time	 points	 were	annotated	 using	 the	 Gene	 Ontology	 categorization	 tool	 in	 DAVID	 (6.8	 Beta).	Biological	processes	were	annotated	using	the	GOTERM_BP_FAT	category	and	the	20	most	 significantly	 up-	 and	down-regulated	biological	 pathways	 at	 6,	 8	and	10	weeks	are	shown	in	Figure	3.9-3.11.	In	Mmp8-null	tumours	at	6	weeks,	most	 up-regulated	 genes	 were	 categorised	 to	 be	 involved	 in	 lymphocyte	activation	 and	 differentiation,	 which	 indicates	 an	 increased	 activation	 of	adaptive	 immune	 responses	 at	 early	 time	 points.	 In	 contrast,	 biological	processes	 associated	 with	 tumorigenesis	 were	 down-regulated	 at	 6	 weeks,	including	 cell	 differentiation	 and	 blood	 vessel	 development.	 Mammary	 gland	development	 was	 also	 down-regulated	 at	 6	 weeks	 (Figure	 3.9).	 At	 8	 weeks,	biological	 processes	 involved	 in	 cell	 adhesion,	 locomotion	 and	 negative	regulation	 of	 insulin	 receptor	 signaling	 were	 up-regulated	 in	 Mmp8-null	tumours.	Further,	lipid	and	carbohydrate	metabolism	and,	acute	inflammatory	responses	were	down-regulated	at	this	stage	(Figure	3.10).		In	contrast	to	these	earlier	time	points,	Mmp8-null	mice	at	10	weeks	showed	an	upregulation	 of	 lipid	 and	 glycerol	metabolism,	 acute	 inflammatory	 responses	and	responses	to	wounding.	Genes	involved	in	regulation	of	gene	transcription	and	 macromolecule	 metabolic	 processes	 were	 down-regulated	 at	 10	 weeks	(Figure	 3.11).	 Altogether,	 these	 results	 suggest	 that	 MMP8	 depletion	 induce	multiple	changes	in	the	tumour	microenvironment	during	tumour	progression	and	that	MMP8	effects	are	highly	time	dependent.			
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Figure	3.11-3.13:	The	most	significantly	changed	biological	processes	in	MMTV-PyMT;	Mmp8-null	
tumours	at	6,	8	and	10	weeks.	Bar	chart	is	showing	the	20	most	up-regulated	biological	processes	(red)	and	the	20	most	down-regulated	biological	processes	(green)	in	Mmp8-null	tumours	at	A)	6	weeks,	B)	8	weeks	and	C)	10	weeks	of	tumour	development,	compared	to	Mmp8-wild-typtumours.		Bars	indicate	the	number	of	genes	in	each	biological	process.	 	The	yellow	 line	indicates	 the	enrichment	significance	(–log	(p-value))	 of	 each	 biological	 process,	 generated	 using	 the	 EASE	 score.	 	 Functional	 annotation	 was	performed	in	DAVID	using	the	GOTERM_BP_FAT	term	for	biological	process	categorisation.			
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As	the	 link	between	MMP8	and	immune	responses	were	of	particular	 interest	for	 the	 present	 study,	 genes	 encoding	 components	 of	 the	 immune	 system	 at	early	time	points	were	selected	for	further	gene	annotation	analysis.	A	list	of	61	genes	 encoding	 components	 of	 the	 immune	 system	 were	 significantly	 up-regulated	 at	 6	weeks.	 To	 build	 up	 a	 picture	 of	 immune	 networks	 affected	 by	MMP8	at	early	time	points,	pathway	analysis	of	all	61	genes	were	conducted	in	DAVID	(Figure	3.12).	Functional	annotation	of	relevant	genes	was	further	used	to	 construct	 a	 table	 of	 components	 of	 the	 immune	 system	 that	 were	significantly	 differentially	 expressed	 in	 Mmp8-null	 tumours	 (Table	 3.3),	compared	 to	 wild-type	 tumours.	 No	 significant	 change	 was	 observed	 for	neutrophil	and	macrophage	marker	genes	(data	not	shown).	However,	multiple	lymphocyte	markers	 including	CD3,	CD4,	CD8	and	CD79,	showed	a	significant	fold	change	 in	Mmp8-null	 tumours.	Further,	 several	B-	and	T-cell	 chemotactic	factors	were	significantly	up-regulated,	including	Ccl22,	Ccl5,	Cxcl13	and	Il23a.	Genes	 encoding	 for	 cytoskeleton	 structures,	 lymphocyte	 migration	 and	cytokine	receptors	were	also	significantly	differentially	expressed	in	Mmp8-null	tumours	 at	 6	 weeks.	 Altogether,	 these	 results	 suggest	 that	 MMP8	 inhibit	adaptive	 immune	 responses	 at	 early	 time	 points,	 possibly	 by	 regulating	 the	chemotaxis	 responsible	 for	 recruitment	 and	 activation	 of	 B-	 and	 T-lymphocytes.		The	observed	change	in	adaptive	immune	responses	were	not	evident	at	later	stages	 of	 development.	 However,	 several	 chemo-attractants,	 including	 Cxcl9,	Ccl9,	Ccl8	and	 Interleukins	as	well	as	components	of	 the	complement	system,	were	 dysregulated	 at	 8	 and	 10	 weeks	 of	 development.	 Although	 MMP8	depletion	appear	to	have	a	predominant	effect	on	immune	responses	at	earlier	time	points,	these	results	suggest	a	link	between	MMP8	and	immune	regulatory		networks	throughout	the	time	course	of	tumour	development.	
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Figure	3.14:	Up-regulated	immune	pathways	in	Mmp8-null	tumours	at	6	weeks	for	development.	Significantly	differentially	 expressed	 genes	 between	 MMTV-PyMT;	 Mmp8-knock-out	 mice	 and	 MMTV-PyMT;	 Mmp8-wild-type	were	 used	 for	 pathway	 analysis	 in	 DAVID.	 	 The	 KEGG_PATHWAY	 was	 selected	 for	 mapping.	 Number	 of	 genes	annotated	within	each	pathway	are	indicated	in	blue,	whereas	the	percentage	of	genes	are	indicated	in	blue.		
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6	Weeks 8	Weeks 10	Weeks
B	and	T	lymphocyte	associated Btla 2.16	(0.0017) 0.05	(ns) 0.60	(ns)
CD22	antigen Cd22 4.21	(0.0017) 1.03	(ns) 0.16	(ns)
CD28	antigen Cd28 5.15	(0.0116) -0.11	(ns) 0.22	(ns)
CD3	antigen,	delta	polypeptide Cd3d 3.04	(0.0017) -0.42	(ns) 1.74	(0.0307)
CD3	antigen,	epsilon	polypeptide Cd3e 2.96	(0.0044) -0.07	(ns) -0.09	(ns)
CD3	antigen,	gamma	polypeptide Cd3g 2.38	(0.0017) -0.35	(ns) 1.25	(ns)
CD4	antigen Cd4 2.93	(0.0017) -0.30	(ns) 0.17	(ns)
CD79A	antigen Cd79a 5.15	(0.0215) 0.70	(ns) -1.28	(ns)
CD79B	antigen Cd79b 2.85	(0.0087) 0.48	(ns) 1.17	(ns)
CD8	antigen,	alpha	chain Cd8a 3.70	(0.0017) 0.49	(ns) 0.39	(ns)
CD83	antigen Cd83 0.98	(0.0441) 0.14	(ns) 0.18	(ns)
CD96	antigen Cd96 2.08	(0.0087) 0.35	(ns) 0.68	(ns)
chemokine	(C-C	motif)	ligand	22 Ccl22 3.30	(0.0017) 0.47	(ns) 0.64	(ns)
chemokine	(C-C	motif)	ligand	5 Ccl5 2.20	(0.0017) 0.08	(ns) 0.74	(ns)
chemokine	(C-C	motif)	receptor	7 Ccr7 3.98	(0.0017) 0.35	(ns) 0.60	(ns)
chemokine	(C-X-C	motif)	ligand	1 Cxcl1 1.37	(0.0435) 1.00	(ns) -0.26	(ns)
chemokine	(C-X-C	motif)	ligand	13 Cxcl13 5.23	(0.0323) -0.53	(ns) -0.26	(ns)
chemokine	(C-X-C	motif)	receptor	5 Cxcr5 3.12	(0.0031) 0.02	(ns) 0.79	(ns)
ciliary	neurotrophic	factor	receptor Cntfr 1.97	(0.0159) 0.97	(ns) -0.36	(ns)
coronin,	actin	binding	protein	1A Coro1a 1.07	(0.0044) -0.11	(ns) 0.12	(ns)
cysteine	rich	protein	61 Cyr61 0.71	(0.0133) 0.39	(ns) -0.14	(ns)
cytoplasmic	FMR1	interacting	protein	2 Cyfip2 2.50	(0.0017) 0.14	(ns) -0.28	(ns)
dedicator	of	cyto-kinesis	2 Dock2 1.36	(0.0017) 0.03	(ns) -0.05	(ns)
ectonucleotide	pyrophosphatase/phosphodiesterase	2 Enpp2 0.93	(0.0461) -0.81	(ns) 1.10	(0.0428)
Fc	receptor-like	1 Fcrl1 3.90	(0.0031) 0.96	(ns) 1.05	(ns)
Fc	receptor,	IgG,	low	affinity	Iib Fcgr2b 0.98	(0.0454) 0.24	(ns) 0.43	(ns)
histocompatibility	2,	O	region	beta	locus H2-Ob 3.23	(0.0017) 0.08	(ns) 0.92	(ns)
IL2	inducible	T	cell	kinase Itk 3.94	(0.0017) -0.53	(ns) 1.15	(ns)
integrin	alpha	4 Itga4 1.35	(0.0098) 0.43	(ns) -0.09	(ns)
integrin	beta	2 Itgb2 0.96	(0.0289) 0.50	(ns) 0.16	(ns)
integrin	beta	7 Itgb7 2.90	(0.0017) -0.11	(ns) 0.66	(ns)
interleukin	2	receptor,	gamma	chain Il2rg 2.04	(0.0017) 0.19	(ns) 0.42	(ns)
interleukin	21	receptor Il21r 1.52	(0.0098) 0.45	(ns) 0.65	(ns)
log2	FC	KO/WT	(FDR-adjusted	p-value)
Gene
Table	3.3:	Genes	annotated	as	components	of	the	immune	system	significantly	altered	in	Mmp8-null	
tumours	at	6	weeks.	
Table	continues	on	next	page	
  
68 
interleukin	23,	alpha	subunit	p19 Il23a 2.31	(0.0375) 1.82	(0.0242) 0.21	(ns)
interleukin	27	receptor,	alpha Il27ra 2.29	(0.0017) -0.46	(ns) 0.79	(ns)
interleukin	7	receptor Il7r 2.51	(0.0017) 0.40	(ns) 0.24	(ns)
lymphocyte	antigen	9 Ly9 2.03	(0.0017) 0.22	(ns) 0.47	(ns)
lymphocyte	protein	tyrosine	kinase Lck 1.67	(0.0031) 0.00	(ns) 0.24	(ns)
lymphocyte	transmembrane	adaptor	1 Lax1 2.38	(0.0067) -0.10	(ns) 1.00	(ns)
moesin Msn 0.62	(0.0107) 0.15	(ns) -0.06	(ns)
myosin	IG Myo1g 1.57	(0.0125) -0.41	(ns) -0.25	(ns)
neuropeptide	Y Npy 3.22	(0.0252) 2.38	(0.0231) 1.30	(0.0423)
nuclear	factor	of	activated	T	cells,	cytoplasmic,	calcineurin	dependent	1 Nfatc1 1.19	(0.0031) 0.00	(ns) 0.01	(ns)
nuclear	factor	of	activated	T	cells,	cytoplasmic,	calcineurin	dependent	2 Nfatc2 1.26	(0.0017) 0.28	(ns) 0.39	(ns)
phosphatidylinositol	3-kinase	catalytic	delta	polypeptide Pik3cd 1.11	(0.0454) 0.28	(ns) 0.43	(ns)
protein	kinase	C,	beta Prkcb 1.26	(0.0382) 0.21	(ns) -0.00	(ns)
protein	tyrosine	phosphatase,	receptor	type,	C Ptprc	(CD45) 1.90	(0.0017) 0.12	(ns) 0.37	(ns)
RAS	guanyl	releasing	protein	1 Rasgrp1 2.21	(0.0017) 0.20	(ns) 0.71	(ns)
sialic	acid	binding	Ig-like	lectin	H Siglech 1.65	(0.0335) 0.60	(ns) 1.33	(ns)
sialophorin Spn 2.26	(0.0017) 0.19	(ns) 0.19	(ns)
spleen	tyrosine	kinase Syk 0.91	(0.0497) 0.07	(ns) 0.13	(ns)
src	family	associated	phosphoprotein	1 Skap1 2.83	(0.0017) 0.00	(ns) 1.51	(0.0407)
suppressor	of	cytokine	signaling	2;	predicted	gene	8000 Socs2 0.82	(0.0044) 0.62	(0.0443) 0.20(ns)
T	cell	immunoglobulin	and	mucin	domain	containing	4 Timd4 3.49	(0.0017) -0.46	(ns) 0.29	(ns)
tenascin	C Tnc 1.25	(0.0017) 0.39	(ns) -0.14	(ns)
tetraspanin	32 Tspan32 2.00	(0.0107) -0.20	(ns) 0.63	(ns)
thrombospondin	1;	similar	to	thrombospondin	1 Thbs1 0.72	(0.0252) 0.55	(0.0307) -0.30	(ns)
tumor	necrosis	factor	receptor	superfamily,	member	13c Tnfrsf13c 2.01	(0.0375) -0.42	(ns) 0.10	(ns)
TXK	tyrosine	kinase Txk 2.23	(0.0238) 0.25	(ns) 0.03	(ns)
B	cell	leukemia/lymphoma	6 Bcl6 -0.75	(0.0289) -0.23	(ns) -0.43	(ns)
complement	factor	D	(adipsin) Cfd -2.09	(0.0017) -1.00	(0.0014) 0.67	(ns)
indoleamine	2,3-dioxygenase	1 Ido1 -1.93	(0.0017) -0.70	(ns) 1.50	(0.0182)
interferon	regulatory	factor	4 Irf4 -1.68	(0.0017) -1.23	(0.0084) -0.22	(ns)
pyruvate	carboxylase Pcx -0.73	(0.0295) -0.93	(0.0015) 0.68	(ns)
serum	amyloid	A	1 Saa1 -0.82	(0.0056) -0.87	(0.0093) -0.67	(ns)
spondin	2,	extracellular	matrix	protein Spon2 -1.94	(0.0017) -0.70	(ns) 0.46	(ns)
transforming	growth	factor,	beta	3 Tgfb3 -0.81	(0.0017) 0.21	(ns) 0.15	(ns)
vanin	1 Vnn1 -1.87	(0.0032) -0.26	(ns) 1.54	(0.0015)
FC,	fold	change	
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6	weeks 8	weeks 10	weeks
ENSMUSG00000019987arginase,	liver Arg1 0.72	(0.0098) 1.39	(0.0014) 0.39	(ns)
ENSMUSG00000032094CD3	antigen,	delta	polypeptide Cd3d 3.04	(0.0017) -0.42	(ns) 1.74	(0.0308)
ENSMUSG00000024610CD74	antigen	(invariant	polypeptide	of	major	histocompatibility	complex,	class	II	antigen-associated) Cd74 0.22	(ns) 0.03	(ns) 0.81	(0.0015)
ENSMUSG00000026573chemokine	(C	motif)	ligand	1 Xcl1 -0.61	(ns) -0.39	(ns) 1.50	(0.0428)
ENSMUSG00000009185chemokine	(C-C	motif)	ligand	8 Ccl8 0.31	(ns) 0.12	(ns) 0.95	(0.0428)
ENSMUSG00000019122chemokine	(C-C	motif)	ligand	9 Ccl9 -0.09	(ns) -0.89	(0.0242) -0.00	(ns)
ENSMUSG00000029417chemokine	(C-X-C	motif)	ligand	9 Cxcl9 -0.15	(ns) -0.18	(ns) 1.53	(0.0229)
ENSMUSG00000055172complement	component	1,	r	subcomponent;	predicted	gene	8551 C1ra -0.28	(ns) -0.26	(ns) 0.91	(0.0358)
ENSMUSG00000024164complement	component	3;	similar	to	complement	component	C3	prepropeptide,	last C3 -0.63	(ns) -0.85	(0.0015) 0.67	(ns)
ENSMUSG00000026365complement	component	factor	h;	similar	to	complement	component	factor	H Cfh -0.12	(ns) 0.34	(ns) 0.95	(0.0015)
ENSMUSG00000061780complement	factor	D	(adipsin) Cfd -2.09	(0.0017) -1.00	(0.0015) 0.67	(ns)
ENSMUSG00000033467cytokine	receptor-like	factor	2 Crlf2 -1.89	(ns) -0.37	(ns) -2.19	(0.0015)
ENSMUSG00000022425ectonucleotide	pyrophosphatase/phosphodiesterase	2 Enpp2 0.93946 -0.81	(ns) 1.10	(0.0428)
ENSMUSG00000003420Fc	receptor,	IgG,	alpha	chain	transporter Fcgrt -0.69	(ns) -0.71	(0.0117) 0.88	(0.0084)
ENSMUSG00000046879immunity-related	GTPase	family	M	member	1 Irgm1 0.22	(ns) 0.64	(0.0207) 0.41	(ns)
ENSMUSG00000067149immunoglobulin	joining	chain Igj 0.18	(ns) 1.27	(0.0413) 0.29	(ns)
ENSMUSG00000031551indoleamine	2,3-dioxygenase	1 Ido1 -1.93	(0.0017) -0.70	(ns) 1.50	(0.0183)
ENSMUSG00000021356interferon	regulatory	factor	4 Irf4 -1.68	(0.0017) -1.23	(0.0084) -0.22	(ns)
ENSMUSG00000027398interleukin	1	beta Il1b 0.87	(ns) 1.32	(0.0222) 0.86	(ns)
ENSMUSG00000070427interleukin	18	binding	protein Il18bp -0.18	(ns) 0.87	(0.0272) 0.22	(ns)
ENSMUSG00000025383interleukin	23,	alpha	subunit	p19 Il23a 2.31	(0.0375) 1.82	(0.0242) 0.21	(ns)
ENSMUSG00000034634lymphocyte	antigen	6	complex,	locus	D Ly6d -0.99	(ns) 0.31	(ns) 0.82	(0.0027)
ENSMUSG00000044678lymphocyte	antigen	6	complex,	locus	K Ly6k -0.48	(ns) -0.19	(ns) 3.58	(0.0015)
ENSMUSG00000033307macrophage	migration	inhibitory	factor-like Mif -0.0	(ns) 0.08	(ns) -0.87	(0.0015)
ENSMUSG00000039196orosomucoid	1 Orm1 -0.54	(ns) -1.47	(0.0015) 1.89	(0.0015)
ENSMUSG00000027832pentraxin	related	gene Ptx3 0.57	(ns) 1.46	(0.0015) 1.09	(0.0015)
ENSMUSG00000024892pyruvate	carboxylase Pcx -0.73	(0.0295) -0.93	(0.0015) 0.68	(ns)
ENSMUSG00000056054S100	calcium	binding	protein	A8	(calgranulin	A) S100a8 -0.65	(ns) -0.62	(ns) -0.67	(0.0403)
ENSMUSG00000074115serum	amyloid	A	1 Saa1 -0.82	(0.0056) -0.87	(0.0093) -0.67	(ns)
ENSMUSG00000040026serum	amyloid	A	3 Saa3 -0.77	(ns) -1.04	(0.0101) -1.25	(0.0027)
ENSMUSG00000057058src	family	associated	phosphoprotein	1 Skap1 2.83	(0.0017) 0.00	(ns) 1.51	(0.0408)
ENSMUSG00000020027suppressor	of	cytokine	signaling	2;	predicted	gene	8000 Socs2 0.82	(0.0044) 0.62	(0.0443) 0.20	(ns)
ENSMUSG00000040152thrombospondin	1;	similar	to	thrombospondin	1 Thbs1 0.72	(0.0253) 0.55	(0.0308) -0.30	(ns)
ENSMUSG00000037440vanin	1 Vnn1 -1.87	(0.0032) -0.26	(ns) 1.54	(0.0015)
Gene
log2	FC	KO/WT	(FDR-adjusted	p-value)
FC, fold change.  
Table	3.4:	Genes	annotated	as	components	of	the	immune	system	significantly	altered	in	Mmp8-null	tumours	at	8	
and	10	weeks.	
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To	control	for	variances	in	the	number	of	total	 leukocytes	present	in	the	TME	and	the	surrounding	tissue,	the	FPKM	scores	of	selected	immune	cell	markers	genes	 were	 normalised	 to	 total	 leukocytes	 (FPKM	 levels	 of	 CD45).	 This	approach	 will	 allow	 for	 a	 more	 precise	 measurement	 of	 the	 proportion	 of	specific	immune	cell	populations	present	in	the	tumour	infiltrate.	Marker	genes	for	 leukocyte	 subpopulations	were	 selected	based	on	previous	 literature	 (e.g.	Gajewski	et	al.,	2013;	Quail	&	Joyce,	2013;	Fridman	et	al.,	2012)	and	are	listed	in	Appendix	3.	FPKM	scores	of	 the	complete	set	of	 leukocyte	markers,	prior	and	after	 normalisation,	 are	 illustrated	 in	 Appendix	 3.	 No	 significant	 change	 in	expression	was	evident	for	most	marker	genes	between	genotypes	at	6,	8	nor	10	weeks	of	development	(see	Appendix	3	and	Figure	3.13).	Interestingly,	these	results	 include	 markers	 for	 B-	 and	 T-lymphocytes	 that	 showed	 a	 significant	increased	expression,	prior	 to	normalization,	 in	Mmp8-null	mice	at	early	 time	points	 of	 disease	 development.	 Notably,	 FPKM	 scores	 for	 CD45	 shows	 a	significant	 change	 at	 6	 week	 of	 development.	 These	 results	 indicate	 that	depletion	of	MMP8	induces	an	increased	infiltration	of	total	leukocytes	and	that	the	proportion	of	leukocyte	subpopulations	remains	equal	between	genotypes	across	all	time	points.	
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Figure	 3.15:	 CD45	 normalised	 expression	 of	 selected	 B-	 and	 T-lymphocyte	
marker	 genes.	 A)	 FPKM	 was	 normalised	 using	 the	 following	 formula:	 marker	FPKM/CD45	 FPKM*100.	 Normalised	 expression	 of	 marker	 genes	 for	 total	 T-lymphocytes	 (CD3),	T-helper	 lymphocytes	 (CD4),	 cytotoxic	T-lymphocytes	 (CD8a	and	 CD8b),	 immature	 B-lymphocytes	 (CD22	 and	 CD79a	 and	 b)	 in	MMTV;PyMT;	Mmp8-knock-out	and	MMTV-PyMT;	Mmp8-wild-type	tumours,	across	time	points.	B)	 Gene	 expression	 levels	 (FPKM)	 of	 CD45.	 Graph	 as	 displayed	 with	 mean	 and	standard	error	of	the	mean.		
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As	previous	studies	have	found	a	disturbance	in	the	protease	web	in	Mmp8-null	mice	and	as	Integrins	are	known	to	interconnect	MMP’s,	the	RNAseq	data	was	also	analysed	for	differentially	expressed	MMPs,	TIMPs,	ADAM,	ADAMTSs	and	Integrins.	 Heatmaps	were	 constructed	 to	 illustrate	 fold	 change	 expression	 in	
Mmp8-null	tumours	in	a	time-dependent	manner	(Figure	3.14	and	Figure	3.15).	The	results	showed	that	depletion	of	MMP8	induces	a	global	disturbance	in	the	protease	web	as	well	as	a	dysregulated	expression	of	various	Integrins	during	tumour	 progression.	 Of	 these,	 statistical	 analysis	 revealed	 that	 MMP3	 was	significantly	 down-regulated	 at	 all	 time	 points	 and	 that	 MMP14	 was	significantly	down-regulated	at	6	weeks	and	up-regulated	at	10	weeks,	whereas	MMP2	 was	 only	 significantly	 up-regulated	 at	 10	 weeks.	 Further,	 ADAMTS-5	was	significantly	up-regulated	at	10	weeks,	whereas	ADAMs	and	TIMPs	showed	no	 significant	 differential	 expression	 at	 any	 time	 points.	 Fold	 change	 in	expression	 and	 statistical	 significance	 for	 MMPs	 and	 TIMPs	 are	 indicated	 in	Table	 3.5.	 Altogether,	 these	 results	 further	 demonstrate	 the	 interconnection	between	MMP8	and	other	proteinases.		In	 addition	 to	 a	 dysregulation	 of	 proteases	 and	 protease	 inhibitors,	 several	Integrins	significantly	changed	at	both	early	and	later	time-points	(Figure	3.14	and	Table	3.5)	 including	 Integrin	beta-3,	 Integrin	beta-8	and	Integrin	alpha-7,	Integrin	 beta-4,	 and	 Integrin	 alpha-4,	 as	 well	 as	 several	 leukocyte	 specific	integrins.	 As	 the	 RNAseq	 also	 identified	 an	 increased	 expression	 of	 several	markers	 for	 leukocyte	 subpopulations,	 the	 dysregulated	 expression	 of	 both	regular	 Integrins	 and	 leukocyte	 specific	 Integrins	 might	 reflect	 an	 increased	adhesion	between	leukocytes	and	endothelial	cells	due	to	leukocyte	migration.
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Figure	 3.16:	 Gene	 expression	 changes	 of	 MMPs,	 TIMPs	 and	 Intergrins	 in	 MMTV-
PyMT;	Mmp8-knock-out	 tumours.	Heatmap	 illustrates	–log2	 (fold	change)	expression	of	selected	genes	in	MMTV-PyMT;	Mmp8-knock-out	tumours,	compared	to	MMTV-PyMT;	Mmp8-wild-type	tumours.	Heatmap	was	constructed	using	Gene	Cluster	3.0,	followed	by	editing	in	Java	TreeView.		
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Figure	3.17:	 Gene	expression	 changes	 for	 ADAM	 and	 ADAMTS’s	 in	MMTV-PyMT;	
Mmp8-knock-out	 compared	 to	 MMTV-PyMT;	 wild-type	 tumours.	 Heatmap	constructed	as	in	Figure	3.14.		
Table	3.5:	MMPs,	ADAMTSs	and	Integrins	
showing	significant	expression	in	MMTV-
PyMT;	Mmp8-knock-out	mice.	
Gene 6	weeks 8	weeks 10	weeks	
Mmp2 -0.50	(ns) 0.28	(ns) 0.65	(0.0189)
Mmp3 -3.73	(0.0017) -1.10	(0.0291) -2.07	(0.0014)
Mmp14 -0.91	(0.0017) 0.30	(ns) 0.65	(0.0428)
Adamts5 -0.68	(ns) -0.18	(ns) 0.97	(0.0229)
Itgal 1.55	(0.0044) -0.31	(ns) 0.37	(ns)
Itgb2 0.96	(0.0289) 0.50	(ns) 0.16	(ns)
Itgb3 -1.02	(0.0017) 0.60	(0.0093) 0.30	(ns)
Itga4 1.35	(0.0098) 0.43	(ns) -0.09	(ns)
Itgb4 -0.33	(ns) -0.05	(ns) -0.71	(0.0048)
Itga7 -0.55	(ns) -0.49	(ns) 1.67	(0.0014)
Itgb7 2.90	(0.0017) -0.11	(ns) 0.66	(ns)
Itgb8 -0.28	(ns) 0.52	(0.0313) 0.20	(ns)
log2	FC	KO/WT	(FDR-adjusted	p-value)
FC,	fold	change.		
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In	Mmp8-null	 mice	 at	 10	 weeks	 of	 development,	 gene	 annotation	 in	 DAVID	revealed	 an	 up-regulation	 of	 multiple	 genes	 involved	 in	 lipid	 and	 glycerol	metabolism,	including	hormone	sensitive	lipase	(LIPE),	perilipin	(PLIN1),	fatty	acid	 binding	 protein	 4	 (FABP4),	 acetyl-CoA	 synthetase	 long-chain	 family	member	 1	 (Acsl1)	 and	 leptin	 (LEP).	 These	 results	 indicate	 that	 depletion	 of	MMP8	induces	a	metabolic	switch	in	MMTV-PyMT	tumours	at	later	time	points	of	 disease	 development.	 The	 complete	 list	 significantly	 increased	 genes	involved	in	lipid	and	glycerol	metabolic	processes	are	listed	in	Table	3.6.		As	 a	 final	 analysis,	 the	 output	 gene	 list	 from	 Cuffdiff	 of	 significantly	differentially	 expressed	 genes	 was	 explored	 to	 look	 for	 other	 relevant	 pro-tumorigenic	 proteins	 that	 were	 affected	 by	 the	 MMP8	 ablation.	 Such	 visual	inspection	of	the	RNAseq	data	identified	two	protein	of	particular	interest;	the	lymphocyte	 antigen	 6K	 (Ly6K)	 and	 neuropeptide	 Y	 (NPY).	 In	 Mmp8-null	tumours,	Ly6K	was	12-fold	significantly	up-regulated	(p	=	0.0015)	at	10	weeks	of	 tumour	development,	whereas	NPY	was	up-regulated	at	6,	8	and	10	weeks	with	 a	 significant	 9-	 (p	 =	 0.0252),	 5-	 (p	 =	 0.0235),	 and	 2.5-fold	 (p	 =	 0.0423)	increase,	 respectively.	 The	 strong	 up-regulation	 of	 Ly6K	 and	 the	 sustained	increased	 in	 NPY	 across	 all	 time	 points	 suggests	 that	 these	 proteins	 play	important	pro-tumorigenic	roles	during	mammary	carcinoma	progression.	
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Table	3.6:	Genes	involved	in	lipid	and	glycerol	metabolism	that	were	significantly	up-regulated	at	10	weeks	of	disease	development	in	
MMTV-PyMT;	Mmp8-knock-out	mice.		
log2	FC	KO/WT	
ID Gene (FDR-adjusted	p-value) Term
ENSMUSG00000018796acyl-CoA	synthetase	long-chain	family	member	1 Acsl1 0.62	(0.0169) Lipid	metabolism
ENSMUSG00000022548apolipoprotein	D Apod 1.27	(0.0014) lipid	binding
ENSMUSG00000022665coiled-coil	domain	containing	80 Ccdc80 1.30	(0.0014) adipose	tissue
ENSMUSG00000030747diacylglycerol	O-acyltransferase	2 Dgat2 1.52	(0.0014) Lipid	metabolism,	glycerol	metabolism
ENSMUSG00000022425ectonucleotide	pyrophosphatase/phosphodiesterase	2 Enpp2 1.10	(0.0428) obesity,	lipid	degradation
ENSMUSG00000062515fatty	acid	binding	protein	4,	adipocyte Fabp4 1.69	(0.0014) lipid	binding
ENSMUSG00000051314free	fatty	acid	receptor	2 Ffar2 2.01	(0.0014) lipid	binding
ENSMUSG00000022579GPI-anchored	HDL-binding	protein	1 Gpihbp1 1.02	(0.0154) lipid	binding
ENSMUSG00000016194hydroxysteroid	11-beta	dehydrogenase	1 Hsd11b1 1.01	(0.0014) Lipid	metabolism
ENSMUSG00000045294insulin	induced	gene	1 Insig1 0.71	(0.0076) Lipid	metabolism
ENSMUSG00000059201leptin Lep 2.63	(0.0014) obesity,	adipose	tissue,	diabetes	mellitus
ENSMUSG00000003123lipase,	hormone	sensitive Lipe 0.76	(0.0260) Lipid	metabolism,	lipid	degradation
ENSMUSG00000015568lipoprotein	lipase;	similar	to	Lipoprotein	lipase	precursor	(LPL) Lpl 1.19	(0.0014) lipid	degradation
ENSMUSG00000041653patatin-like	phospholipase	domain	containing	3 Pnpla3 1.38	(0.0014) Lipid	metabolism,	lipid	degradation
ENSMUSG00000030546perilipin Plin1 1.29	(0.0076) Lipid	metabolism
ENSMUSG00000056220phospholipase	A2,	group	IVA	(cytosolic,	calcium-dependent) Pla2g4a 0.63	(0.0025) lipid	degradation
ENSMUSG00000029134phospholipase	B1 Plb1 0.93	(0.0161) lipid	degradation
ENSMUSG00000012705resistin Retn 1.94	(0.0014) obesity,	diabetes	mellitus
ENSMUSG00000045954serum	deprivation	response Sdpr 0.69	(0.0015) lipid	binding
ENSMUSG00000012187similar	to	monoacylglycerol	O-acyltransferase	1;	monoacylglycerol	O-acyltransferase	1 Mogat1 1.52	(0.0109) Lipid	metabolism,	glycerol	metabolism
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4.	DISCUSSION	The	 overall	 aim	of	 the	 present	 study	was	 to	 explore	 the	 underlying	mechanisms	that	drive	the	suppressive	effects	of	MMP8	during	tumour	progression	 in	MMTV-PyMT	mice.	Based	on	previous	results	in	the	current	literature,	it	was	hypothesized	that	 MMP8	 acts	 via	 the	 innate	 immune	 system	 by	 polarizing	 pro-tumorigenic	neutrophils	 and	macrophages	 towards	 their	more	 anti-tumorigenic	 counterparts	(Fridlender	 et	 al.,	 2009;	 Gong	 et	 al.,	 2012;	 Soria-Valles	 et	 al.,	 2014).	 In	 line	with	this,	 the	present	study	found	that	depletion	of	MMP8	induces	an	up-regulation	of	markers	for	anti-	and	pro-tumorigenic	myeloid	cells	at	later	time	points	of	tumour	development,	when	quantifying	 expression	by	 qRT-PCR.	However,	 these	 changes	were	not	evident	by	RNAseq,	which,	in	contrast,	predominantly	identified	a	strong	up-regulation	of	 adaptive	 immune	 responses	 at	 early	 time	points,	 in	 response	 to	the	 MMP8	 ablation	 (see	 Table	 4.1	 for	 an	 overview	 of	 differentially	 expressed	genes).	Whether	an	up-regulation	of	such	adaptive	immune	responses	is	causative	of	tumour	aggressiveness	remains	unclear	as	B-	and	T-lymphocytes	can	act	both	as	host-protective	 and	 tumour-promoting,	 depending	 on	 cues	 from	 the	 tumour	microenvironment	 (e.g.	 Burkholder	 et	 al.,	 2014;	 Sakaguchi,	 2004;	 Andreu	 et	 al.,	2010;	 de	 Visser	 et	 al.,	 2005;	Milne	 et	 al.,	 2009).	 A	 characterization	 of	 B-	 and	 T-lymphocyte	 phenotypes	 present	 in	 the	 infiltrate	 are	 thus	 required	 for	 further	elucidation.		In	 addition	 to	 dysregulated	 immune	 pathways,	 the	 current	 study	 also	 found	that	MMP8	depletion	induces	a	global	disturbance	in	the	protease	web,	as	well	as,	 an	 upregulation	 of	 several	 oncogenic	 proteins	 at	 later	 time	 points.	 For	example,	 several	 MMPs	 and	 ADAMTS-5	 were	 significantly	 dysregulated	 in	
Mmp8-null	tumours	and,	neuropeptide	Y	and	Ly6K	were	up-regulated	across	all	time	 points	 and	 at	 10	weeks,	 respectively.	 Another	 interesting	 finding	was	 a	metabolic	alteration	observed	in	Mmp8-null	mice	at	10	weeks	of	development.	More	 specifically,	 these	 tumours	 showed	 an	 enhanced	 lipid	 and	 glycerol	metabolism,	 which	 reflects	 a	 more	 proliferative	 and	 aggressive	 tumour	microenvironment	 (Currie	 et	 al.,	 2013).	Taken	 together,	 these	 results	 suggest	that	 depletion	 of	 MMP8	 induces	 pleiotropic	 changes	 within	 the	 tumour	microenvironment	that	are	causative	of	a	more	aggressive	phenotype.	
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Table	4.1:	Summary	table	showing	genes	significantly	differentially	expressed	in	MMTV-PyMT;	Mmp8-knock-out	compared	to	MMTV-
PyMT;	Mmp8-wild-type	tumours.		
Gene 6	Weeks 8	Weeks 10	Weeks
Immune	pathways B	and	T	lymphocyte	associated Btla 2.16	(0.0017) 0.05	(ns) 0.60	(ns)
CD22	antigen Cd22 4.21	(0.0017) 1.03	(ns) 0.16	(ns)
CD28	antigen Cd28 5.15	(0.0116) -0.11	(ns) 0.22	(ns)
CD3	antigen,	delta	polypeptide Cd3d 3.04	(0.0017) -0.42	(ns) 1.74	(0.0307)
CD3	antigen,	epsilon	polypeptide Cd3e 2.96	(0.0044) -0.07	(ns) -0.09	(ns)
CD3	antigen,	gamma	polypeptide Cd3g 2.38	(0.0017) -0.35	(ns) 1.25	(ns)
CD4	antigen Cd4 2.93	(0.0017) -0.30	(ns) 0.17	(ns)
CD79A	antigen Cd79a 5.15	(0.0215) 0.70	(ns) -1.28	(ns)
CD79B	antigen Cd79b 2.85	(0.0087) 0.48	(ns) 1.17	(ns)
CD8	antigen,	alpha	chain Cd8a 3.70	(0.0017) 0.49	(ns) 0.39	(ns)
Chemokine	(C-C	motif)	ligand	22 Ccl22 3.30	(0.0017) 0.47	(ns) 0.64	(ns)
Chemokine	(C-C	motif)	ligand	5 Ccl5 2.20	(0.0017) 0.08	(ns) 0.74	(ns)
Chemokine	(C-X-C	motif)	ligand	1 Cxcl1 1.37	(0.0435) 1.00	(ns) -0.26	(ns)
Chemokine	(C-X-C	motif)	ligand	13 Cxcl13 5.23	(0.0323) -0.53	(ns) -0.26	(ns)
Interleukin	23,	alpha	subunit	p19 Il23a 2.31	(0.0375) 1.82	(0.0242) 0.21	(ns)
C-C	motif	chemokine	3 Ccl3 0.65 (ns)a 0.74	(ns)a 5.52	(0.006)a
Vascular	endothelial	growth	factor	A VEGFA 0.61	(ns)a 0.45	(ns)a 8.97	(0.002)a
Arginase-1 Arg1 0.56	(ns)a 1.49	(ns)a 6.08	(0.031)a
Arginase-2 Arg2 1.27	(ns)a 0.49	(ns)a 6.08	(0.021)a
Scavenger	receptor	cysteine-rich	type	1	protein	M130 CD163 0.36	(ns)a 0.37	(ns)a 6.38	(0.005)a
Interleukin	1	beta Il1b 0.87	(ns) 1.32	(0.0222) 0.86	(ns)
log2	FC	KO/WT	(FDR-adjusted	p-value)
Table	continues	on	next	page	
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Interleukin	1	beta Il1b 0.87	(ns) 1.32	(0.0222) 0.86	(ns)
Integrins Integrin	beta-2 Itgb2 0.96	(0.0289) 0.50	(ns) 0.16	(ns)
Integrin	beta-3 Itgb3 -1.02	(0.0017) 0.60	(0.0093) 0.30	(ns)
Integrin	alpha-4 Itga4 1.35	(0.0098) 0.43	(ns) -0.09	(ns)
Integrin	beta-4 Itgb4 -0.33	(ns) -0.05	(ns) -0.71	(0.0048)
Integrin	alpha-7 Itga7 -0.55	(ns) -0.49	(ns) 1.67	(0.0014)
Integrin	beta-7 Itgb7 2.90	(0.0017) -0.11	(ns) 0.66	(ns)
Integrin	beta-8 Itgb8 -0.28	(ns) 0.52	(0.0313) 0.20	(ns)
Integrin	alpha-L Itgal 1.55	(0.0044) -0.31	(ns) 0.37	(ns)
Protease	web Matrix	metalloproteinase-2 Mmp2 -0.50	(ns) 0.28	(ns) 0.65	(0.0189)
Matrix	metalloproteinase-3 Mmp3 -3.73	(0.0017) -1.10	(0.0291) -2.07	(0.0014)
0.06	(0.0013)a 2.66	(ns)a 0.01	(0.000)a
Matrix	metalloproteinase-13 Mmp13 1.90	(ns)a 0.78	(ns)a 0.04	(0.000)a
Matrix	metalloproteinase-14 Mmp14 -0.91	(0.0017) 0.30	(ns) 0.65	(0.0428)
A	disintegrin	and	metalloproteinase	with	thrombospondin	motifs	5 Adamts5 -0.68	(ns) -0.18	(ns) 0.97	(0.0229)
Tissue	inhibitor	of	metalloproteinases	1 Timp1 0.41	(ns) 3.53	(0.032) 0.20	(ns)
Tissue	inhibitor	of	metalloproteinases	3 Timp3 0.82	(ns) 0.37	(0.044) 0.20	(ns)
Serine	(or	cysteine)	peptidase	inhibitor,	clade	E,	member	2 Serpine2 0.82	(0.0078) 1.15	(0.0014) 0.71	(0.0101)
Oncogenes Neuropeptide	Y Npy 3.22	(0.0253) 2.38	(0.0235) 1.30	(0.0424)
Lymphocyte	antigen	6	complex,	locus	K Ly6k -0.48	(ns) -0.19	(ns) 3.58	(0.0015)
Lipid	metabolism Acyl-CoA	synthetase	long-chain	family	member	1 Acsl1 -0.00	(ns) -0.56	(0.0296) 0.62	(0.0169)
Fatty	acid	binding	protein	4,	adipocyte Fabp4 -0.33	(ns) -1.09	(0.0014) 1.69	(0.0014)
Lipase,	hormone	sensitive Lipe -0.79	(0.0176) -0.81	(0.0015) 0.76	(0.0260)
Perilipin Plin1 -1.04	(0.0088) -1.05	(0.0015) 1.29	(0.0076)
a 	=	qRT-PCR	data	showing	fold	change	and	p-value	
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4.1.	MMP8	as	a	player	in	immune	regulatory	networks	MMP8	 has	 previously	 been	 described	 as	 an	 important	 regulator	 of	 innate	immune	responses.	For	instance,	Balbin	et	al.	(2003)	and	Gutierrez-Fernandez	et	al.	(2007)	showed	that	depletion	of	MMP8	in	mice	induces	a	delayed	influx	of	neutrophils	at	early	time	points	in	skin	tumours	and	wounds,	respectively.	Both	studies	also	reported	an	increased	infiltration	of	neutrophils	in	Mmp8-null	mice	at	 later	 inflammatory	 stages.	 This	 is	 in	 line	 with	 the	 study	 by	 Decock	 et	 al.	(2015)	 that	 found	 a	 sustained	 infiltration	 of	 neutrophils	 in	 MMTV-PyMT;	Mmp8-knock-out	 tumours	 at	 week	 10	 of	 development,	 compared	 to	 a	decreased	 infiltration	 from	 8	 to	 10	 weeks	 in	 the	 wild-type	 littermates.	However,	a	delayed	neutrophil	infiltration	was	not	evident	at	earlier	time	point	of	 disease	 development,	 which	 is	 inconsistent	 with	 the	 previous	 findings	(Balbin	et	al.	2003;	Gutierrez-Fernandez	et	al.,	2007).		These	 studies	 have	 been	 further	 supported	 on	 a	more	mechanistic	 level.	 Studies	has	shown	that	recombinant	MMP8	are	able	to	activate	both	human	interleukin-8	(IL-8)	and	its	mouse	orthologue	lipopolysaccharide	induced	CXC	chemokine	(LIX)	that,	in	turn,	is	known	to	recruit	neutrophils	to	the	site	of	inflammation	(Tester	et	al.,	 2007).	 Consistent	 with	 the	 current	 literature,	 the	 present	 study	 found	 an	increased	 expression	 of	N1	 and	N2	markers	 in	Mmp8-null	 tumours	 at	 10	weeks,	which	suggest	an	increased	influx	of	both	pro-	and	anti-tumorigenic	neutrophils	at	later	stages	of	 tumour	development.	However,	 these	results	are	 inconclusive	as	a	significant	differential	expression	of	N1	and	N2	markers	where	not	evident	in	the	RNAseq	 data.	 At	 early	 time-points	 however,	 the	 RNAseq	 data	 revealed	 an	 up-regulation	of	a	neutrophil	chemo-attractant	(Cxcl1),	but	this	was	not	accompanied	by	 differential	 expression	 of	 markers	 specific	 for	 neutrophils.	 However,	 it	 is	important	 to	 note	 that	 Ly6G,	 which	 is	 an	 established	 neutrophil	 marker,	 was	identified	 as	 not	 expressed	 in	 the	RNAseq	data.	 Also,	 the	 Ly6.B	marker	 that	was	used	 for	 immunostaining	 of	 MMTV-PyMT	 sections	 were	 not	 detected	 in	 the	RNAseq	data,	which	suggests	that	this	gene	is	epigenetic	silenced	or	absent	in	the	MMTV-PyMT	 mice.	 This	 might	 also	 explain	 why	 the	 immunostaining	 was	unsuccessful.	 Thus,	 further	 characterisation	 of	 the	 presence	 of	 neutrophils	 in	the	tumour	infiltrate	are	required	in	order	to	conclude	these	findings.		
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In	addition	to	neutrophil	marker	genes,	the	present	study	found	an	increase	in	M1	and	M2	markers	at	10	weeks	 in	Mmp8-null	mice.	However,	and	as	 for	N1	and	 N2	 markers,	 the	 differential	 expression	 was	 not	 confirmed	 by	 RNA	sequencing.	 In	 concurrence	with	 this,	 RNAseq	 and	 immunostaining	 of	 F4/80	revealed	 no	 change	 in	 total	 macrophages	 between	Mmp8-null	 and	 wild-type	tumours	 at	 10	 weeks	 nor	 at	 other	 time	 points	 of	 tumour	 development.	Accordingly,	 Decock	 et	 al.	 (2015)	 reported	 no	 change	 in	 macrophage	infiltration	 in	 MMTV-PyMT;	Mmp8-null	 and	 heterozygote	 mice,	 compared	 to	wild-type,	throughout	the	time	course	of	mammary	carcinoma	development.	It	is,	however,	important	to	note	that	the	results	obtained	by	Decock	et	al.	(2015)	should	be	 interpreted	with	caution,	as	 the	comparison	of	macrophage	density	was	performed	on	a	limited	MMTV-PyMT	mice	cohort.		The	 inconsistency	 between	 qRT-PCR	 and	 RNAseq	might	 be	 explained	 by	 the	technical	 and	 statistical	 differences	 between	 the	 two	 technologies.	 qRT-PCR	detects	 transcripts	 based	 on	 sequence	 specific	 primer/probe	 sets,	 whereas	RNAseq	technologies	detects	mRNA	molecules	at	a	single	nucleotide	resolution.	Alternatively	spliced	transcripts	that	lack	the	primer/probe	specific	region	will	not	 be	 detected	 by	 qRT-PCR,	 but	 quantified	 by	 RNA	 sequencing,	 which	 will	produce	conflicting	results.	Further	analysis	to	assess	the	presence	of	multiple	transcripts	 are	 thus	 required	 to	 investigate	 whether	 this	 is	 causative	 of	 the	observed	inconsistencies	between	the	two	methods.	In	summary,	the	increased	expression	 of	 anti-	 and	 pro-tumorigenic	 myeloid	 cells	 at	 10	 weeks	 of	development	 are	 inconclusive	 due	 to	 the	 inconsistency	 between	 the	 two	technologies.	Future	experiments	are	 thus	 required	 to	more	comprehensively	assess	 the	 whether	 MMP8	 play	 a	 role	 in	 the	 polarisation	 of	 myeloid	 cells	towards	anti-tumorigenic	phenotypes.		In	 contrast	 to	 effects	 on	 innate	 immune	 pathways,	 genes	 sets	 involved	 in	adaptive	 immune	 responses	 were	 prevalent	 among	 up-regulated	 genes	 at	 6	weeks	 in	Mmp8-null	 tumours.	 Up-regulation	 of	 B-	 and	 T-lymphocyte	marker	genes	and	respective	chemo-attractants,	as	well	as	leukocyte	specific	integrins,	might	 suggest	 that	 MMP8	 regulates	 tumour	 infiltration	 of	 such	 adaptive	
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immune	responses	at	early	stages	of	tumour	development.	An	increased	influx	of	 lymphocyte	 subpopulations	 might	 be	 linked	 to	 the	 accelerated	 tumour	growth	and	metastasis	previously	observed	in	MMTV-PyMT;	Mmp8-knock-out	mice	 (Decock	 et	 al.,	 2015).	 However,	 a	 phenotypic	 profiling	 of	 lymphocyte	subpopulations	 is	 required	 in	order	 to	 investigate	 this	 statement	 further.	The	up-regulation	 of	 CD8	 at	 6	weeks	 is	 indicative	 of	 the	 presence	 of	 cytotoxic	 T-lymphocytes,	which	 is	 highly	protective	 against	 cancer	progression	 (Maher	&	Davides,	2004)	and	are,	thus,	inconsistent	with	this	assumption.		Interestingly,	several	markers	for	pro-tumorigenic	lymphocyte	action	were	also	significantly	up-regulated	in	Mmp8-null	tumours,	including	Ccl22,	Il-23a,	and	Il-1b,	which	might	participate	in	the	accelerated	tumour	progression	observed	in	MMTV-PyMT;	 Mmp8-knock-out	 mice	 (Decock	 et	 al.,	 2015).	 Tumour-secreted	Ccl22	 has	 been	 shown	 to	 recruit	 Tregs	 through	 binding	 of	 the	 chemokine	receptor	 CCR4	 that	 is	 expressed	 on	 Tregs	 (Gobert	 et	 al.,	 2009).	 Tumour	infiltration	 of	 Tregs	 has	 been	 associated	 with	 more	 invasive	 and	 metastatic	cancer	 (Sakaguchi,	 2004),	 in	which	 immunosuppression	 via	 inhibition	 of	 Th1	polarisation	 has	 been	 described	 as	 an	 underlying	 mechanism	 (Bettelli	 et	 al.,	2006).	Treg	cells	are	characterised	by	the	expression	of	CD4,	CD25	and	FoxP3	(Legoux	 et	 al.,	 2015).	 CD4	was	 significantly	 up-regulated	 at	 6	 weeks,	 but	 no	significant	 change	 was	 identified	 for	 CD25	 and	 FoxP3.	 Although	 Ccl22	 is	significantly	up-regulated	in	Mmp8-null	tumours,	these	results	suggest	that	the	presence	 of	 Tregs	 are	 similar	 between	 genotypes.	 However,	 a	 more	 precise	profiling	 of	 Tregs	 in	 Mmp8-null	 and	 wild-type	 tumours	 are	 required	 to	determine	whether	the	up-regulated	expression	of	Ccl22	is	associated	with	an	increased	tumour	infiltration	of	Tregs	in	Mmp8-null	tumours.		In	 contrast	 to	 Ccl22,	 Il-23a	 (alpha	 subunit	 of	 Il-23)	 and	 Il-1b	 are	 known	 to	stimulate	 differentiation	 of	 Th0	 cells	 into	 Th17	 cells.	 Th17	 cells	 have	 been	described	to	possess	context	dependent	anti-	or	pro-tumorigenic	functions.	For	instance,	Martin-Orozco	 et	 al.	 (2009)	 showed,	 in	 the	 context	 of	 a	mouse	 B16	melanoma	 model,	 that	 Th17	 cells	 perform	 host-protective	 functions	 by	activating	cytotoxic	T-lymphocytes.	In	contrast,	a	positive	correlation	has	been	
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found	 between	 Th17	 infiltration	 and	 poor	 prognosis	 in	 several	 cancers,	including	breast,	ovarian	and	colon	cancer	(Miyahara	et	al.,	2008;	Sfanos	et	al.,	2008;	 Zhang	 et	 al.,	 2009).	 Although	 an	 up-regulation	 of	 Il23a	 and	 Il-1b	were	evident	in	Mmp8-null	mice,	other	markers,	 including	Il-17,	IL-2,	IFNg	and	GM-CSF/CS2	(Zou	et	al.,	2006),	characteristic	 for	Th17	cells	were	not	significantly	differentially	 expressed.	 These	 results	 might	 rule	 out	 the	 initial	 suggestion,	however,	 as	 these	marker	 genes	 also	 can	 be	 expressed	 by	 other	 cell	 types,	 a	more	precise	phenotyping	of	immune	cells	populations	are	required	in	order	to	determine	 whether	 MMP8	 ablation	 induces	 an	 increased	 infiltration	 and	polarisation	of	Th17	cells.		The	 present	 study	 also	 identified	 a	 significant	 up-regulation	 of	 a	 gene	 set	specific	 for	 B-lymphocyte	 recruitment,	 activation,	 and	 differentiation	 at	 6	weeks	 of	 tumour	 development,	 in	 Mmp8-null	 tumours.	 Analogous	 to	 T-lymphocytes,	 B-lymphocytes	 has	 shown	 to	 play	 dual	 roles	 during	 tumour	progression,	where	 its	actions	are	highly	context	dependent	 (e.g.	Coronella	et	al.,	2001;	Milne	et	al.,	2009;	Qin	et	al.,	1998;	Andreu	et	al.,	2010).	For	instance,	subpopulations	 of	 B-lymphocytes	 have	 been	 reported	 to	 support	 activity	 of	pro-tumorigenic	T-helper	lymphocytes	by	secreting	Il-2,	Il	-4	and	Il-6	(Nelson,	2010).	 In	support	of	 this,	Olkhanud	et	al.	 (2011)	 found	 that	 the	presence	of	a	specific	B-lymphocyte	subpopulation	(termed	Bregs)	positively	correlated	with	an	increased	metastasis	to	the	lungs	in	a	breast	cancer	mouse	model.	However,	infiltration	of	B-lymphocytes	has	also	been	associated	with	a	better	prognosis	in	ovarian	and	mammary	carcinoma	(Coronella	et	al.,	2010;	Milne	et	al.,	2009).	Thus,	a	better	insight	into	the	action	of	B-lymphocytes	in	MMTV-PyMT;	Mmp8-knock-out	mice	 is	 required	 in	order	 to	 explore	whether	 they	are	 causative	of	the	more	aggressive	phenotype	observed	in	Mmp8-null	tumours.		Although	 an	 increased	 expression	 of	marker	 genes	 for	 B-	 and	T-lymphocytes	was	 evident	 at	 6	 weeks	 in	 Mmp8-null	 mice,	 subsequent	 calculations	 of	 the	proportional	 relationship	 of	 leukocyte	 subpopulations	 relative	 to	 total	leukocytes	 (CD45+)	 showed	 different	 results.	 More	 specifically,	 when	normalising	 the	 expression	of	 leukocyte	marker	 genes	 to	CD45,	 no	 change	 in	
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expression	was	 identified	 between	Mmp8-null	 and	wild-type	 tumours.	 These	results	 reflect	 that	 the	 proportion	 of	 leukocyte	 subpopulations,	 including	 B-	and	T-lymphocytes,	present	in	the	infiltrate	are	similar	in	both	genotypes.	Thus,	the	increased	expression	of	lymphocyte	markers	observed	at	6	weeks	might	be	explained	 by	 an	 increased	 tumour	 infiltration	 of	 leukocytes	 in	 total.	 This	argument	concurs	with	the	significant	change	in	expression	of	CD45	at	6	weeks,	but	 raises	 the	 questions	 of	 why	 other	 leukocytes	 subpopulations	 were	 not	identified	 as	 significantly	 changed.	 Possibly,	 looking	 at	 subpopulations	 in	isolation,	 a	 slightly	 increased	 infiltration	 will	 not	 necessarily	 result	 in	 a	significant	 change	 in	 expression	 of	marker	 genes	 specific	 for	 that	 phenotype,	but	when	looking	at	CD45	expression	in	total	a	significance	would	be	evident.	In	 conclusion,	 this	 might	 suggest	 that	 MMP8	 directly,	 or	 through	 secondary	pathways,	accelerates	the	onset	of	inflammation	in	Mmp8-null	mice.	However,	a	more	accurate	profiling	of	populations	of	immune	cells	present	in	the	infiltrate	are	 required	 to	 assess	 this	 in	 more	 depth.	 For	 instance,	 by	 fluorescence-activated	 cell	 sorting	 (FACS)	 of	 leukocytes	 followed	 by	 gene	 expression	profiling	of	marker	genes.		
4.2.	MMP8	ablation	induces	global	changes	in	the	protease	web	In	 addition	 to	 an	 effect	 on	 immune	 regulatory	 networks,	MMP8	 ablation	 has	shown	to	 induce	changes	 in	 the	protease	web.	More	specifically,	Decock	et	al.	(2015)	 showed	 that	depletion	of	MMP8	 induces	 a	dysregulated	expression	of	several	 MMPs	 as	 well	 as	 Timp2.	 MMP8	 has	 also	 been	 shown	 to	 cleave	 and	inactivate	 Alpha1-Proteinase	 Inhibitor	 (α1-PI),	 which	 is	 a	 potent	 inhibitor	 of	neutrophil	 elastase	 (Knäuper	 et	 al.,	 1990).	 Such	 interconnections	 in	 the	protease	web	 has	 also	 been	 identified	 for	 other	members	 of	 the	MMP	 family	(Fortelny	 et	 al.,	 2014)	 and	 thus	 reflects	 the	 importance	 of	 investigating	 the	effect	 on	 the	 protease	 web	 in	 response	 to	 ablation	 of	 specific	 MMP	 species.	Hence,	 MMP8	 ablation	 might	 influence	 the	 activity	 of	 other	 proteases	 or	protease	inhibitors.		In	 the	present	 study,	a	global	disturbance	 in	 the	protease	web	 in	 response	 to	the	 MMP8	 ablation	 was	 evident	 both	 from	 qRT-PCR	 and	 RNAseq	 analysis.	
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However,	 inconsistencies	 in	 differential	 expression	 between	 the	 two	 gene	expression	 methods	 occurred,	 as	 for	 the	 immune	 cell	 marker	 genes.	 For	instance,	qRT-PCR	data	revealed	that	MMP3	were	significantly	down-regulated	at	10	weeks,	whereas	the	RNAseq	data	showed	a	significant	reduced	expression	of	MMP3	at	 all	 time	points.	The	 latter	 is	 consistent	with	previous	 findings,	 of	which	Decock	et	al.	(2015)	reported	a	significant	down-regulation	of	MMP3	at	6,	8	and	10weeks	in	MMTV-PyMT;	Mmp8-knock-out	mice.	A	down-regulation	of	MMP3	might	 contribute	 to	 the	 accelerated	 tumour	 progression	 observed	 for	
Mmp8-null	 mice.	 A	 study	 using	 a	 squamous	 cell	 carcinoma	 model	 described	MMP3	 as	 a	 tumour	 suppressive	 metalloproteinase;	Mmp3-null	 mice	 showed	accelerated	initial	tumour	growth	rates	compared	to	wild-type	littermates.	No	difference	 was	 observed	 in	 tumour	 onset	 or	 incidence,	 but	 the	 enhanced	growth	 rate	 was	 accompanied	 by	 an	 elevated	 proliferative	 index.	Mmp3-null	mice	also	showed	more	undifferentiated	tumours	and	an	enhanced	metastasis	to	the	lung	surface	(McCawley	et	al.,	2004).	A	more	recent	study	supports	these	findings	 by	 showing	 that	 tumour	 produced	 MMP3	 reduces	 the	 number	 of	papillomas	and	carcinomas,	whereas	no	difference	was	found	in	tumour	onset.		Analysis	of	epidermal	biopsies	revealed	that	keratinocyte	expression	of	MMP3	decreased	 and	 increased	 proliferation	 and	 differentiation,	 respectively	(McCawley	et	al.,	2008).	The	effect	on	proliferation	is	interesting	as	the	present	study	 found	 an	 increase	 in	 lipid	 metabolism,	 a	 hallmark	 of	 a	 proliferative	microenvironment,	at	later	time	points	in	Mmp8-null	mice.	Thus,	the	decreased	MMP3	expression	might	 contribute	 to	 the	accelerated	 tumour	progression	by	regulating	 proliferative	 activity.	 Another	 study	 by	 Witty	 et	 al.	 (1995)	 found	significant	 reduction	 in	 development	 of	 breast	 tumours	 following	 7,12-Dimethylbenz[a]anthracene	 (DMBA)	 induced	 carcinogenesis	 in	 MMTV-MMP3	transgenic	 mice.	 They	 suggested	 that	 MMP3	 act	 as	 a	 tumour	 suppressor	 by	influencing	 the	 rate	 of	 cell	 turnover.	 More	 specifically,	 they	 found	 a	 4-fold	increase	in	apoptotic	cells	in	MMTV-MMP3	transgenic	mice	when	comparing	to	non-transgenic	 littermates.	 However,	 no	 significant	 effect	 on	 apoptosis	 was	found	 by	 McCawley	 et	 al.	 (2004)	 when	 comparing	Mmp3-null	 and	 wild-type	tumours.	Future	studies	are	thus	required	in	order	to	conclude	whether	MMP3	inhibits	tumour	growth	by	regulating	apoptosis	of	carcinogenic	cells.		
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	In	 addition	 to	 the	 down-regulated	 expression	 of	 MMP3,	 MMP2	 was	 up-regulated	at	mid-late	time-points	in	both	datasets,	which	concur	with	previous	findings.	Decock	et	al.	(2015)	reported	an	increased	expression	of	MMP2	at	10	and	14	weeks	of	disease	development	in	MMTV-PyMT;	Mmp8-knock-out	mice.	Additionally,	Mmp2-null	mice	have	shown	a	reduced	angiogenesis	and	tumour	progression	 compared	 to	 wild-type	 animals	 (Itoh	 et	 al.,	 1998).	 This	 is	supported	by	several	studies	showing	that	MMP2	promotes	angiogenesis	(Fang	et	al.,	2000;	Kolb	et	al.,	1997).	In	the	present	study,	an	up	-regulation	of	several	proangiogenic	 factors	 were	 detected	 at	 10	 weeks,	 including	 neurophilin-1,	kinase	 domain	 receptor	 and	 chondroitin	 sulfate	 proteoglycan	 4	 (data	 not	shown).	These	findings	are	in	line	with	the	proangiogenic	properties	described	for	MMP2.		In	contrast	 the	 indications	of	a	proangiogenic	environment,	 the	present	study	did	not	identify	a	difference	in	vascular	density	between	Mmp8-null	and	wild-type	tumours	when	staining	tumour	sections	for	Endomucin.	However,	a	more	comprehensive	 immunostaining	 study	might	 be	 required	 to	 assess	 this	more	accurately.	More	 specifically,	 selection	 of	 tissue	 sections	 that	matches	 similar	areas	of	the	tumours	(e.g.	invading	margins	vs	hypoxic	regions)	will	provide	a	more	 precise	 comparison	 of	 blood	 vessel	 density	 between	 the	 genotypes.	Quantification	of	blood	vessel	density	is	also	required	to	more	comprehensively	assess	 whether	 depletion	 of	 MMP8	 promote	 angiogenesis	 via	 MMP2.	 MMP2	might	 also	play	other	 roles	 in	 the	 context	of	 the	MMTV-PyMT	 tumour	model.	During	invasion,	MMP2	has	been	shown	to	re-localize	to	invadopodia	where	the	proteinase	promotes	cell	invasion	together	with	MMP14	(Nakahara	et	al.,	1997;	Brooks	et	al.,	1996).	MMP2	and	MMP14	also	triggers	cell	motility	by	cleavage	of	laminin-5	(Giannelli	et	al.,	1997;	Koshikawa	et	al.,	2000).	This	in	consistent	with	the	present	findings	showing	a	significant	up-regulation	of	MMP14	at	10	weeks	in	 Mmp8-null	 tumours.	 MMP2	 and	 MMP14	 might	 thus	 coordinately	 trigger	invasion	at	later	time	points	of	disease	development	in	the	absence	of	MMP8	in	MMTV-PyMT	mice.	However,	 verification	of	 the	 increased	MMP14	expression	
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by	qRT-PCR,	and	further	validation	at	protein	level	for	both	MMP2	and	MMP14	is	required	in	order	to	conclude	these	findings.		TIMPs	are	major	 inhibitors	of	metalloproteinases,	which	play	key	roles	 in	 the	regulation	 of	MMP	activity	 (Nagase	 et	 al.,	 2006).	 Thus,	members	 of	 the	TIMP	family	was	quantified	to	investigate	if	MMP8	ablation	had	a	significant	effect	on	expression	of	these	proteinase	inhibitors.	TIMP	members	was	profiled	based	on	the	availability	of	primer/probes	for	qRT-PCR	analysis.	No	significant	change	in	expression	 was	 identified	 for	 TIMP1,	 TIMP3	 and	 TIMP4	 between	Mmp8-null	and	 wild-type	 tumours.	 This	 was	 further	 confirmed	 by	 RNAseq,	 where	 non-significant	change	in	expression	also	was	evident	for	TIMP2.		RNAseq	 data	 allowed	 for	 a	 more	 in-depth	 investigation	 into	 inhibitors	 of	protease	 web	 members,	 and	 a	 significant	 dysregulation	 of	 several	 protease	inhibitors	 were	 evident.	 Notably,	 the	 results	 revealed	 that	 several	 serine	protease	 inhibitors	 (Serpins)	 changed	 expression	 pattern	 in	 Mmp8-null	tumours,	at	both	early	and	late	time	points.	Serpins	are	known	to	target	trypsin,	thrombin,	plasmin,	plasminogen	activator	(Baker	et	al.,	1980,	Scott	et	al.,	1985),	T	 cell	 proteinase-1	 (Gurwitz	 et	 al.,	 1989),	matriptase	 (Myerburg	et	 al.,	 2008),	and	prostasin	(Chen	et	al.,	2004).		In	 the	current	 study,	and	of	particular	 interest,	 Serpine2	was	 found	 to	be	up-regulated	 throughout	 the	 time	course	of	 the	disease,	 in	Mmp8-null	mice.	This	serine	peptidase	 inhibitor	has	previously	been	 reported	 to	play	 an	 important	role	 in	 tumour	 growth	 and	 metastasis.	 More	 specifically,	 Serpine2	 has	 been	implied	 to	 promote	 invasion	 of	 breast	 (Candia	 et	 al.,	 2006),	 pancreatic	(Buchholz	et	al.,	2003),	 and	 lung	cancer	cells	 (Yang	et	al.,	2009).	Accordingly,	Serpine2	 has	 been	 shown	 to	 be	 over-expressed	 in,	 colorectal,	 pancreatic	 and	breast	 tumours	 (Candia	 et	 al.,	 2006,	 Buchholz	 et	 al.,	 2003,	 Selzer-Plon	 et	 al.,	2009),	 and	 in	 liposarcoma	 (Thelin-Jarnum	 et	 al.,	 1999)	 and	 oral	 squamous	carcinoma	(Gao	et	al,	2008).	In	conclusion,	these	findings	suggest	that	Serpine2	play	 a	 role	 in	 the	observed	 accelerated	 growth	 and	metastasis	 in	Mmp8	 -null	mice.	 However,	 a	 better	 insight	 into	 its	 mechanisms	 of	 action	 is	 required	 in	
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order	to	explore	the	link	between	MMP8	and	Serpin2	expression,	and	to	further	elucidate	its	role	in	mammary	carcinoma	progression.			
4.3.	Novel	pathways	affected	by	MMP8	signaling	
4.3.1.	The	link	between	MMP8,	Ly6K	and	Neuropeptide	Y	In	 addition	 to	 changes	 in	 the	 immune	 cell	 repertoire	 and	 in	 the	 web	 of	proteases,	 whole-genome	 RNA	 sequencing	 revealed	 that	 MMP8	 depletion	induces	a	dysregulation	of	several	proteins	 that	has	previously	been	reported	to	 play	 important	 roles	 during	 tumour	 progression.	 Of	 these,	 lymphocyte	antigen	 6K	 (Ly6K)	 was	 significantly	 up-regulated	 at	 10	 weeks	 of	 tumour	development	in	Mmp8-null	mice.	Ly6K	is	a	cancer-testis	antigen	that	has	been	suggested	as	a	diagnostic	biomarker	and	therapeutic	target	in	several	cancers,	including	breast,	bladder,	esophangeal	squamous	cell	carcinoma	and	non-small	cell	 lung	 carcinoma	 (Lee	 et	 al.,	 2006;	 Ishikawa	 et	 al.,	 2007;	 Matsuda	 et	 al.,	2011).	Ly6K	has	been	shown	to	positively	regulate	cell	growth,	migration	and	invasion	 of	 several	 bladder	 cancer	 cell	 lines	 (Matsuda	 et	 al.,	 2011).	 Likewise,	Kong	 et	 al.	 (2012)	 reported	 an	 increased	 cell	 invasion	 and	 metastasis	 in	response	 to	 over-expression	 of	 Ly6K	 in	 breast	 cancer	 cells.	 This	 effect	 was	shown	to	be	mediated	trough	the	Ras/ERK	pathway,	and	was	accompanied	by	an	increased	expression	of	MMP2	and	MMP9.	Thus,	the	increased	expression	of	MMP2	 observed	 at	 10	 weeks	 in	 the	 present	 study	 might	 be	 induced	 by	 the	increased	expression	of	Ly6K.	These	results	are	highly	suggestive	of	Ly6K	and	MMP2	as	 important	players	 in	 the	accelerated	metastasis	observed	 in	MMTV-PyMT;	 Mmp8-knock-out	 tumours.	 However,	 the	 mechanisms	 of	 Ly6K	 action	needs	 to	 be	 explored	 to	 investigate	 whether	 this	 protein	 are	 interconnected	with	MMP2	and	to	further	evaluate	its	metastatic	effects.		Neuropeptide	Y	(NPY),	which	is	a	sympathetic	neurotransmitter,	was	strongly	up-regulated	 across	 all	 time	 points	 in	 Mmp8-null	 tumours.	 More	 than	 two	decades	 ago,	 neuropeptides	 were	 recognized	 as	 important	 mitogens	 during	cancer,	 in	which	 they	 function	 in	an	autocrine/paracrine	manner	 to	stimulate	proliferation	 and	 migration	 (Rozengurt,	 2002).	 Accordingly,	 NPY	 has	 been	recognised	as	an	important	mediator	of	both	growth	and	metastasis	of	several	
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cancers	(Antoni	et	al.,	2006;	Tilan	et	al.,	2010;	Elenkov	et	al.,	2000;	Marsland	et	al.,	 2002;	 McEwen	 et	 al.,	 1993).	 NPY	 receptors	 (i.e.	 Y1R,	 Y2R	 and	 Y5R)	 are	highly	expressed	in	several	malignancies,	including	breast	(Reubi	et	al.,	2001),	ovarian	(Korner	et	al.,	2003)	and	prostate	cancer	(Magni	&	Motta,	2001).	Reubi	et	 al.	 (2001)	 found	 that	Y1R	was	more	highly	 expressed	 compared	 to	Y2R	 in	breast	cancers,	and	that	normal	breast	tissue	only	express	Y2R.	The	expression	of	Y5R	has	not	been	extensively	studied	but	Sheriff	et	al.	 (2010)	has	reported	expression	 of	 Y5R	 in	 several	 human	 breast	 cancer	 cell	 lines.	 NPY	 and	 NPY	receptor	 signaling	 has	 been	 shown	 to	 stimulate	 both	 proliferation	 and	migration	of	 cancer	cells	 (e.g.	Sheriff	et	al.,	2010;	Korner	&	Reubi,	2008)	and,	thus,	 might	 participate	 in	 the	 accelerated	 tumour	 growth	 and	 metastasis	recently	 observed	 in	MMTV-PyMT;	Mmp8-null	 tumours	 (Decock	 et	 al.,	 2015).	Neuroendocrine	 tumour	 studies	 have	 demonstrated	 that	 Y2R	 activation	increases	 cell	proliferation	 (Korner	&	Reubi,	2008;	Kitlinska	et	al.,	2005).	For	instance,	Sheriff	et	al.	(2010)	reported	an	Y5R	mediated	cell	growth	in	BT-549	breast	 cancer	 cells	 via	 MAPK	 activation,	 which	 was	 accompanied	 by	 an	increased	 phosphorylation	 of	 ERK1/2	 (Sheriff	 et	 al.,	 2010).	 This	 was	 further	supported	 by	 Medeiros	 et	 al.	 (2011),	 which	 showed	 that	 treatment	 of	 NPY	increased	proliferation	of	4T1	cells	in	a	concentration-dependent	manner,	and	that	this	effect	was	mediated	via	an	increased	phosphorylation	of	ERK1/1.		NPY	 signaling	 has	 also	 been	 demonstrated	 to	 promote	migration	 of	multiple	cell	types,	including	endothelial	and	malignant	cells	(Sheriff	et	al.,	2010,	Drell	et	al.,	 2003).	For	 instance,	 Sheriff	 et	 al.	 (2010)	 showed	 that	 treatment	with	NPY	increased	the	migratory	potential	 to	MDA	MB-231	cells	by	acting	via	Y2R	and	Y5R.	A	subsequent	study	described	NPY	as	a	chemo-attractant	that	acts	via	Y2R	and	 Y5R	 to	 stimulate	 cell	 migration	 (Medeiros	 et	 al.,	 2011).	 Further,	 NPY	stimulated	activation	of	Y2R	and	Y5R	has	been	shown	to	promote	migration	of	endothelial	cells	(Movafagh	et	al.,	2006).	These	results	imply	that	NPY	and	NPY	receptors	play	a	crucial	role	in	metastasis	of	cancer	cells,	which	together	with	its	 evident	 effect	 on	 cell	 proliferation,	 strongly	 suggest	 NPY	 as	 an	 important	mediator	 of	 growth	 and	 metastasis	 in	 MMTV-PyMT;	 Mmp8-null	 tumours.	However,	 subsequent	 studies	 exploring	 the	NPY	 signaling	 pathway	 in	Mmp8-
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null	 tumours	 more	 comprehensively	 are	 required	 to	 firmly	 establish	 this	statement.		
4.3.2.	MMP8	ablation	affects	lipid	and	glycerol	metabolism	at	later	time	points	of	
tumour	development	Bioinformatics	 analysis	 of	 RNAseq	 data	 also	 revealed	 a	 metabolic	 change	 in	response	to	the	MMP8	ablation,	especially	at	10	weeks	of	disease	development.	The	 best	 known	metabolic	 alteration	 in	 tumour	 cells	 are	 the	Warburg	 effect,	which	describes	the	glycolysis-switch	from	low-rate	oxidative	phosphorylation	towards	 high-rate	 glycolysis	 and	 lactate	 production	 in	 the	 cytosol	 (Warburg,	1956).	 More	 recently,	 tumour	 cells	 have	 been	 shown	 to	 alter	 their	 lipid	metabolism	in	response	to	high	proliferation,	a	metabolic	switch	that	has	been	associated	 with	 tumour	 growth	 and	 metastasis	 (Currie	 et	 al.,	 2013).	 Cancer	cells	 satisfy	 their	 increased	 fatty	acid	 consumption	by	an	 increased	uptake	of	exogenous	 lipids	 and	 lipoproteins	 or	 by	 an	 up-regulation	 of	 endogenous	synthesis	of	 lipids	and	cholesterols	 (Beloribi-Djefaflia	et	al.,	2016).	Lipids	and	cholesterol	 that	 are	 not	 used	 immediately	 are	 stored	 in	 lipid	 droplets	 (LDs)	which	has	recently	been	considered	as	a	hallmark	of	aggressive	cancers	(Yue	et	al.,	 2014,	 Bozza	 et	 al.,	 2010,	 de	 Gonzalo-Calvo	 et	 al.,	 2015,	 Abramczyk	 et	 al.,	2015).		In	the	present	study,	Mmp8-null	tumours	appear	to	have	an	up-regulated	lipid	metabolism	 at	 later	 time	 points,	 compared	 to	 wild-type	 littermates.	 These	findings	are	consistent	with	the	recently	observed	accelerated	tumour	growth	and	metastasis	 reported	 for	MMTV-PyMT;	Mmp8-null	 tumours	 (Decock	 et	 al.,	2015).	 Interestingly,	 several	 of	 the	 genes	 that	were	 significantly	up-regulated	are	 identified	 as	 key	 players	 of	 metabolic	 lipid	 pathways.	 For	 instance,	hormone	sensitive	lipase	(LIPE)	is	an	enzyme	involved	in	lipid	catabolism	and	degradation	 (Liew	 et	 al.,	 2013).	 Further,	 Perilipin	 (PLIN1)	 and	 fatty	 acid	binding	protein	4	(FABP4)	are	both	important	in	uptake	and	transport	of	fatty	acids	(Greenberg	et	al.,	1991).	Acetyl-CoA	synthetase	long-chain	family	member	1	(Acsl1)	are	involved	in	synthesis	and	degradation	of	cellular	lipids	(Soupene	&	Kuypers,	2008).	
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	Furthermore,	 leptin	 (LEP),	 which	 was	 strongly	 up-regulated	 at	 10	 weeks	 in	
Mmp8-null	 tumours,	 is	 a	 major	 regulator	 of	 energy	 homeostasis	 and	 weight	control	 (Surmacz,	 2007)	 and,	 induce	 a	 variety	 of	 signaling	 pathways	 upon	binding	to	the	leptin	receptor	(LEPR)	in	peripheral	tissues.	In	cancer,	leptin	has	been	 shown	 to	 induce	 proliferation	 and	 survival	 through	 LEPR	 activation,	which	activates	Jak/STAT3,	ERK1/2	and	phospohoinostitide	3-kinase	signaling	pathways.	 Additionally,	 LEPR	 activation	 induces	 expression	 of	 cyclin	 D	 and	causes	 a	 hyperphosphorylation	 of	 the	 retinoblastoma	 protein	 (Garofalo	 &	Surmacz,	2006,	Frankenberry	et	al.,	2006).		Altogether,	these	results	might	suggest	that	MMP8	act	as	a	suppressor	of	lipid	metabolism	 pathways	 to	 protect	 the	 host	 from	 tumour	 aggressiveness.	However,	a	link	between	MMP8	and	lipid	metabolism	has	not	previously	been	reported,	 and	 a	 more	 comprehensive	 investigation	 is	 required	 in	 order	 to	assess	 this	 assumption.	Alternatively,	MMP8	might	 act	more	directly	 to	 drive	proliferation	(e.g.	via	Leptin),	which,	in	turn,	might	reprogram	the	tumour	cells	to	 change	 their	 metabolic	 phenotype	 as	 an	 adaption	 to	 a	 harsh	 and	 highly	proliferative	tumour	microenvironment.		
4.4.	Limitations	It	 is	 important	to	note	the	methodological	 limitations	of	the	present	study.	As	previously	 discussed,	 the	 majority	 of	 RNA	 species	 that	 showed	 significant	differential	 expression	 in	 CuffDiff	 were	 not	 subject	 for	 further	 validation.	Follow-up	 studies	 are	 thus	 required	 in	 order	 to	 conclude	 the	 findings.	Additionally,	 several	mRNA	 species	 showed	 inconsistent	 expression	 between	RNAseq	 and	 qRT-PCR	 experiments.	 It	 is	 important	 to	 characterise	 the	underlying	 cause	 if	 these	 conflicting	 results	 in	 subsequent	 studies.	 This	includes	an	investigation	into	the	presence	of	multiple	transcripts	for	candidate	genes	to	evaluate	whether	RNAseq	technologies	quantifies	transcripts	that	are	not	detected	by	qRT-PCR	due	to	alternative	splicing	events.	 If	 this	 is	 the	case,	customised	 primer/probe	 sets	 can	 be	 developed	 for	 a	 more	 accurate	quantification	of	target	genes.	
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	Differences	in	statistical	methodologies,	such	as	normalization	methods,	might	also	contribute	to	data	variability	(Huggett	et	al.,	2005).	Normalization	against	endogenous	 reference	 genes	 is	 essential	 in	 qRT-PCR	 to	 control	 for	 between-sample	variations	and	errors	 in	 sample	quantification.	 Ideally,	 such	 reference	genes	should	be	stably	expressed	in	all	tissues	or	cells	at	all	time	points,	even	under	 experimental	 treatment	 (Dheda	 et	 al.,	 2005;	 Bonefeld	 et	 al.,	 2008).	However,	 investigations	 into	 the	 validity	 of	 such	 genes	 has	 questioned	 the	reliability	of	endogenous	controls	in	qRT-PCR	experiments	and	no	definite	gold	standard	has	been	suggested	for	this	purpose	(Dheda	et	al.,	2005,	de	Kok	et	al.,	2004).	I	 lieu,	several	reports	have	suggested	the	use	of	multiple	control	genes	as	references,	where	 the	geometric	mean	between	the	control	genes	are	used	for	normalization	(e.g.	Pérez	et	al.,	2007;	Vandesompele	et	al.,	2002).	This	will	enhance	 the	 reliability	 of	 the	 quantification	 process,	 which	 might	 have	 a	significant	 impact	 on	 experimental	 conclusions.	 This	 should	 be	 taken	 into	consideration	when	validating	selected	candidate	genes	in	future	experiments.		The	approach	used	to	profile	for	different	leukocyte	subpopulations	is	possibly	the	 primary	 limitation	 of	 this	 study.	 The	 tumour	microenvironment	 is	 highly	heterogeneous	consisting	of	a	variety	of	different	cell	types,	including	a	range	of	different	 immune	 cells	 populations	 (Mantovani	 et	 al.,	 2008).	 Populations	 of	immune	 cells	 are	 mainly	 characterised	 by	 receptor	 status	 and	 expression	patterns	of	cytokines	and	growth	factors.	However,	such	marker	genes	can	be	expressed	by	multiple	cell	types	within	the	microenvironment	(Gajewski	et	al.,	2013).	 This	might	 interfere	with	 gene	 expression	 results	 and,	 thus,	 enhances	the	chances	of	 false	negative	and	 false	positive	 results.	The	presence	of	areas	with	normal	breast	and	necrotic	tissue	within	the	tumour	might	also	contribute	to	 a	 mis-interpretation	 of	 gene	 expression	 data	 and	 should	 preferably	 be	removed	 by	microdissection	 of	 tumours	 prior	RNA	 isolation.	 A	more	 optimal	approach	however,	especially	when	profiling	for	 immune	cell	populations,	are	to	 separate	 and	 quantify	 cells	 by	 FACS	 based	 on	 a	 combination	 of	 cell	surface/intracellular	 marker	 genes.	 Complementing	 this	 with	 profiling	 of	selected	 markers	 at	 both	 RNA	 and	 protein	 levels	 should	 provide	 a	 more	
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comprehensive	and	robust	approach	 for	 immunophenotyping.	Alternatively,	a	transgenic	 mouse	 model	 whose	 selected	 leukocyte	 subsets	 express	 colour-coded	 proteins	 can	 be	 employed.	 This	 allow	 for	 in-vivo	 visualization	 and	imaging	 of	 leukocytes	 and,	 simplifies	 ex-vivo	 quantification	 of	 immune	 cell	populations	 (Pitsillides	 et	 al.,	 2011;	 Fan	 et	 al.,	 2010).	 Using	 more	 optimal	approaches	for	immune	phenotyping	will	allow	future	investigators	to	build	up,	in	 a	 systemic	 manner,	 a	 picture	 of	 the	 altered	 immune	 defense	 pathways	 in	
Mmp8-null	mice.			It	 is	 also	 important	 to	 note	 the	 number	 of	 biological	 replicates	 that	 were	selected	for	differential	expression	analysis	in	Cuffdiff.	A	number	of	four-to-five	biological	replicates	were	initially	selected	for	sequencing,	but	due	to	poor	RNA	quality	of	some	samples	and	due	to	extreme	outlier	replicates,	this	number	was	reduced	 to	 three	 replicates	 in	 two	 of	 the	 conditions.	 Although	 no	 universal	recommendation	 of	 the	 number	 of	 biological	 replicates	 for	 RNAseq	experiments	 are	 established,	 several	 reports	 have	 suggested	 that	 at	 least	 six	replicates	 are	 required	 to	 produce	 data	 with	 high	 validity,	 especially	 when	working	 with	 heterogeneous	 systems,	 such	 as	 cancer	 (Conesa	 et	 al.,	 2016;	Schurch	et	al.,	2016).	Thus,	a	higher	number	of	biological	replicates	should	be	considered	in	future	studies	to	ensure	high	validity	of	biological	interpretation.		In	 the	 present	 study	 and	 in	 the	 study	 by	 Decock	 et	 al.	 (2015),	 tumour	development	 was	 measured	 as	 number	 of	 days	 from	 birth,	 which	 might	challenge	 the	 interpretation	 of	 significantly	 changed	 immune	 responses	between	 genotypes.	 The	 presence	 of	 palpable	 tumours	 varied	 both	 between	and	 within	 genogroups,	 of	 which	 MMTV-PyMT;	 Mmp8-knock-out	 mice	developed	 palpable	 tumours	 between	 3.6	 -	 5.7	 weeks,	 whereas	 wild-type	littermates	showed	palpable	tumours	between	3.6	and	7.8	weeks	(Decock	et	al.,	2015).	 Also,	 about	 90%	 of	Mmp8-null	 tumours	 were	 palpable	 at	 3.6	 weeks,	whereas	only	about	67%	of	wild-type	tumours	were	palpable	at	this	stage.	In	a	tumour	 environment,	 host	 defense	 responses	 are	 initiated	 by	 recruitment	 of	NK-cells,	 dendritic	 cells	 and	 macrophages.	 Adaptive	 immune	 cells	 are	 then	recruited	to	the	tumour	in	response	to	the	action	of	innate	immune	cells	(Finn,	
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2012;	Dranoff,	2004).	Thus,	the	significant	up-regulation	of	markers	for	B-	and	T-lymphocytes	 in	 Mmp8-null	 tumours	 at	 6	 weeks	 might	 reflect	 that	 these	tumours	have	reached	a	later	stage	of	development	rather	than	an	accelerated	influx	of	lymphocytes	at	early	stages.	Pro-tumorigenic	leukocytes	are	generally	not	 present	 before	 later	 stages	 of	 tumour	 development,	 which	 explains	 why	these	lymphocytes	appear	to	possess	anti-tumorigenic	phenotypes.			It	would	be	of	 importance	to	characterise	time	of	 tumour	 initiation	 in	MMTV-PyMT	 in	 future	 studies	 and,	 consider	 interpreting	 tumour	 changes	 as	 weeks	from	 tumour	 initiation	 rather	 than	 weeks	 from	 birth.	 Tumour	 palpability	 as	measure	 for	 tumour	 initiation	 has	 its	 limitations	 as	 tumours	 have	 already	initiated	once	they	become	palpable.	To	ensure	a	more	precise	identification	of	tumour	initiation,	a	model	containing	luciferase	expressing	tumour	cells	can	be	employed.	This	allows	for	bioluminescence	imaging	of	luciferase	activity	in-vivo	that	 can	 be	 utilized	 to	 track	 tumour	 growth	 from	 the	 stage	 of	 initiation	 to	metastasis	(Welsh	&	Kay,	2005).			Finally,	 it	 is	 necessary	 to	 evaluate	 obstacles	 associated	with	 the	 time	 course	profiling	 of	 expression	 patterns	 in	 the	MMTV-PyMT	model.	 Looking	 at	 global	statistics	 (i.e.	 replicate	 PCA	 analysis	 and	 dendrogram)	 of	 data	 from	 whole	genome	 RNA	 sequencing,	 6	 and	 8	 weeks	 genotypes	 are	 clustered	 together	whereas	 groups	 from	 10	weeks	 are	 clustered	 separately.	 This	might	 suggest	that	the	rate	of	tumour	development	varies	between	replicates	at	earlier	time	points	and,	 that	such	variances	equalizes	at	 later	stages	of	development.	Such	biases	might	have	a	 significant	 impact	on	differential	 expression	analysis	and	should	 thus	 be	 characterized	 for	 future	 studies	 in	 order	 to	 achieve	 a	 more	precise	interpretation	of	gene	expression	data.		
4.5.	Concluding	remarks	This	was	the	first	study	to	explore	the	effect	of	MMP8	ablation	by	analysing	the	transcriptome	of	whole	MMTV-PyMT	tumours.	The	overall	results	suggest	that	MMP8	 plays	 pleiotropic	 roles	 during	 mammary	 tumour	 progression.	 More	specifically,	 the	 results	 found	 that	 depletion	 of	MMP8	 induces	 changes	 in	 the	
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inflammatory	cell	repertoire	and	the	protease	web,	as	well	as	inducing	an	up-regulation	 of	 important	 genes	 involved	 in	 metabolism	 and,	 growth	 and	metastasis	of	 tumour	 cells.	However,	 further	validation	of	 the	present	 results	by	 more	 optimal	 approaches	 for	 immunophenotyping	 and	 by	 qRT-PCR	 for	validation	of	 candidate	genes	are	 required	 in	order	 to	 state	 final	 conclusions.	The	role	of	MMP8	is	complex	as	multiple	genes	expression	networks	appear	to	be	affected	by	MMP8	depletion.	Future	studies	are	thus	suggested	to	investigate	such	 system	 in	 isolation	 (e.g.	 lipid	 metabolism)	 to	 explore	 whether	 MMP8	directly	affect	these	pathways	or	 if	 this	 is	a	secondary	consequence	of	a	more	inflammatory	and	 tumour	aggressive	environment.	Also,	an	 in-depth	profiling	of	leukocyte	subpopulations	in	Mmp8-null	mice	will	build	up	a	better	picture	of	the	immune	regulatory	role	of	MMP8.			
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Appendices		
APPENDIX	1:	FPKM	distribution	and	dendrogram	of	replicate	samples	before	(A)	and	after	(B)	excluding	outlier	replicates.	
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APPENDIX	2:	Principal	Component	Analysis	(PCA)	of	replicate	samples	before	(A)	and	after	(B)	removing	outlier	replicates.	
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APPENDIX	3:	Marker	genes	for	leukocyte	subpopulations	
Ensembl	gene	ID Gene Expressed
ENSMUSG00000000982 CCL3 N1	high	N2	low
ENSMUSG00000029417 CXCL9 N1	high
ENSMUSG00000034855 CXCL10 N1	high
ENSMUSG00000024401 TNF⍺ N1	high	M1	high	M2	low
ENSMUSG00000018916 GM-CSF N1	high
ENSMUSG00000027776 Il12a N1	M1	high	M2	low
ENSMUSG00000004296 Il12b N1	M1	high	M2	low
ENSMUSG00000023951 VEGF N1	high
ENSMUSG00000025929 Il-17a N1	high
ENSMUSG00000019987 Arginase-I N1	low	N2	high	M1	low	M2	high
ENSMUSG00000021125 Arginase-II M1	high	M2	low
ENSMUSG00000025383 IL-23a M1	high	M2	low
ENSMUSG00000027398 IL1b M1	high	M2	low
ENSMUSG00000031779 MCP-1	(Ccl2) M1	high
ENSMUSG00000029417 CXCL9 M1	high
ENSMUSG00000034855 CXCL10 M1	high
ENSMUSG00000025746 IL6 M1	high	M2	low
ENSMUSG00000026712 MRC1/CD206	mannose	receptor M2	high
ENSMUSG00000008845 CD163 M2	high
ENSMUSG00000016529 IL-10 M2	high	M1	low
ENSMUSG00000031494 cd209a M2	high
ENSMUSG00000031495 cd209d M2	high
ENSMUSG00000040165 cd209c M2	high
ENSMUSG00000051906 cd209f M2	high
ENSMUSG00000079168 cd209g M2	high
ENSMUSG00000065987 cd209b M2	high
ENSMUSG00000040197 cd209e M2	high
ENSMUSG00000040950 Mgl2 M2	high
ENSMUSG00000061100 Fizz1	 M2	high
ENSMUSG00000025044 Macrophage	scavenger	receptor	1 M2	high
ENSMUSG00000000318 MGL-1 M2	high
ENSMUSG00000079293 Dectin-1	 M2	high
ENSMUSG00000026712 Mannose	receptor	1	 M2	high
ENSMUSG00000026981 IL-1RA	 M2	high
ENSMUSG00000023274 CD4 Tregs,	Th1,	Th2,	Th17
ENSMUSG00000039521 FoxP3 Tregs
ENSMUSG00000026770 CD25 Tregs
ENSMUSG00000053977 cd8a Cytotoxic	T	cells
ENSMUSG00000053044 cd8b1 Cytotoxic	T	cells
ENSMUSG00000004730 F4/80 Macrophages
ENSMUSG00000026395 CD45 Leukocytes
ENSMUSG00000032094 CD3d Total	T	cells
ENSMUSG00000032093 CD3e Total	T	cells
ENSMUSG00000002033 CD3g Total	T	cells
ENSMUSG00000003379 CD79a B-cell
ENSMUSG00000040592 CD79b B-cell
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APPENDIX	4:	Relative	gene	expression	of	selected	immune	marker	genes	after	normalising	against	CD45.	Graphs	show	mean	and	standard	error	of	mean.		
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